THE ROLE OF PRC1 IN B CELL DEVELOPMENT AND ADAPTIVE IMMUNE RESPONSES by F. Alberghini
PhD Degree in Molecular Medicine 
European School of Molecular Medicine (SEMM), 
University of Milan and University of Naples “Federico II” 
Faculty of Medicine 
Settore disciplinare: BIO/10 
 
The role of PRC1 in B cell development and adaptive 
immune responses 
 
Federica Alberghini, MSc 
IFOM, Istituto FIRC di Oncologia Molecolare 
IFOM-IEO Campus, Milan, Italy 
Matricola n. R08893 
 
 
Supervisor:   Dott. Stefano Casola, Ph.D., M.D.  
  IFOM-IEO Campus, Milan, Italy 
Co-supervisor:  Dott. Gioacchino Natoli, Ph.D., M.D. 
   IFOM-IEO Campus, Milan, Italy 
Co-supervisor:  Prof. Dott. Matthias Merkenschlager, Ph.D. 
MRC Clinical Sciences Center, London, United 
Kindgom. 
 
 
Anno Accademico 2012-2013 
 
 
1 
Table of Contents 
 
Table of Contents .................................................................................................. 1 
List of Abbreviations ............................................................................................ 4 
Index of Figures .................................................................................................... 9 
Index of Tables .................................................................................................... 13 
Abstract ................................................................................................................ 14 
Introduction ......................................................................................................... 16 
1.1. Chromatin and epigenetics ................................................................................. 16 
1.1.1. Chromatin compaction and nucleosomes ....................................................... 16 
1.1.2. Epigenetics ...................................................................................................... 17 
1.2. Polycomb group proteins .................................................................................... 18 
1.2.1. Polycomb group proteins in life ....................................................................... 18 
1.2.2. Polycomb- mediated gene silencing ................................................................ 19 
1.2.3. Diversity of PRC1 complexes .......................................................................... 20 
1.2.4. PRC1, H2AK119Ub and chromatin silencing .................................................. 22 
1.2.5. Targeting Polycomb activity to the appropriate genomic loci. ......................... 25 
1.2.6. Polycomb in development and lineage commitment ....................................... 28 
1.2.7. Polycomb function in post-natal life ................................................................. 30 
1.3. B cell development ............................................................................................... 38 
1.3.1. Early B cell development ................................................................................. 39 
1.3.2. Peripheral B cell development. ........................................................................ 42 
1.3.3. B cell-mediated immunity ................................................................................ 49 
1.3.4. Terminal B cell differentiation. ......................................................................... 55 
2. Materials and Methods ................................................................................... 61 
 
 
2 
2.1. Mice ........................................................................................................................ 61 
2.1.2. Genomic DNA extraction from tail biopsy ...................................................... 62 
2.1.3. Genotyping strategy .......................................................................................... 62 
2.1.4. Mice immunization ............................................................................................ 63 
2.1.5. In vivo proliferation assay ................................................................................ 64 
2.2. Cell culture techniques ........................................................................................ 64 
2.2.1. B cell purification ............................................................................................. 64 
2.2.2. In vitro B cell culture ........................................................................................ 65 
2.3. Imaging Techniques ............................................................................................. 67 
2.3.1. Immunostaining for flow cytometry and cell sorting ......................................... 67 
2.3.2. Intracellular immunostaining for flow cytometry ............................................... 67 
2.3.4. Immunostaining of SPL sections ..................................................................... 68 
2.3.5. Immunostaining for detection of apoptosis. ..................................................... 70 
2.3.6. Cell cycle analysis ............................................................................................. 71 
2.4. Biochemical techniques. ..................................................................................... 72 
2.4.1. Enzyme-Linked Immunosorbent Assay (ELISA). ............................................. 72 
2.4.2. Immunoblot analysis. ....................................................................................... 74 
2.4.3. Immunoprecipitation. ....................................................................................... 75 
2.5. Molecular Biology Techniques ............................................................................ 76 
2.5.1. RNA and DNA extraction ................................................................................. 76 
2.5.2. cDNA synthesis ............................................................................................... 76 
2.5.3. Real-time quantitative PCR (RT-QPCR). ........................................................ 77 
2.5.4. RT-QPCR using TaqMan® Micro Fluidic Cards. ............................................. 78 
2.6. Statistical Analysis ............................................................................................... 80 
2.6.1 Student’s t-test. ................................................................................................. 80 
2.6.2. 2-way ANOVA. ................................................................................................ 80 
2.6.3. Microarray analysis. ......................................................................................... 81 
2.6.4. Gene Ontology Analysis. ................................................................................. 81 
3. Results ............................................................................................................. 83 
 
 
3 
3.1. Normal B cell development in Ring1a and Ring1b single mutants. ................ 83 
3.2. PRC1 in early B cell development. ..................................................................... 89 
3.3. PRC1 in peripheral B cell development ............................................................. 92 
3.3.1. PRC1 is critical for peripheral B cell maturation .............................................. 92 
3.3.2. PRC1 mutant B cells migrate into follicles and the marginal zone .................. 98 
3.3.3.  PRC1 inactivation in mature B cells delays bone marrow exhaustion ......... 102 
3.3.4.  PRC1 regulates  the transcriptome profile of mature B cells ........................ 104 
3.4. PRC1 and B cell immunity ................................................................................. 107 
3.4.1. PRC1 inactivation in GC B cell founders impairs germinal center responses107 
3.4.2. PRC1 inactivation triggers counter-selection of mutant GC B cells .............. 113 
3.4.3. Antibody responses are compromised upon PRC1 inactivation ................... 117 
3.4.4. PRC1 is required for memory B cell formation .............................................. 120 
3.5. How does PRC1 regulate B cell function? ....................................................... 124 
3.5.1. PRC1 protects GC B cells from apoptosis .................................................... 124 
3.5.2. Does AID contribute to apoptosis of PRC1 mutant B cells? .......................... 127 
3.5.3. PRC1 facilitates G1-to-S transition in activated B cells ................................. 129 
3.5.4. Bcl6 function is altered in PRC1 mutant GC B cells. ..................................... 135 
3.5.5. PRC1 regulates plasma cell differentiation onset .......................................... 137 
3.6. PRC1 is necessary to sustain PC function ...................................................... 143 
4. Discussion ..................................................................................................... 147 
4.1. PRC1 in early B cell development .................................................................... 148 
4.2. PRC1 in peripheral B cell maturation ............................................................... 149 
4.3. PRC1 in immune responses .............................................................................. 152 
4.4. PRC1 in B cell terminal differentiation ............................................................. 157 
Acknoledgements ............................................................................................. 159 
Reference List ................................................................................................... 163 
 
 
 
4 
List of Abbreviations 
 
AID Activation Induced Deaminase 
Arf Alternative Reading Frame 
Atm ataxia telangiectasia mutated 
Atr ataxia telangiectasia and Rad3 related protein  
BAFF B-cell activating factor 
BAFF-R BAFF receptor 
Bcl2 B cell CLL/lymphoma 2  
Bcl6 B cell CLL/lymphoma 6  
Bcor Bcl6 corepressor  
BCR B cell receptor 
BER base excision repair 
BM bone marrow 
Bmi1 Bmi1 polycomb ring finger oncogene  
bp base pair 
BrdU Bromodeoxyuridine 
C-term Carboxy terminus 
Casp-glow FITC-conjugated VAD-FMK, a general caspase inhibitor 
CB centroblast 
Cbx chromobox homolog 
CC centrocyte 
Ccng1 CyclinG1 
CD Cluster of differentiation 
CDKNA cyclin dependent kinase inhibitor A 
cDNA complementary DNA 
CDR3 Complementarity Determining Region 3 
ChIP chromatin immunoprecipitation 
CHK checkpoint homolog (S. pombe) 
cKit 
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog; CD117 
CLP common lymphoid progenitor 
Cr2 complement component (3d/Epstein Barr virus) receptor 2  
CSR Class Switch Recombination 
 
 
5 
DDR DNA damage response 
DLBCL Diffuse Large B cell Lymphoma 
Dll-1 Delta-like 1 
DMEM Dulbecco's Modified Eagle Medium 
DNA Deoxyribonucleic acid 
dNTP deoxynucleoside triphosphate 
DSB Double Strand Break 
E2a E2a immunoglobulin enhancer binding factors E12/E47 
E2f E2f transcription factor 
Ebf1 early B-cell factor 1 
Eed embryonic ectoderm development  
ELISA Enzyme-linked immunosorbent assay 
ER Endoplasmic reticulum 
ESC Embryonic Stem Cell 
EYFP Enhanced Yellow Fluorescent Protein 
Ezh2 enhancer of zeste homolog 2 (Drosophila)  
DAPI 4',6-diamidino-2-phenylindole 
FACS Fluorescence Activated Cell Sorting 
Fbxl10/Kdm2b lysine (K)-specific demethylase 2B 
FDC Follicular Dendritic Cell 
Flt3 fms-related tyrosine kinase 3  
FO Follicular 
g relative centrifugal force expressed in units of gravity 
GC Germinal center 
H histone 
Hi High 
H2Ak119Ub mono-ubiquitinated Histone H2A at Lysine 119 
H3K27me2 di-methylated Histone H3 at Lysine 27 
H3K27me3 tri-methylated Histone H3 at Lysine 27 
H3K4me3 tri-methylated Histone H3 at Lysine 4 
HSC Hematopoietic Stem Cell 
Ig Immunoglobulin 
IgV Variable gene 
IgH Immunoglobulin heavy chain 
IL interleukin 
 
 
6 
Ink  inhibitor of cyclin-dependent kinase 
Irf4 interferon regulatory factor 4 
kDa Kilodalton 
LMPP lymphoid-primed multipotent progenitor 
LN lymph node 
Lo Low 
loxP locus of X-over of P1 
LPS lipopolysaccharide 
mAb monoclonal antibody 
MACS Magnetic-activated cell sorting 
Mb-1 CD79a molecule, immunoglobulin-associated alpha 
Mcl1 myeloid cell leukemia sequence 1 (BCL2-related)  
MHC Major Histocompatibility Complex 
MITF Microphthalmia-associated transcription factor 
MLN mesentheric lymph nodes 
MMR mismatch repair 
MPP multipotent progenitor 
MRN protein complex consisting of Mre11, Rad50 and Nbs1 
mRNA Messenger RNA 
MZ Marginal zone 
N-term Amino terminus 
NCOR Nuclear receptor co-repressor 
NCOR2/SMRT Nuclear receptor co-repressor 2 
ncRNA Non-coding RNA 
NFAT Nuclear factor of activated T-cells 
NHEJ non-homologous end joining 
NP Nitrophenyl 
NP-CGG Nitrophenyl coupled to chicken gamma globulin 
Pax5 paired box 5 
PBS Phosphate buffered saline 
PC plasma cell 
PcG Polycomb group 
PCGF polycomb group ring finger 
Pcl Polycomblike 
PCR Polymerase Chain Reaction 
 
 
7 
PFA Paraformaldehyde 
Pho Pleiohomeotic 
Pmaip1 phorbol-12-myristate-13-acetate-induced protein (Noxa) 
PP Peyer’s Patches 
PRC Polycomb reppresive complex 
Prdm1 PR domain containing 1, with ZNF domain (Blimp1) 
PRE Polycomb response element 
R26 Rosa26 
RAG Recombination activation genes 
Ring1 Ring finger protein 1, Ring1a, R1a 
RNA Ribonucleic acid 
Rnf2 ring finger protein 2, Ring1b, R1b 
RSS Recombination Signal sequence 
RT room temperature  
RT-PCR Reverse Transcriptase PCR 
RT-QPCR quantitative real time-PCR 
RYBP Ring1 and Yy1 binding protein 
Runx1 Runt related transcription factor 1 
Sca1 stem cell antigen-1; Ly-6A/E 
SEM Standard Error of the Mean 
SET Su(var)3-9, Enhancer-of-zeste, Trithorax 
SHM Somatic Hypermutation 
SPL Spleen 
SRBC Sheep Red Blood Cell 
ssDNA single stranded DNA 
Suz12 suppressor of zeste 12 homolog (Drosophila)  
SWI/SNF SWItch/Sucrose NonFermentable 
TGF-β Transforming growth factor beta 
TF transcription factor 
TFH T follicular helper cell 
TLR Toll-like receptor 
Tp53 Tumor protein 53 
UPR Unfolded protein response 
Wnt Wingless-related MMTV integration site 1 
WT Wild-type 
 
 
8 
Xbp1 X-box binding protein 1  
Xist X inactive specific transcript 
  
 
 
9 
 
Index of Figures 
 
Figure 1. Polycomb repressive complexes and their components. .......................................... 20	  
Figure 2. Diversity of PRC1 compexes. ....................................................................................... 21	  
Figure 3. Simplified view of the DNA damage repair pathways. ............................................... 33	  
Figure 4. Schematic view of B cell development. ....................................................................... 38	  
Figure 5. V(D)J recombination at Ig heavy chain locus. ............................................................ 41	  
Figure 6. Schematic view of peripheral B cell development. ..................................................... 44	  
Figure 7. Schematic view of the GC reaction. ............................................................................. 51	  
Figure 8. Biological functions and pathways regulated by Bcl-6. ............................................. 54	  
Figure 9. Opposing transcriptional networks in GC and PC development. ............................. 60	  
Figure 10. PRC1 catalytic subunits are expressed throughout B cell development. .............. 83	  
Figure 11. Structure of conditional Ring1b and Ring1a null alleles in PRC1 mutant mice. ... 84	  
Figure 12. Schematic view of B cell development and timing of Mb1-cre- and Cr2-cre- 
mediated deletion. ................................................................................................................. 85	  
Figure 13. Ring1a-/- cells are able to proceed through early B cell developmental stages. .... 85	  
Figure 14. Absolute numbers of CD19+ cells in spleens of control and mutant animals. ....... 86	  
Figure 15. Ring1a is dispensable for peripheral B cell development. ...................................... 87	  
Figure 16. Ring1a-/- cells can give rise to germinal centers. ...................................................... 87	  
Figure 17. Up-regulation of Ring1a following Cre-mediated deletion of Ring1b in peripheral 
B cells. .................................................................................................................................... 88	  
Figure 18. B cells devoid of PRC1 are blocked at the pro B cell stage. Flow cytometric 
analysis of control (left) and mutant (right) BM (a) and B220+IgM- (b) pro/pre B cells. 
Numbers indicate frequency of corresponding gated populations and are 
representative of 3 independent experiments. R1b=Ring1b. ............................................ 90	  
Figure 19. Absolute numbers of progenitor (pro and pre) and IgM+ (immature and 
recirculating) B cells upon conditional PRC1 ablation in pro-B cells. ............................. 91	  
Figure 20. Counter-selection of Ring1a-/-Ring1b-/- B cells. ......................................................... 92	  
 
 
10 
Figure 21. Absolute numbers of Cd19+ cells in secondary lymphoid organs are not affected 
by loss of Ring1a and Ring1b. ............................................................................................ 93	  
Figure 22. The majority of CD19+ cells in the periphery of mutant animals are AA4.1+. ........ 94	  
Figure 23. Absolute numbers of AA4.1+ and AA4.1- cells in spleens of control and mutant 
animals. ................................................................................................................................. 94	  
Figure 24.  Levels of surface markers within AA4.1+ cells in Ring1a/Ring1b mutants is 
comparable to those of wild-type transitional B cells. ...................................................... 95	  
Figure 25. Levels of Cr2/CD21 and BAFF-R are similar between AA4.1+ PRC1 mutant cells 
and AA4.1- wild-type cells. ................................................................................................... 96	  
Figure 26. Ring1a/Ring1b mutant cells express surface IgM and IgD. ..................................... 97	  
Figure 27. Loss of Ring1a and Ring1b is compatible with peripheral B cell maturation. ...... 98	  
Figure 28. Ring1a/Ring1b mutant cells display markers of mature cells and segregate into 
mature B cell subsets. .......................................................................................................... 99	  
Figure 29. Loss of PRC1 impairs maturation in the follicular B cell subset. ......................... 100	  
Figure 30. Ring1a-/-Ring1b-/- B cells home to spleen follicles and form the marginal zone 
layer. .................................................................................................................................... 101	  
Figure 31. Marginal zone and B cell follicles are formed upon knock-out of Ring1a and 
Ring1b. ................................................................................................................................. 101	  
Figure 32. Ring1a-/-Ring1b-/- mice display more sustained B cell production and lower 
frequencies of recirculating B cells. ................................................................................. 103	  
Figure 33. Gene deregulation in Ring1a-/-Ring1b-/- CD19+ cells. .............................................. 104	  
Figure 34. Up-and down-regulated genes in Ring1a;Ring1b double mutant B  cells belong to 
different functional GO categories. ................................................................................... 105	  
Figure 35. Relative enrichment for H3K27me3-marked loci among genes up- and down- 
regulated in CD19+ cells from Ring1a/Ring1b mutants. .................................................. 106	  
Figure 36. GC B cell development is impaired upon loss of Ring1a and Ring1b. ................ 108	  
Figure 37. GC B cell numbers are reduced upon PRC1 inactivation. ..................................... 108	  
Figure 38. Significant reduction of GC number in PRC1 mutants. ......................................... 109	  
Figure 39. Significant reduction in GC frequency in Ring1a/Ring1b mutants. ...................... 110	  
Figure 40. Status of the Ring1b gene in GC B cells from Ring1a-/-Ring1bfl/fl Cd23-cre mutant 
and control mice. ................................................................................................................ 111	  
Figure 41. Schematic view of the R26-EYFPfl-STOP reporter system. .................................. 112	  
 
 
11 
Figure 42. Ring1a-/-Ring1b-/- GC B cells are counter-selected in vivo. .................................... 113	  
Figure 43 . Schematic view of B cell development and timing of Cγ1-cre-mediated deletion.
 .............................................................................................................................................. 114	  
Figure 44. Efficiency of GC formation by Ring1a-/-; Ring1bfl/fl; Cγ1-cre animals is 
comparable to that of controls. .......................................................................................... 115	  
Figure 45. Status of the Ring1b gene in GC B cells from Ring1a-/-Ring1bfl/fl Cγ1-cre mutant 
and control mice. ................................................................................................................. 116	  
Figure 46. Schematic view of B cell development and timing of Aicda-cre-mediated deletion.
 .............................................................................................................................................. 116	  
Figure 47. Impaired GC formation in Ring1a-/-Ring1bfl/fl Aicda-cre animals. .......................... 117	  
Figure 48. Sera collection scheme for the analysis of primary and secondary antibody 
responses. ........................................................................................................................... 118	  
Figure 49. PRC1-deficient mice display an impaired antibody response. .............................. 119	  
Figure 50. PRC1-deficient mice display impaired recall resposes. ......................................... 120	  
Figure 51. Timeline for the analysis of memory B cell formation. .......................................... 120	  
Figure 52. Frequency of memory B cells in Ring1a-/-Ring1bfl/fl Cγ1-cre animals is lower  than 
that of controls. ................................................................................................................... 121	  
Figure 53. Frequency of memory B cells is lower in Ring1a/Ring1b mutants compared to 
controls. ............................................................................................................................... 122	  
Figure 54. Absence of Ring1a and Ring1b interferes with memory B cell formation. .......... 123	  
Figure 55. Increased apoptosis upon in vitro stimulation of Ring1a-/-Ring1b-/- cells. ........... 124	  
Figure 56. Apoptosis in GC B cells. ........................................................................................... 125	  
Figure 57. Increased frequency of apoptotic GC B cells upon lack of Ring1a and Ring1b. . 125	  
Figure 58. Loss of PRC1 leads to de-regulation of pro- and anti-apoptotic genes in GC B 
cells. ..................................................................................................................................... 126	  
Figure 59. Reduction in frequency of isotype-switched cells in Ring1a-/-Ring1b-/- cultures. 128	  
Figure 60. Lack of AID induction prevents apoptosis of Ring1a-/-Ring1b-/- cells. .................. 129	  
Figure 61. Loss of PRC1 leads to aberrant expression of cell cycle regulators. ................... 130	  
Figure 62. In vitro system to generate GC-like B cells from MACS-isolated naïve splenic B 
cells. ..................................................................................................................................... 131	  
Figure 63. Efficient deletion of Ring1b and loss of H2AK119Ub in the iGB culture system. 132	  
 
 
12 
Figure 64. Loss of Ring1a and Ring1b affects cell cycle progression in vitro. ..................... 133	  
Figure 65. Loss of PRC1 de-regulates expression of cell cycle regulators in vitro. ............. 134	  
Figure 66. De-regulation of Bcl-6 target genes in GC B cells following loss of PRC1. ......... 135	  
Figure 67. Ring1b and Bcl6 do not interact. ............................................................................. 136	  
Figure 68. Absence of Ring1a and Ring1b accelerates plasma cell development. .............. 138	  
Figure 69. Increased fraction of Irf4-expressing cells in GCs of mutant animals. ................ 138	  
Figure 70. Loss of PRC1 in GC B cells leads to de-repression of plasma cell fate 
determinants. ...................................................................................................................... 139	  
Figure 71. Expression of PRC1 members is modulated during B cell activation in vitro. ... 140	  
Figure 72. Premature appearance of CD138+ plasmablasts in LPS+IL-4-stimulated Ring1a-/-
Ring1b-/- cultures. ............................................................................................................... 141	  
Figure 73. Frequency of plasmablasts and plasma cells upon in vitro stimulation of  Ring1a-/-
Ring1b-/- cells. ..................................................................................................................... 141	  
Figure 74. Increased expression of plasma cell master regulators in mutant cells activated 
with LPS and IL-4. ............................................................................................................... 142	  
Figure 75. Plasma cells frequency in Ring1a/Ring1b mutants is comparable to that of 
controls. ............................................................................................................................... 143	  
Figure 76. . Plasma cell frequency is not affected by loss of Ring1a and Ring1b. ............... 144	  
Figure 77. Ring1a-/-Ring1b-/- plasma cells cells are counter-selected in vivo. ....................... 144	  
Figure 78. Counter-selection of Ring1b mutant cells upon induction of the plasma cell 
program. .............................................................................................................................. 145	  
  
 
 
13 
Index of Tables 
 
Table 1. Primers used for genotyping, annealing temperatures and amplicon sizes.
 ................................................................................................................................... 62 
Table 2. PCR Reagents ................................................................................................... 63 
Table 3. Genotyping PCR conditions. ........................................................................... 63 
Table 4. Antibodies used for flow cytometry. ............................................................... 67 
Table 5. ELISA reagents for total antibody titers detection of resting mice. ............. 72 
Table 6. ELISA reagents for antigen specific antibody titers detection of immunized 
mice. ......................................................................................................................... 73 
Table 7. Antibodies used for immunoblot protein detection. ..................................... 76 
Table 8. Primer sequences for quantitative PCR analysis. ......................................... 77 
Table 9. List of genes of the TaqMan® Microfluidic Cards. ........................................ 78 
   
 
 
14 
Abstract 
 
Polycomb (PcG) proteins are epigenetic modifiers that modulate accessibility of 
genomic loci by covalent modification of N-terminal histone tails. In mammals, PcG 
proteins act within at least two functionally and biochemically distinct complexes, 
named Polycomb repressive complex 1 and 2 (PRC1 and PRC2). Within PRC2, 
the Ezh2 methyltransferase is able to di- and tri-methylate lysine 27 of histone H3. 
This mark is recognized by chromodomain-containing PRC1 subunits. Once 
bound, PRC1 catalyzes monoubiquitination of lysine 119 of histone H2A, which 
results in permanent, yet reversible, and heritable locus silencing. PcG proteins 
modulate expression of genes involved in development, lineage specification and 
cell identity, and their deregulation leads to aberrant differentiation of a number of 
cellular lineages, including the hematopoietic subsets. Recently, independent 
studies on a number of PcG mutants have highlighted an essential contribution of 
the Polycomb system to homeostasis of the lymphoid lineage.  
Expression of Ring1a and Ring1b, the catalytic subunits of PRC1, is maintained 
throughout B cell development. Using a conditional gene targeting approach in 
vivo, we addressed their function in resting naïve B lymphocytes and in B cells 
participating in a T cell-dependent immune response.  Removal of a single subunit 
did not affect B cell development nor immune responses in mice. Instead, 
complete ablation of PRC1 function in B cells at early developmental stages 
resulted in a nearly complete block at the pro- to pre-B cell stage. Moreover, 
selective PRC1 inactivation in transitional B cells led to aberrant differentiation, 
with B cells acquiring features of mature cells while simultaneously retaining 
markers of earlier developmental stages. At the molecular level, loss of PRC1 in 
resting B cells read out in extensive transcriptional deregulation involving aberrant 
expression of several lineage determinants. Selective loss of Ring1a and Ring1b 
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in GC B cells caused a significant reduction in numbers and frequency of GC B 
cells. As a result of the impaired GC reaction, serum titers of antigen-specific, 
class-switched antibodies were significantly decreased and formation of memory B 
cells significantly impaired in mutant mice. Instead, mutant GC B cells showed 
premature onset of terminal differentiation, as assessed by the induction of genes 
coding for the master regulators of plasma cell differentiation Prdm1, Irf4 and 
Xbp1. This result was confirmed by performing in vitro LPS stimulation assays, 
which showed an accelerated appearance of plasmablasts co-expressing 
Syndecan-1/CD138 and high levels of the Irf4 transcription factor in Ezh2 mutant B 
cell cultures. Increased apoptosis of PRC1 mutant cells as compared to control 
was also observed in the context of in vitro B cell activation. Importantly, activation 
of B cells with the RP105 Toll-Like Receptor agonist, which does not induce 
expression of Activation Induced Deaminase (AID) normalized the apoptotic rate 
of PRC1 deficient cells to wild-type levels. Moreover, several target genes of the 
germinal center master regulator Bcl6 were found up-regulated in PRC1 mutant 
cells. Together, this suggests that PRC1 may support GC function through at least 
two mechanisms. On the one hand, it may co-operate in establishing Bcl6 
transcriptional program, thereby preventing premature terminal differentiation. On 
the other, it may participate in the repair of DNA damage caused by AID activity, 
thereby allowing tolerance of AID genotoxic activity by GC B cells.  
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 Introduction 
1.1. Chromatin and epigenetics 
1.1.1. Chromatin compaction and nucleosomes 
 
In each mammalian cell, DNA is wound up in the nuclear compartment, which is 
about 6 µm in size. Packaging of the DNA in such a restricted physical space is 
achieved thanks to the activity of specific proteins, named Histones (H), which 
bind to DNA and help its folding. Histones are a family of positively charged 
proteins that form a heptamer complex, each consisting of two subunits of 
Histones H2A, H2B, H3 and H4 around which 146 base pairs (bp) of negatively 
charged DNA are wrapped up. The complex of Histones and DNA is called 
nucleosome and represents the basic unit of chromatin. Nucleosomes 
interconnected by stretches of linker DNA form the so-called “beads-on-a-string” 
structure. Addition of Histone H1 leads to a higher degree of chromatin 
compaction, as the beads are pulled together on the string and coil into a helical 
structure known as the 30 nm fiber, or chromatosome. This packaging shortens 
the DNA molecule about 6-fold. Upon cell division, chromatin is further condensed 
and becomes visible under the microscope as chromosomes. This compaction 
level is achieved through mechanisms that are yet not fully understood (Kornberg 
and Lorch, 1999). Chromatin structure determines local chromatin accessibility, 
thereby affecting gene expression. Chromatin compaction is regulated in several 
ways, one of which is represented by post-translational modifications targeting the 
N-terminal region of Histones, which protrudes from nucleosomes. Such 
modifications include acetylation, phosphorylation, methylation, and ubiquitination, 
which do not only change the proteins’ biochemical properties, but also constitute 
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a “Histone code”, which is read by functional domains of chromatin-bound factors, 
including transcription factors (TFs). Because of their role in the modulation of 
gene expression, histone modifiers have received increasing attention over the 
last two decades (Strahl and Allis, 2000). 
 
1.1.2. Epigenetics 
 
In multicellular organisms, tissue and organ homeostasis rely on the correct 
functioning of a variety of differentiated cell types, each of which carries specific 
blueprints consisting of a specific set of genes that is turned on and off. Differential 
gene expression arising from a shared genome distinguishes for example 
fibroblasts from stem cells, determines signal responsiveness, secretory functions 
and defines cell identity. Research carried out over the last decade has highlighted 
the importance of epigenetic regulation in the establishment and maintenance of 
gene expression patterns. Epigenetic changes are defined as heritable, 
functionally relevant, modifications in the genome that do not alter the primary 
DNA sequence. Epigenetic changes may influence chromatin structure, 
determining whether genomic loci are comprised within the less compacted 
euchromatin (transcriptionally active conformation) or belong to the tighter 
heterochromatin (transcriptionally inactive). Furthermore, the heterochromatic 
state can be constitutive (stably repressed) or facultative (de-repressed upon 
certain conditions). 
In the present work, we focused our attention on dissecting in vivo the role of 
Polycomb group (PcG) protein family members and epigenetic regulators 
Rnf2/Ring1b and Ring1a in B-cell lymphopoiesis.  
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1.2. Polycomb group proteins 
1.2.1. Polycomb group proteins in life 
 
PcG proteins are evolutionarily conserved epigenetic silencers first identified in 
Drosophila melanogaster, where they were shown to be crucial for the 
specification of anterior/posterior body segmentation and axial patterning. Across 
evolution, genes encoding PcG proteins have diversified, with vertebrates 
exhibiting several homologs for each PcG protein encoded by the Drosophila 
genome (Sparmann and van Lohuizen, 2006). PcG proteins play crucial roles 
during development and in a wide variety of biological processes including cell 
cycle progression, apoptosis, response to DNA damage, DNA replication, X-
chromosome inactivation, genomic imprinting, regulation of stem cell function, 
establishment and restriction of cell identity and tissue homeostasis (Sparmann 
and van Lohuizen, 2006). The importance of the Polycomb axis in mammalian 
development is best underscored by the embryonic/perinatal lethality exhibited by 
several mouse PcG mutants including Eed (embryonic ectoderm development), 
Ezh2 (enhancer of zeste 2), Suz12 (Suppressor of Zeste 12 homolog), Rnf2 (Ring 
finger protein 2; Ring1b) and Bmi-1 (Bmi1 polycomb ring finger oncogene) 
(Voncken et al., 2003) (O'Carroll et al., 2001) (Pasini et al., 2004) (van der Lugt et 
al., 1994). PcG proteins exert their function in the context of functionally and 
biochemically distinct multimeric complexes, of which the best characterized and 
most extensively studied are Polycomb Repressive Complex 1 and 2 (PRC1 and 
PRC2). 
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1.2.2. Polycomb- mediated gene silencing 
 
In mammals, the currently accepted model for Polycomb function involves the 
concerted action of PRC1 ad PRC2 to achieve silencing of targeted genomic loci. 
According to this model, PRC2 acts first and modifies chromatin through the 
catalytic activity of the Ezh2 methyltransferase, which catalyzes di- and tri-
methylation of lysine-27 of Histone H3 (H3K27me2 and H3K27me3, respectively). 
Trimethylated Histone H3 serves then as a docking site for the chromodomain-
containing proteins family, whose components can function as PRC1 subunits. 
CBX-mediated recognition of H3K27me3 brings along PRC1, which catalyzes the 
monoubiquitination of lysine-119 of Histone H2A (H2AK119Ub) through the 
enzymatic action of its E3 ubiquitin ligases Ring1b and, to a lesser extent, Ring1a 
(Sparmann and van Lohuizen, 2006) (Figure 1). However, recent studies have 
challenged this model. For instance, the existence of a subset of PRC2 target 
genes that lack H2AK119Ub was reported (Ku et al., 2008). Conversely, it has 
been shown that PRC1 can function independently of PRC2 (Schoeftner et al., 
2006), (Sing et al., 2009). Furthermore, PRC1 has been reported to have 
chromatin-compacting activities that are independent of its catalytic function 
(Eskeland et al., 2010). Nevertheless, the majority of PcG target genes require 
activity of both PRC1 and PRC2 for stable gene repression (Ku et al., 2008).  
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Figure 1. Polycomb repressive complexes and their components. 
PcG proteins assemble into two main complexes: PRC1 and 2. Originally, PcG proteins 
were discovered in Drosophila, and several homologs have been found in mammals. 
Combinatorial heterogeneity of PRC1 is depicted by the availability of multiple Cbx 
subunits and the ability of Ring1a/b and Bmi-1 to assemble with other cellular 
components, too. Adapted from Margueron and Reinberg, Nature. 2011 Jan 20;469. 
 
 
1.2.3. Diversity of PRC1 complexes 
 
PRC1 is evolutionary more recent and biochemically and functionally more diverse 
than PRC2. The mammalian PRC1 is defined as a multi-subunit complex 
consisting of five core protein families, each of which consists of several members, 
namely chromobox proteins (Cbx2/4/6/7/8), Ring1 (Ring1A/B), Polyhomeotic-like 
(PHC 1/2/3), polycomb group ring finger 1 to 6 (PCGF 1-6) and Rybp/Yaf2 (Gao et 
al., 2012). Different combinations of these subunits can generate a diverse array 
of PRC1 sub-complexes, which are believed to exert their function in a tissue- and 
cell-specific manner. The catalytic activity of PRC1 resides in its Ring1 subunit and 
can be enhanced through binding to one of the PCGF orthologs (Gao et al., 2012) 
(Figure 2). Recent reports have described the existence of at least two PRC1 sub-
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complexes in embryonic stem cells (ESCs), which are distinguished based on the 
presence of either Rybp or one of the Cbx family members. Using a combination 
of high-throughput analyses, authors were able to show that PRC1/Rybp-bound 
genes tend to be more expressed than PRC1/Cbx7-bound ones. Additionally, it 
was shown that the PRC1/Rybp complex can bind chromatin in an H3K27me3-
independent fashion and Gene Ontology analyses revealed segregation of 
biological functions between the two complexes. Rybp-bound genes were mainly 
involved in cell cycle progression and metabolism regulation, whereas Cbx-bound 
ones primarily controlled developmental pathways (Tavares et al., 2012) (Yu et al., 
2012) (Morey et al., 2013). 
 
 
 
Figure 2. Diversity of PRC1 compexes. 
PRC1 is more heterogeneous than PRC2 due to the availability of several orthologs for 
each component (listed within light green squares in a), which can give rise to multiple 
PRC1 sub-complexes. In addition, PRC1 subunits can form non-canonical PRC1 
complexes with several cellular components as shown in b). Adapted from Turner and 
Bracken, Cell Stem Cell. 2013 Feb 7;12(2):145-6. 
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Adding to PRC1 complexity, recent studies have reported the association between 
PRC1 components and cell type-specific DNA-binding TFs. For instance, one of 
the PCGF homologs, Bmi-1, has been shown to associate with the Runx1/CBFβ 
TF on a subset of genomic targets in primary human thymocytes (Yu et al., 2012). 
Additionally, Ring1b was shown to participate in a complex with the B-cell 
CLL/lymphoma 6 (Bcl6) co-repressor Bcor, and to bind bona fide Bcl6 target 
genes in B lymphoma cells (Gearhart et al., 2006) (Sanchez et al., 2007). More 
evidence suggesting association between members of the PRC1 and cell-specific 
TFs has come from studies reporting association between the E2F family member 
E2F6 and PcG subunits (Attwooll et al., 2005) (Ogawa et al., 2002) (Trimarchi et 
al., 2001). Taken together, this supports a view of the PRC1 as a dynamic and 
plastic complex, whose subunit composition and association to specialized DNA 
binding proteins change in a cell-type- and stage-specific manner. 
 
1.2.4. PRC1, H2AK119Ub and chromatin silencing 
 
Histone modification and/or chromatin binding by PcGs correlate with repression 
of gene expression from targeted loci. Recent reports have started to shed light on 
the mechanisms through which epigenetic modifications imposed by PcG proteins 
read out into transcriptional repression. For PRC1, two separate classes of targets 
have been identified, namely those for which efficient silencing requires 
H2AK119Ub and those that are independent on E3 ligase activity for 
transcriptional repression. 
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1.2.4.1. H2AK119Ub and the transcriptional machinery. 
 
H2AK119Ub is catalyzed by the Ring1 subunits of PRC1. In embryonic stem cells 
(ESCs) and in the mouse embryos, PRC1 catalytic activity is largely carried out by 
Ring1b, as its depletion leads to genome-wide loss of H2AK119Ub and, in the 
case of the mouse embryo, in embryonic lethality (Voncken et al., 2003). This 
suggests that in these biological systems, Ring1a is not able to compensate for 
Ring1b loss of function (van der Stoop et al., 2008). Efficient ubiquitination also 
requires association of the Ring subunits with one of the 6 mammalian PCGF 
orthologs and with the Kdm2/Fbxl10 subunit (Wu et al., 2013). How deposition of 
H2AK119Ub is able to prevent gene transcription and whether this modification 
alone is sufficient to ensure silencing is unknown. A recent study suggests that 
H2AK119Ub may hamper transcriptional elongation rather than initiation by 
preventing switches in RNA polymerase II (RNA pol II) phosphorylation status. 
Upon Ring1b inactivation and subsequent H2AK119Ub depletion, RNA pol II 
switches from the paused phosphorylation status (phosphorylated serine-5 of the 
C-terminal domain, CTD) to the one associated with active transcription (serine-2 
phosphorylation on the CTD) on transcribed targets (Stock et al., 2007) (Dellino et 
al., 2004). 
1.2.4.2. Chromatin compaction. 
 
Evidence for PRC1-mediated chromatin compaction has come from studies 
showing decreased filament size when naked DNA was incubated with Pho-PRC1 
(Francis et al., 2004). PRC1-compacted chromatin was shown to be resistant to 
remodeling activity mediated by the SWI/SNF complex (Francis et al., 2004). 
Importantly, chromatin compaction imposed by PRC1 was independent of its 
catalytic activity, as it was not affected in ESCs expressing a catalytically mutant 
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form of Ring1b (Eskeland et al., 2010). So far, the only PRC1 subunit able to 
compact chromatin was shown to be CBX (Grau et al., 2011). This observation 
may provide a link between H3K27me3 and chromatin compaction, as CBX 
contains chromodomains responsible for recognition of the H3K27me3 histone 
mark. 
Together, this shows that Polycomb-mediated gene silencing is achieved through 
several, in part redundant, mechanisms. Recent evidence by our lab (Caganova et 
al., 2013) showed the existence of bivalent domains, namely loci simultaneously 
displaying activating and repressing chromatin marks, in differentiated somatic 
cells  (see paragraph 1.2.6. for a more detailed description of bivalent domains). 
Bivalent domains were found on genes whose activation status critically defined 
the cell’s fate.  
Such evidence allows to speculate that Polycomb silencing may differ depending 
on the nature of the targeted locus. In case of loci in the need of stable repression 
(i.e. lineage-inappropriate genes), Polycomb may compact chromatin leading to 
formation of constitutive heterochromatin, thereby locking genes in highly 
condensed regions. Instead, if loci contain genes that need to be kept poised for 
future activation (i.e. genes likely to be activated following exposure to 
environmental stimuli), Polycomb may limit its activity to transcriptional silencing 
through inhibition of the activity of RNA pol II. However, more studies on local 
chromatin architecture and its changes during development are needed to clarify 
this issue. 
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1.2.5. Targeting Polycomb activity to the appropriate genomic 
loci. 
 
PcG proteins are crucial in both the establishment and maintenance of cell-type-
specific gene expression profiles. How PcG proteins are dynamically targeted to 
their respective target sites in a cell- and stage-specific fashion has been long 
studied and definitive answers are still missing. In Drosophila, Polycomb targeting 
is accomplished thanks to the presence of DNA sequences known as Polycomb 
Response Elements (PREs), which map many kilobases away from promoters 
they control and which bind several sequence-specific binding proteins, among 
which the Polycomb member Pleiohomeotic (PHO). Binding of PHO to Drosophila 
PREs is necessary for PcG complex recruitment and effective gene 
silencing(Bloyer et al., 2003; Ringrose et al., 2003). In mammals, multiple modes 
of Polycomb targeting have been proposed. 
 
1.2.5.1. PcG proteins bind specific DNA elements 
 
In ESCs, genome-wide mapping of PRC2 occupancy has led to the identification 
of GC-rich regions within CpG islands as preferred binding sites for PRC2. DNA 
methylation and presence of binding sites for transcriptional activators prevented 
PRC2 binding, suggesting a role for DNA methylation in regulating PRC2-
chromatin interactions (Hunkapiller et al., 2012; Ku et al., 2008) (Dietrich et al., 
2012). Further evidence for a role for CpG islands in PcG recruitment was recently 
provided by studies showing their involvement in recruitment of PRC1 in a PRC2-
independent fashion. Work carried out in Klose’s group has shown that 
Kdm2b/Fbxl10 subunit co-localizes with Ring1b on CpG-rich DNA regions in ESCs 
and mediates PRC1 recruitment. Recent studies in Helin’s group have confirmed 
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and extended work by Klose and colleagues showing that Kdm2b/Fbxl10 interacts 
with a PRC1 complex including Ring1b and NSPc1 and binds DNA through its 
CXXC domain (Wu et al., 2013). Genome-wide analysis of Kdm2b/Fbxl10 
occupancy in ESCs confirmed enrichment at un-methylated CpG islands. 
Interestingly, Kdm2b/Fbxl10 was shown to bind both active and silenced gene loci, 
but co-localization with Ring1b was observed only on the latter class of targets. 
Additionally, it was shown that Kdm2b/Fbxl10 is required for efficient ubiquitination 
of H2A, which was necessary to sustain ESC pluripotency (Farcas et al., 2012; Wu 
et al., 2013). Together, these studies support a model whereby Kdm2b/Fbxl10 
favors PRC1 recruitment and hence H2A ubiquitination at CpG-containing target 
genes in ESCs. 
 
1.2.5.2. PcG proteins interact with DNA-binding proteins 
 
It is becoming increasingly evident that PcG targeting to genomic sites is 
contributed by the direct interaction between PRCs and ubiquitous or cell-type-
specific transcriptional regulators. Recent studies have revealed an association 
between the transcriptional repressor Jarid2 and PRC2 in ESCs. Jarid2 is a 
catalytic- dead member of the Jumonji (Jmj) domain-containing family of lysine 
demethylases with DNA-binding activity. Jarid2 was reported to co-localize with 
PRC2 at 90% of PcG targets in ESCs and its loss correlated with decreased 
recruitment of PRC2 to chromatin and impaired differentiation (Landeira et al., 
2010) (Pasini et al., 2010) (Shen et al., 2009). However, Jarid2 inactivation did 
neither result in substantial changes in the genome-wide distribution of H3K27me3 
nor did it lead to a significant up-regulation of PRC2 silenced genes, which is 
instead a common feature of PcG mutants (Landeira et al., 2010). While Jarid2 
was reported to modulate Ezh2 methyltransferase activity, the effects of such 
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regulation on Ezh2 silencing function remain unclear (Herz and Shilatifard, 2010). 
The current model based on experimental data supports the idea that Jarid2 is 
instrumental for the fine-tuning of PRC2 activity rather than for its recruitment to 
chromatin. A marginal role for the recruitment of PRC2 to target sites has been 
proposed for the accessory Polycomb-like (PCL) subunits, which in mammals are 
represented by Pcl1, Pcl2 and Pcl3. PCLs were first defined as factors able to 
boost Ezh2 catalytic activity. The finding that PRC2 occupancy on the inactive X-
chromosome decreases following PCL2 depletion provided the first indication of 
the involvement of PCL subunits in PRC2 recruitment (Casanova et al., 2011). 
Further evidence came from studies in ESCs, where depletion of PCL3 resulted in 
loss of PRC2 binding at most genomic targets and in genome-wide H3K27me3 
loss. Interestingly, PCL2 inactivation had minor effects in ESCs (Hunkapiller et al., 
2012) (Walker et al., 2011). Together, these results point to non-redundant 
functions exerted by the two PCLs in ESCs. Both PRC2 and PRC1 have been also 
shown to interact with E2F6, YY1 and SNAIL1, which may provide sequence 
specificity to PcG recruitment (Trimarchi et al., 2001) (Ogawa et al., 2002) (Brown 
et al., 1998) (Caretti et al., 2004) (Herranz et al., 2008). Accumulating evidence 
indicates the existence of PRC1-like complexes recruited to target sites in the 
absence of H3K27me3 (Gearhart et al., 2006) (Yu et al., 2012) (Sanchez et al., 
2007). 
Finally, the interaction of PcG proteins with cell-type-specific TFs provides insights 
into the relatively unexplored mechanism of TF-mediated chromatin remodeling. 
 
1.2.5.3. PcG proteins associate with non-coding RNAs 
 
Non-coding RNAs (ncRNAs) have been shown to play an important role in 
Polycomb recruitment both in cis and trans. One of the first ncRNAs for which 
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interaction with PcG proteins was reported is X-inactive specific transcript (Xist). 
Xist binds to Ezh2, and this binding is required for the deposition of H3K27me3 on 
the inactive X-chromosome (Plath et al., 2003). Following Xist, other ncRNAs have 
been shown to bind PcG components and affect PcG-mediated gene silencing 
(Zhao et al., 2010). HOTAIR, a ncRNA transcribed from the HOXC locus binds to 
and targets PRC2 to the HOXD locus and few other genomic loci to achieve 
transcriptional silencing. Additionally, HOTAIR deregulation in epithelial cancer 
cells leads to PRC2 re-localization and changes in H3K27me3 levels, which 
ultimately influence cancer invasiveness and metastasis (Rinn et al., 2007) (Gupta 
et al., 2010). An example of ncRNA-mediated control of PcG function in cis is 
provided by ANRIL, which is transcribed from the Cdkn2a locus. Two independent 
studies showed that ANRIL binds to Cbx7 and Suz12, and ANRIL depletion leads 
to defective H3K27me3 deposition and Cdkn2a de-repression (Yap et al., 2010) 
(Kotake et al., 2011). Taken together, multiple mechanisms account for PcG 
targeting to specific genomic loci. The contribution of each of these mechanisms is 
likely to vary depending on the cellular context. 
 
1.2.6. Polycomb in development and lineage commitment 
 
ESCs are derived from the mammalian embryo inner cell mass at the blastocyst 
stage. ESCs can be kept in culture in an undifferentiated state and have been 
widely used to unravel molecular mechanisms underlying cell fate transitions 
occurring during early stages of mammalian development. ESCs are endowed 
with the opposing abilities to self-renew, thereby guaranteeing the maintenance of 
an undifferentiated state, and to undergo multi-lineage differentiation upon 
appropriate stimulation. Therefore, the genome of ESCs needs on the one hand to 
preserve a pluripotency-specific gene expression pattern, while on the other it 
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requires the ability to respond quickly to a plethora of differentiation stimuli. A large 
body of evidence has pointed at seminal roles played by epigenetic modifiers, 
including PcG proteins, in the regulation of these processes. In ESCs, PcG 
proteins share target occupancy with Sox2, Nanog and Oct4, whose activity is 
essential for the maintenance of pluripotency (Boyer et al., 2005; Lee et al., 2006) 
(Boyer et al., 2006).  Evidence showing that deprivation of Oct4 from ESCs results 
in Suz12 loss at specific promoters suggests a possible role for these transcription 
factors in PcG recruitment (Squazzo et al., 2006). Genome-wide studies in ESCs 
have reported the existence of “bivalent domains”, namely genomic loci, often 
encoding for critical lineage determinants, that display simultaneous presence of 
activating (H3K4me3) and repressing (H3K27me3) chromatin marks in proximity of 
the transcriptional start site (TSS). Bivalent promoters are characterized by RNA 
pol II binding and minimal transcriptional activity. It has been suggested that 
bivalency poises genes for activation and is resolved once ESCs receive a 
differentiation signal into two alternative ways: i) H3K27me3 is removed and the 
target gene marked now only by H3K4me3 is transcriptionally activated, or ii) 
H3K4me3 is removed while H3K27me3 is retained, which leads to stable gene 
repression. However, this model has been challenged by recent studies on ESCs 
lacking H3K4me3 (Hu et al., 2013).   PcG inactivation in ESCs causes bivalent 
genes, including lineage determinants, to be aberrantly expressed, which 
contributes to abnormal differentiation and, in some instances, to impaired 
proliferation (Bernstein et al., 2006; Roman-Trufero et al., 2009). 
Polycomb targets often control early developmental steps involved in axial 
patterning and organogenesis. The PcG axis modulates also critical signal 
transduction pathways (TGFβ, Wnt), which are active during gastrulation and 
lineage commitment (Boyer et al., 2006). 
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1.2.7. Polycomb function in post-natal life  
 
In addition to their role in embryonic development, a growing body of evidence 
implicates PcG proteins in the homeostasis of adult stem cells and in the 
differentiation of lineage-committed precursors. PcG proteins exert their function 
through the regulation of essential cellular processes including cell proliferation, 
survival and differentiation.  
 
1.2.7.1. PcG proteins regulate cell cycle progression and survival 
 
A growing body of evidence implicates PcG proteins in the control of cell cycle 
progression. PcG proteins exert their function regulating the checkpoint that 
enables cells to transit from G1 to S.  The latter transition is under the control of 
the retinoblastoma tumor suppressor protein 1 (Rb1), which regulates the E2F 
transcription factor and thereby initiation of DNA replication. In its hypo-
phosphorylated form, Rb1 prevents S phase entry by interacting with E2F. Upon 
mitogenic stimulation, Rb is phosphorylated by cyclin-dependent kinase 4 (Cdk4), 
causing E2F factors to be released. The latter event leads to E2F-dependent 
activation of a substantial number of target genes, including several necessary for 
DNA replication (Nevins, 2001). Polycomb genes Ezh2 and Eed are directly 
targeted by E2F transcriptional activation and facilitate proliferation of both normal 
and cancer cells (Bracken et al., 2003). Both PRC1 and PRC2 regulate the 
transcription of several cyclin-dependent kinase inhibitors (Cdkn), including 
Cdkn1a/ p21CIP1, Cdkn2a, which encodes for p16INK4A and p19ARF and 
Cdkn2b/p15INK4B (Jacobs et al., 1999). p21CIP1 and p16INK4A exert their roles by 
binding to Cdk4 and inhibiting its activity. Instead, p19ARF binds to and antagonizes 
the activity of MDM2, thereby stabilizing p53 expression that can ultimately induce 
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cell cycle-arrest or apoptosis (Sherr, 2001). By modulating the functions of cell 
cycle inhibitors, PcG proteins also regulate cellular senescence. Senescence is 
defined as a permanent arrest at the G0 phase of the cell cycle, usually resulting 
from excessive telomere shortening and/or irreparable DNA damage (Campisi and 
d'Adda di Fagagna, 2007). Entry into senescence was shown to coincide with 
dissociation of PRC complexes from the Cdkn2a locus. Accordingly, deprivation of 
PcG members accelerates cellular senescence, while their overexpression inhibits 
its bypass (Agherbi et al., 2009).  
The role of PcG proteins in the regulation of apoptosis is not fully understood. 
Genes coding for the pro-apoptotic factors Phorbol-12-myristate-13-acetate-
induced protein (Pmaip1/Noxa) and BCL2-like 11 (Bcl2l11) are direct targets of 
Polycomb (Yamashita et al., 2008) (Wu et al., 2010). Additionally, both PcG 
complexes repress the locus encoding the p19Arf tumor suppressor, which 
induces p53-dependent apoptosis (Kamijo et al., 1998) (Zhang et al., 1998). The 
involvement of PRC1 in the regulation of p53-dependent apoptosis came from 
studies in hematopoietic stem cells, where loss of the PRC1 component Bmi1 
results in proliferative arrest and p53-dependent cell death (Park et al., 2003). 
Moreover, two independent studies have recently reported a role for Ring1b in the 
regulation of p53-dependent apoptosis in germ cell tumors. Specifically, it was 
shown that Ring1b interacted directly with Mdm2 and p53 to induce Mdm2-
dependent p53 ubiquitination and degradation. Conversely, loss of Ring1b 
resulted in p53 stabilization and induction of apoptosis (Su et al., 2013) (Wen et 
al., 2013). Of note, Bmi1-/- memory T cells undergo apoptosis in a Cdkn2a-
independent manner, primarily as a result of Pmaip1/Noxa up-regulation 
(Yamashita et al., 2008). 
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1.2.7.2. Polycomb group proteins and DNA damage 
 
Chromatin accessibility influences the cellular response to genotoxic damage (Sulli 
et al., 2012). The DNA damage response (DDR) features DNA lesion sensing, 
checkpoint activation, cell cycle arrest, transduction of the damage signal and 
ultimately assembly of the repair machinery. Successful DDR allows cell cycle 
resumption, while failure to repair DNA damage leads to senescence or apoptosis. 
The DDR relies on the sequential recruitment of several proteins to sites of DNA 
damage, whose activity is regulated by post-translational modifications (d'Adda di 
Fagagna, 2008; Sulli et al., 2012) (Figure 3). Mounting evidence implicates PcG 
proteins as regulators of the DDR in mammalian cells. 
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Figure 3. Simplified view of the DNA damage repair pathways. 
Following DNA damage induction from various agents, DNA damage sensing is thought to 
be mediated by the MRN complex, the Rad complex and ssDNA (single stranded DNA) 
binding protein protein Rpa and its partner Atrip. Sensing of DNA damage results in 
phosphorylation and activation of the crucial ATM and ATR kinases, which in turn activate 
Chek1 and Chek2. This leads to the recruitment of effector molecules that mediate DNA 
repair, transcriptional regulation, chromatin remodeling, DNA replication, cell cycle control 
and apoptosis, among which CDC25 and p53. Adapted from Sulli, G. et al., Nat Rev 
Cancer. 2012 Oct;12(10):709-20. 
 
Upon DNA damage induction, PRC1 components Ring1b, Bmi-1 and Cbx subunits 
are rapidly recruited to sites of DNA damage (Ginjala et al., 2011), (Ismail et al., 
2010). The mechanism mediating recruitment of PRC1 components to chromatin 
is not fully understood. Once recruited to sites of damage, Ring1b and Bmi-1 
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mediate ubiqutination of Histone H2AX, which is required for DDR activation. In 
accordance with this, cells devoid of Bmi-1 display increased sensitivity to ionizing 
radiation and genotoxic insults (Facchino et al., 2010; Ginjala et al., 2011; Ismail et 
al., 2010). In addition to PRC1 members, Ezh2 and H3K27me3 binding at sites of 
DNA damage has been documented, and removal of PRC2 components increases 
cells sensitivity to ionizing radiation (Facchino et al., 2010) (Chou et al., 2010) 
(Caganova et al., 2013). Ezh2 was shown to be required to mediate 
phosphorylation of Chek1 and suppress p21 degradation, which is necessary to 
maintain cell cycle arrest rather than apoptosis (Wu et al., 2011). Therefore, 
current evidence suggests that PcG proteins favor DDR by distinct mechanisms, 
which include suppression of transcription at sites of DNA damage, DDR factor 
recruitment and contribution to the repair process. 
 
 
1.2.7.3. Polycomb proteins in hematopoiesis 
 
Hematopoietic stem cells (HSCs) are multipotent cells endowed with the ability to 
self-renew and differentiate into all blood cell types. Similarly to ESCs, HSCs carry 
bivalent domains at promoters of lineage-specific TFs poised for expression (or 
stable repression) once HSCs differentiate into a particular type of blood cell (Cui 
et al., 2009). The essential role of the Polycomb axis in hematopoiesis is 
underscored by several studies reporting hematologic dysfunctions in mouse PcG 
mutants (Cales et al., 2008; Su et al., 2003; van der Lugt et al., 1994). Expression 
of the PRC1 component Bmi-1 is high in HSCs, while it decreases upon 
differentiation, suggesting a role in HSCs. Indeed, Bmi-1-/- mice, while displaying 
unaffected fetal hematopoiesis, experience severe progressive post-natal anemia 
due to progressive HSC exhaustion (van der Lugt et al., 1994). Bmi-1-/- HSCs are 
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unable to support long-term hematopoietic reconstitution due to a failure to self-
renew. Bmi-1-dependent control of HSCs self-renewal is mainly achieved through 
repression of the Cdkn2a locus (Park et al., 2003). Indeed, Bmi-1 deficient HSCs 
display increased levels of both p16INK4A and p19ARF, which results in cell-cycle 
arrest and p53-dependent apoptosis (Park et al., 2003). Bmi-1 has also been 
implicated in the control of mitochondrial function, as it was observed that Bmi-1-/- 
cells display increased levels of reactive oxygen species (ROS) and sustained 
activation of the DDR pathway. Notably, Chk2 deletion was able to rescue many of 
the defects observed in Bmi-1-deficient mice, and, hence, to improve their survival. 
In particular, the rescue was primarily beneficial to very early hematopoietic 
progenitors (Liu et al., 2009). This suggests that, in addition to de-repression of the 
Cdkn2a locus, also hyper-activation of the DDR pathway plays a role in HSC 
dysfunction following Bmi-1 inactivation. In addition to loss of self-renewal ability, 
Bmi-1-/- HSCs display premature expression of the B cell lineage developmental 
regulators Ebf1 and Pax5 and their downstream target genes (Oguro et al., 2010). 
Taken together, Bmi-1 activity is crucial to ensure HSC maintenance by restricting 
proliferation and lineage differentiation, thereby supporting self-renewal. The 
function of other PRC1 components in the hematopoietic system has also been 
addressed. Inactivation of Mel-18 in mice resulted in decreased bone marrow (BM) 
cellularity, with the lymphoid compartment being predominantly affected. This was 
due to impaired proliferation of lymphocyte progenitors in response to interleukin 7 
(IL-7), suggesting a role for Mel-18 in cell cycle progression (Akasaka et al., 1997). 
Another study reported that loss of Mel-18 results in increased HSC self-renewal 
(Kajiume et al., 2004). This suggests that Mel-18 deficiency may have different 
functions depending on the state of differentiation. Analogously, selective Ring1b 
inactivation in mouse HSCs resulted in overall BM hypoplasia, with a concomitant 
enlargement of the fraction of lineage-negative (Lin-) cells. Ring1b was shown to 
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restrict progenitor’s cell proliferation by inhibiting cyclin D2 (Ccnd2) expression and 
to support expansion of lymphoid and myeloid-committed progeny through 
repression of the Cdkn2a locus (Cales et al., 2008). 
The function of PRC2 components in the regulation of the early stages of 
hematopoiesis remains controversial. Ezh2 loss-of-function studies did not reveal 
alteration in HSC homeostasis nor myeloid development. Instead, these studies 
revealed that loss of Ezh2 resulted primarily in impaired B- and T-cell 
development, as a result of inefficient VDJ recombination (Su et al., 2003). On the 
other hand, over-expression of Ezh2 prevents HSC exhaustion during serial 
transplantation. Similarly, loss of Eed and Suz12 enhances the proliferative 
capacity of HSCs (Majewski et al., 2008; Neff et al., 2012; Tanaka et al., 2012). 
Overall, this shows that removal of PcG activity affects HSC homeostasis, with 
different, and sometimes opposing, outcomes depending on the stage of 
differentiation where PcG function is lost and the specific PcG component that is 
inactivated. 
 
1.2.7.4. Polycomb proteins and lymphocyte development 
 
Accumulating evidence implicates several members of the Polycomb family in the 
regulation of lymphocyte development. Indeed, as previously mentioned, 
conditional ablation of Ezh2 results in impaired rearrangement of immunoglobulin 
(Ig) genes, resulting in B cell lymphopenia and severe immunodeficiency (Su et 
al., 2003). Members of the PRC1 have also been implicated in early steps of B cell 
development, with Mel-18 dictating mitotic response to IL-7 stimulation (Akasaka 
et al., 1997). Mel-18 was also reported to prevent proliferation of mature B cells 
following B cell receptor (BCR) stimulation through the failure to induce c-MYC 
expression (Tetsu et al., 1998). This suggests that Mel-18 fulfills different functions 
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depending on the differentiation state of the B cell. Additionally, it has been long 
known that Polycomb proteins are expressed in mature B cells, in particular upon 
recruitment into an immune response (Raaphorst et al., 2000b). Moreover, 
deregulated expression of PRC1 and PRC2 members is commonly detected in 
human Hodgkin and Non-Hodgkin B cell lymphomas arising from mature B cells 
(Raaphorst et al., 2000a; van Kemenade et al., 2001). Recently, our group has 
shown that Ezh2 function is crucial to prevent premature terminal differentiation of 
mature B cells. This regulation is manly exerted through the direct repression of 
the PC determinants Blimp1 and Irf4 (Caganova et al., 2013). In agreement with 
data from our lab showing a critical role for Ezh2 in mature B cells recruited into 
the germinal center reaction (Caganova et al., 2013), recent studies have reported 
relevant frequencies of Ezh2 gain-of-function mutations in human follicular and 
large B cell lymphoma that originate from GC B cells (FL and DLBCL, respectively) 
(Morin et al., 2010). Importantly, inhibition of Ezh2 by recently identified small 
molecule inhibitors has been proposed as a novel therapeutic target for the 
treatment of Non-Hodgkin lymphomas featuring Ezh2-activating mutations 
(McCabe et al., 2012). While evidence is available concerning the role of PRC2 in 
early and late B lymphocyte development, fewer studies have addressed the role 
of PRC1 in the same processes. In particular, to our knowledge there has been yet 
no functional dissection of the role of PRC1 in peripheral B cell maturation and B-
cell responses. Therefore, the present study has primarily focused on the 
understanding of PRC1 function in resting mature B cells and in terminal 
differentiation.  
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1.3. B cell development 
 
B cell development is a tightly controlled process whereby HSCs undergo 
stepwise proliferation and differentiation to ultimately generate functional, non-
autoreactive cells (Figure 4). Research carried out over the past decades has 
dissected the main molecular events underlying B lineage specification, which now 
allow high-resolution investigations of processes that instruct each differentiation 
step. 
 
 
 
Figure 4. Schematic view of B cell development. 
Post-natal B cell development starts in the BM, where CLPs give rise to pro-B cells that 
start VDJ recombination. Upon expression of a functional surface Ig, they leave the BM 
and transit to secondary lymphoid organs. The three major mature B cell subsets are 
follicular (FO), marginal zone (MZ) and B-1 B cells. MZ and B-1 B cells are mainly 
devoted to the production of low-affinity antibodies by differentiating into antibody-
secreting plasma cells following pathogen encounter. FO B cells are instead mainly 
recruited in T cell-dependent antigen responses. Following antigen encounter and 
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supported by T cell help, they form germinal centers (GC), which feature robust B cell 
proliferation, Ig gene mutations, selection of high-affinity Ig mutants and eventually their 
terminal differentiation. The GC reaction aims at producing high-affinity Ig-expressing 
memory B cells and plasma cells secreting high-affinity antibodies for the cognate antigen. 
 
 
1.3.1. Early B cell development 
 
In mice and humans, the early steps of B cell development take place in the BM, 
where HSCs start a stepwise developmental path featuring progressive loss of 
multilineage differentiation potential. In order to give rise to lymphocytes, HSCs 
first differentiate into multipotent progenitors (MPP), which are characterized by 
loss of self-renewal ability. Together, the pool of HSCs and MPP are characterized 
by lack of lineage determinants, high expression of stem cell antigen-1 (Sca-1)hi 
and the protein tyrosine-kinase receptor Kit. They are commonly referred to as the 
LSK subset (Ikuta and Weissman, 1992; Li and Johnson, 1995). Loss of self-
renewal ability coincides with expression of FMS-related tyrosine kinase 3  (FLT3), 
which is dependent on the Ikaros (IKZF1) and PU.1 TFs. FLT3 expression is 
believed to mark the first commitment of progenitors towards the lymphoid lineage, 
as its overexpression decreases the differentiation of MPP into megakaryocytes 
and erythrocytes (Adolfsson et al., 2001; Adolfsson et al., 2005; Forsberg et al., 
2006; Yoshida et al., 2006). In response to Flt-3 ligand and IL-7 stimulation, MPPs 
start expressing early B cell factor 1 (Ebf1) and the TF E2a, which mark the entry 
into the common lymphoid progenitor (CLP) pool (Medina et al., 2004; Nutt and 
Kee, 2007). Further exposure of CLPs to IL-7 yields up-regulation of Paired box 
protein 5 (Pax5), which marks the definitive commitment towards the B cell lineage 
(Hagman and Lukin, 2006; Lin and Grosschedl, 1995; Sun, 2004). 
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1.3.1.1. V(D)J recombination. 
 
The ability of lymphocytes to exert their protective functions relies on the 
expression of diversified immunoglobulin (Ig) molecules on the surface of B and T 
cells, namely the B and T cell receptor (TCR) respectively, which mediate 
pathogen recognition. The BCR consists of two identical Ig heavy (H) and light 
chains (L) assembled together via disulfide bonds. Each Ig chain consists of a 
variable region responsible for the recognition of antigen and a constant region, 
which mediates the effector function of the receptor. The variable region of the 
receptor is generated via a gene rearrangement process termed VDJ 
recombination, whereby starting from an array of gene segments, a unique 
variable (V), diversity (D) and joining (J) gene segments are joined together (only 
V and J segments are joined to yield the IgL chain) (Tonegawa, 1983). VDJ is 
dependent on the activity of the gene products of the Recombination Activating 
Genes 1 and 2 (RAG1 and RAG2) (McBlane et al., 1995; Melek et al., 1998; van 
Gent et al., 1995). RAG proteins bind to and cleave DNA at specific recombination 
signal sequences (RSSs) flanking each V, D and J gene segment (Eastman et al., 
1996). Through the action of RAG proteins V, D and J gene segments are brought 
in close proximity and ultimately joined by components of the classical non-
homologous end joining (NHEJ) repair pathway (Difilippantonio et al., 2000; Li et 
al., 1995) (Figure 5). 
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Figure 5. V(D)J recombination at Ig heavy chain locus. 
The variable region of the IgH chain is assembled from variable (VH), diversity (DH), and 
joining (JH) gene segments by V(D)J recombination. The process of rearrangement 
involves cleavage of the recombination signal sequences (RSS) in the DNA, which flank 
the rearranging gene segments, by the RAG1 and RAG2 enzymes. Joining of the DNA 
ends requires non-homologous end-joining (NHEJ) proteins, including Ku70, Ku80, 
ARTEMIS, X-ray repair cross-complementing protein 4 (XRCC4), DNA ligase IV and the 
catalytic subunit of DNA-dependent protein kinase (DNA-PKcs). Transcription of the 
rearranged locus is driven by an upstream promoter (blue arrow). Adapted from Chauduri 
and Alt, Nat Rev Immunol. 2004 Jul;4(7):541-52. 
 
 
V(D)J is a highly regulated process, which involves introduction of DNA DSBs and 
deletion of large genomic segments. Chromatin accessibility and regulation of 
RAG expression are central mechanisms that modulate V(D)J recombination 
(Johnson et al., 2004; Morshead et al., 2003; Osipovich et al., 2004). Upon 
successful VDJ recombination, a pre-BCR complex is assembled on the cell 
surface, which consists of the newly rearranged IgH chain and a surrogate IgL 
chain. Signaling through the pre-BCR inhibits further rearrangement at the IgH 
locus, a process which is called allelic exclusion, whereas it stimulates clonal 
expansion of pre-B cells (Gorman and Alt, 1998). Following clonal expansion, pre-
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B cells exit cell cycle and rearrange their IgL chain genes. Successful pairing of 
IgH and IgL chains to form a functional BCR marks the transition from pre-B to 
immature B cells. Should these cell fail to express an auto-reactive BCR, they are 
allowed to leave the BM and migrate to secondary lymphoid organs to complete 
their maturation (Rajewsky, 1996). 
 
1.3.2. Peripheral B cell development. 
 
1.3.2.1. Transitional B cells. 
 
Once released from the BM, B cells migrate to the spleen as “so-called” 
transitional B cells (Allman et al., 1992) (Allman et al., 1993). While uniformly 
retaining expression of the early differentiation markers AA4.1/CD93 and the Heat 
Stable Antigen (HSA)/CD24, transitional B cells are divided into two main subsets 
based on expression of additional surface molecules. T1 B cells are defined as 
IgMhi,IgD-,CD21-,CD23-, while T2 B cells, the direct precursors of the long-lived 
mature B cell pool, acquire expression of IgD, CD21 and CD23 (Norvell and 
Monroe, 1996) (Loder et al., 1999) (Figure 6). An additional subset named T3, 
resembling T2 cells except for lower surface IgM expression, has been described, 
but its origin function remain poorly understood (Allman et al., 2001a). Within the 
spleen, T1 cells localize to the outer zone of the periarteriolar lymphoid sheath 
(PALS) (Liu, 1997). Here, they are in close proximity to macrophages, which 
engulf self-reactive, negatively selected lymphocytes. T2 cells, on the contrary, 
reside in B cell follicles (Loder et al., 1999) (Liu, 1997). Besides residing in 
different splenic areas, T1 and T2 cells are also functionally distinct. T1 B cells 
retain sensitivity to negative selection and are driven into apoptosis upon BCR 
engagement due to failure to up-regulate pro-survival molecules and progress in 
 
 
43 
the cell cycle (Chung et al., 2002; Norvell et al., 1995). T2 B cells, on the contrary, 
acquire sensitivity to T helper cell-derived survival signals and respond to BCR 
engagement with proliferation and survival rather than apoptosis (Chung et al., 
2002)(Figure 6). In vivo bromodeoxyuridine (BrdU) labeling studies revealed rapid 
turnover of transitional B cells, including T2 cells, as compared with the mature B 
cell compartment. This reflects a shorter life-span of transitional B cells (1-4 days) 
in comparison with mature B cells (80-120 days) (Allman et al., 1993). At the 
molecular level, the B cell activating factor (BAFF/TNFSF13B/BLyS/TALL1) plays 
a major role in sustaining the transition from the transitional to the mature B cell 
compartment. Indeed, B cell-specific ablation of BAFF or its receptor, BAFF-R, 
resulted in impaired development beyond the T1 stage (Sasaki et al., 2004; 
Schiemann et al., 2001). 
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Figure 6. Schematic view of peripheral B cell development. 
Upon exit from the BM, newly formed T1 B cells undergo negative selection aimed at 
purging the system from auto-reactive B cells. Non-autoreactive T2 B cells are then driven 
towards the FO, MZ or B-1 fate depending on expression of specific TFs. Markers used 
for immunophenotipic characterization of each developmental stage are listed. 
 
 
1.3.2.2. Mature B cell subsets 
 
In the mouse, mature B cells comprise three major phenotypically and functionally 
distinct subsets represented by Follicular (FO), Marginal Zone (MZ) and B1 B cells 
(Casola, 2007). 
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FO B cells  
Also called B2 B cells, they are the most abundant mature B cell subset present in 
secondary lymphoid organs. Identified as IgMhiIgDhiCD21loCD23+, FO B cells are 
endowed with the ability to recirculate through B cell areas of the spleen, lymph 
nodes (LNs) and mucosa-associated lymphoid tissues. FO B cells are the main 
mediators of T cell-dependent immune responses, although they can also take 
part to T cell-independent responses (Casola, 2007). 
 
MZ B cells   
MZ B cells are identified as IgMhiIgD-CD21hiCD23lo. They consist of a self-
replenishing subset residing in the spleen in close proximity to the marginal sinus. 
MZ B cells capture and transport antigens in the form of immune complexes to FO 
B cells residing in the nearby splenic follicle. MZ B cells respond to BCR-mediated 
recognition of blood-borne pathogens by rapidly proliferating and differentiating 
into plasma cells (PC) secreting low-affinity antibodies in a T-cell independent 
manner (Cinamon et al., 2008; Martin and Kearney, 2002; Song and Cerny, 2003).  
B-1 B cells  
This mature B cell subset, identified as IgMhiIgD-B220loCD19hiCD23lo, mainly 
resides in body cavity sierosa. Based on surface expression of CD5, B-1 B cells 
can be further divided into the B-1a (CD5+) and B-1b (CD5-) B cell subsets (Stall et 
al., 1992). While B-1a B cells originate predominantly from fetal liver progenitors, 
B1-b B cells derive from BM progenitors (Montecino-Rodriguez et al., 2006). B-1 B 
cells are capable of self-renewing and can respond to bacterial antigens by rapidly 
differentiating into short-lived PCs (Alugupalli et al., 2004; Fagarasan and Honjo, 
2003; Hardy, 2006) (Haas et al., 2005). They represent the main source of so-
called natural antibodies that represent our first protection against invading 
pathogens. 
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1.3.2.3 Determinants of peripheral B cell development 
 
1.3.2.3.1. BAFF  
 
Receptors for BAFF include B cell maturation antigen (BCMA), transmembrane 
activator and calcium modulator and cyclophilin ligand interactor (TACI) and BAFF 
receptor (BAFF-R). They are expressed on the surface of B lymphocytes (Bossen 
and Schneider, 2006; Li et al., 2008), activated T cells and regulatory T cells 
(BAFF-R) (Mackay and Leung, 2006) and monocytes (Chang et al., 2006) and 
dendritic cells (Chang et al., 2008) (TACI). In humans, the BAFF-R is expressed at 
low levels on the surface of early BM B cell emigrants and its expression increases 
upon cell maturation (Darce et al., 2007; Sasaki et al., 2004). BAFF-R is crucial for 
the survival of late transitional B cells, as mice lacking either BAFF or its receptor 
display a prominent block in the transition from the T1 to the T2 stage (Schiemann 
et al., 2001). In addition, BAFF is required for survival of FO and MZ B cells, while 
it is dispensable for B-1 B cell persistence (Crowley et al., 2008; Scholz et al., 
2008). BAFF induces survival of B cells via activation of the Nuclear Factor Kappa-
light-chain-enhancer of activated B cells (NF-kB) pathway (Sasaki et al., 2006) and 
promotes cell growth, protein synthesis and glycolysis through activation of the 
protein kinase mammalian target of rapamycin (mTOR) pathway (Matsuzawa et 
al., 2008; Patke et al., 2006; Vallabhapurapu et al., 2008; Woodland et al., 2008). 
Central to the pro-survival activity of BAFF is the up-regulation of the anti-apoptotic 
B cell lymphoma 2 (Bcl-2) family member myeloid cell leukaemia sequence 1 
(Mcl1) (Bouillet et al., 1999; Cariappa et al., 2007; Mills et al., 2008; Opferman et 
al., 2003; Wang et al., 1999). 
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1.3.2.3.2. The BCR 
 
Surface expression of a functional BCR is critical for survival of mature B cells. 
Indeed, acute ablation of the BCR signaling complex in peripheral resting B cells 
results in rapid disappearance of the cells (Kraus et al., 2004; Lam et al., 1997). 
Additionally, antigen specificity, BCR surface density and strength of intracellular 
signaling have all been implicated in transitional B cell fate decisions (Casola, 
2007). Cells receiving strong signaling through the BCR are thought to differentiate 
towards the B1 B cell compartment. Weaker signaling coupled to additional cues 
will instead favor the development of FO and MZ B cells (Casola et al., 2004).  
 
1.3.2.3.3. Pax5 
 
Pax5 is the major determinant of B cell identity. Pax5 is expressed starting from 
the pro-B cell stage, where it regulates antigen receptor assembly and establishes 
the transcriptome profile that enables further B cell maturation and function, at the 
same time preventing the expression of lineage-inappropriate genes (Cobaleda et 
al., 2007b; Nutt et al., 1999; Revilla et al., 2012; Souabni et al., 2002). In 
peripheral B cells, while preserving the B cell-specific gene expression program 
and thereby cell identity, Pax5 promotes the survival of B lymphocytes, in part 
through the regulation of BCR signaling (Cobaleda et al., 2007b; Delogu et al., 
2006). In addition, Pax5 is also responsible for preventing premature onset of 
terminal differentiation (Delogu et al., 2006).  
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1.3.2.3.4. Notch2 
 
Notch2 belongs to the Notch family of receptors, which play important functions in 
the development of hematopoietic lineages (Maillard et al., 2005). Notch2 is 
expressed on all mature B cells, and its natural ligand is Delta-like 1 (Dll-1), which 
is produced by splenic dendritic cells (DCs). B cell-specific deletion of Notch2 
impairs development of MZ B cells, while the FO B cell compartment remains 
untouched (Saito et al., 2003). Similarly, inducible inactivation of Dll-1 leads to 
selective loss of MZ B cells (Hozumi et al., 2004). The role of Notch2 in MZ B cell 
development is further supported by the fact that animals carrying B cell-specific 
inactivation of the RBP-Jκ (Igκ-J region recombination-signal-binding protein 1) 
TF, which mediates the effects of Notch2 on gene expression, lack MZ B cells 
(Tanigaki et al., 2002). Conversely, B cells lacking the Notch2 transcriptional 
repressor, MINT (MSH homeobox homologue 2 (MSX2)-interacting nuclear 
target), display preferential commitment towards the MZ B cell compartment, with 
a concomitant decrease in FO B cells (Kuroda et al., 2003). Together, this 
indicates that Notch2 plays a pivotal role in MZ B cell development. 
 
1.3.2.3.5. Aiolos 
 
Aiolos is a zinc-finger transcription factor of the Ikaros gene family expressed 
throughout B cell development (Morgan et al., 1997). Aiolos expression levels are 
low during early B cell developmental stages and rise in peripheral B cells. Indeed, 
in Aiolos-deficient animals early B cell development is unaffected (Wang et al., 
1998). Instead, development of the MZ and B-1 subsets is impaired, while FO B 
cells are normal, but display reduced activation thresholds following BCR 
engagement (Wang et al., 1998). In accordance with this, Aiolos mutant mice 
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display spontaneous GC development. Moreover, lack of Aiolos leads to the 
production of autoantibodies and development of autoimmune disease in aged 
animals (Sun et al., 2003). 
1.3.2.3.6. NFAT 
 
Nuclear factor of activated T cells (NFAT) was originally identified as a calcium-
inducible TF necessary for expression of inteleukin (IL)-2 in T cells (Shaw et al., 
1988).  NFAT proteins are a family of four related TFs that can bind to regulatory 
elements of several different genes in different cell types (Crabtree and Olson, 
2002; Kiani et al., 2000). The NFAT family members NFATc1, NFATc2 and 
NFATc3 are expressed in B cells and can be activated by BCR cross-linking or 
CD40 signaling (Ho et al., 1995; Timmerman et al., 1997; Venkataraman et al., 
1994; Verweij et al., 1990). Lack of NFATc1, but not NFATc2, in B cells leads to 
selective loss of the B1-a compartment through a cell intrinsic mechanism. This 
indicates that NFATc1 function is necessary to sustain development/survival of 
B1-a cells and that its function cannot be compensated by the presence of 
NFATc2, which is also expressed in B-1a cells (Berland and Wortis, 2003). 
 
1.3.3. B cell-mediated immunity 
 
1.3.3.1. The germinal center response 
 
During T cell-dependent immune responses, antigens are presented to naïve FO 
B cells in the form of immune complexes often exposed on the surface of follicular 
dendritic cells (FDCs). Antigens are recognized and internalized by B cells via their 
BCR. Once internalized, protein antigens are cleaved and the resulting peptides 
loaded on MHC-class II (MHCII) molecules, which are eventually exposed on the 
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cell’s surface. Antigen-primed B cells migrate towards the edge of the follicular T 
cell zone, where they present the antigen to follicular helper T cells (TFH). 
Concomitant MHCII/TCR pairing and co-stimulatory signals delivered following 
CD40/CD40L and CD80/CTLA4 interactions result in full B cell activation, which 
triggers the GC response. GCs consist of a densely packed dark zone, where 
antigen-specific B cell centroblasts proliferate at high rate, and a light zone, where 
resting B cell centrocytes, TFH cells, FDCs and macrophages reside in close 
proximity (Klein and Dalla-Favera, 2008a). Within the dark zone, centroblasts 
undergo clonal expansion and diversify their V genes through a process called Ig 
somatic hypermutation (SHM), which leads to non-templated single nucleotide 
substitutions/deletions preferentially within the portion of the V gene coding for the 
hypervariable regions (also called complementarity determining regions or CDRs) 
of the BCR. SHM depends on the activity of the Activation-Induced cytidine 
Deaminase (AID) enzyme, whose expression is induced in GC B cells (Muramatsu 
et al., 2000). GC Centroblasts up-regulate a substantial number of genes 
associated with cell proliferation, while limiting the expression of negative 
regulators of the cell cycle. GC B cells also prevent full activation of the DDR 
pathway in order to undergo Ig SHM and class switch recombination (CSR) 
(Ranuncolo et al., 2007; Ranuncolo et al., 2008a; Ranuncolo et al., 2008b). 
Centroblasts are highly prone to undergo apoptosis as a result of the up-regulation 
of pro-apoptotic factors including CD95/Fas and down-regulation of anti-apoptotic 
proteins including members of the BCL2 protein family (Martinez-Valdez et al., 
1996) (Klein et al., 2003) (Basso et al., 2010). Rapid execution of programmed cell 
death is instrumental for the clearance of B cells displaying non-functional or low 
affinity BCRs as a result of Ig SHM (Figure 7) (Basso and Dalla-Favera, 2010). 
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Figure 7. Schematic view of the GC reaction. 
In T cell-dependent immune responses, following antigen encounter, FO B cells enter the 
GC reaction. The GC is characterized by the presence of a dark zone, where large 
centroblasts undergo massive proliferation and SHM of their Ig gene loci, and a light zone. 
In the light zone, smaller resting centrocytes are tested for improved antigen binding, 
undergo CSR and differentiate into high-affinity B or memory B cells. From Klein and Dalla 
Favera, Nat Rev Immunol. 2008 Jan;8(1):22-33. 
 
B cells expressing mutated BCRs migrate to the light zone of the GC, where they 
turn into resting centrocytes. In the light zone, centrocytes are selected on the 
basis of improved antigen binding via their BCR (Rajewsky, 1996). Only B cells 
expressing BCRs with the best affinity for the cognate antigen will succeed in 
capturing the antigen presented on FDCs and present it TFH cells. Co-stimulatory 
signals provided by TFH cells represent the key event for positive selection of GC 
B cells (Vinuesa et al., 2005). This stringent selection process leads the majority of 
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GC B cells to succumb by apoptosis and to be rapidly cleared by local 
macrophages (Klein and Dalla-Favera, 2008b). TFH cells residing in the GC also 
provide signals that promote Ig CSR, whereby B cells exchange their IgH constant 
region through a recombination process dependent on AID, to improve the effector 
function of their BCR (Kawabe et al., 1994; Vinuesa et al., 2005). In vivo imaging 
experiments have provided evidence that GC trafficking is not limited to a 
unidirectional movement of B cells from the dark to the light zone, but is 
contributed by a substantial migration in the opposite direction. This observations 
support a model whereby B cells undergo iterative rounds of proliferation, Ig 
mutation and antigen-based selection, with the goal to express antibodies with 
increasing affinity for cognate antigen (Victora et al., 2010). Eventually, through 
mechanisms that remain poorly understood, antigen-selected GC B cells activate 
differentiation programs that lead to their exit form the GC as long-lived, terminally 
differentiated, antibody-secreting plasma cells (PCs) of memory B cells. 
 
1.3.3.2. Bcl6: an essential transcription factor for GC B cells 
 
The transcription factor BCL6 is a master regulator of the GC response (Cattoretti 
et al., 2005; Fukuda et al., 1997). Bcl6 encodes a zinc finger transcription factor, 
which acts primarily as a sequence-specific transcriptional repressor. Bcl6 exerts 
its repressive function primarily via interaction with co-repressors including BCOR, 
SMRT and NCOR (Dhordain et al., 1998; Huynh and Bardwell, 1998; Wong and 
Privalsky, 1998).  Through the latter complexes, Bcl6 is thought to silence genes 
involved in cell growth inhibition and apoptosis (Hatzi et al., 2013). Instead, Bcl6 
influences B cell development through the interaction with the Mi-2-NuRD complex 
(Dent et al., 1997; Fujita et al., 2004; Parekh et al., 2007; Ye et al., 1997). Bcl6 
renders GC B cells tolerant to DNA damage through direct suppression of the 
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DNA damage sensor ATR and other DDR factors such as Tp53 and Chek1 (Phan 
and Dalla-Favera, 2004; Ranuncolo et al., 2008a; Ranuncolo et al., 2008b). On the 
other hand, excessive accumulation of DNA damage is prevented by a signaling 
pathway that, in response to high levels of genotoxic stress, promotes ATM-
dependent phosphorylation and degradation of Bcl6 (Phan et al., 2007b; 
Ranuncolo et al., 2007). Bcl6 supports GC B cell proliferation by inhibiting CDK 
inhibitors such as Cdkn1a and Cdkn2a (Basso et al., 2010) (Klein et al., 2003). In 
GC B cells, Bcl6 also inhibits premature onset of the plasma cell (PC) 
transcriptional program via direct repression of the Prmd1/Blimp1 locus, which is 
required for PC development (Vasanwala et al., 2002) (Figure 8A). Reduction of 
Bcl6 expression is needed to allow the differentiation of GC B cells into antibody-
secreting PCs. In centrocytes, down-regulation of Bcl6 is mediated by: 1) CD40 
signaling, which leads to Bcl6 transcriptional silencing (Niu et al., 1998; Polo et al., 
2008) and 2) BCR signaling, which leads to phosphorylation and hence 
degradation of Bcl6 protein (Phan et al., 2007a) (Figure 8B). 
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Figure 8. Biological functions and pathways regulated by Bcl-6. 
a) In centroblasts, Bcl6 supports the function of Aid and SHM by inhibiting the DDR 
pathway and stimulating cell cycle progression. In addition, Bcl-6 prevents 
premature differentiation towards the plasma cell or memory B cell fate by 
repressing key TFs. 
b) In centrocytes, interaction of B cells with TFH cells through CD40 activates NF-kB 
signaling, which stimulates expression of the Bcl6 repressor Irf4. In addition, 
signals delivered trough the BCR induce proteasomal degradation of Bcl6. Down-
modulation of Bcl6 releases the break on the Prmd1 gene, allowing terminal 
differentiation towards the PC fate. From Klein and Dalla Favera, Nat Rev 
Immunol. 2008 Jan;8(1):22-33. 
 
 
Interestingly, Ring1b forms a protein complex with BCOR and thus has been 
suggested to regulate Bcl6-mediated gene silencing (Sanchez et al., 2007). The 
functional relationship between Polycomb- and Bcl6-mediated gene silencing has 
been recently confirmed by our lab. Indeed, we could show that a substantial 
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number of Bcl6 targets were up-regulated upon conditional inactivation of Ezh2 in 
GC B cells (Caganova et al., 2013). This suggests that Polycomb and Bcl6 may 
co-operate in silencing at least a subset of common targets (Velichutina et al., 
2010).  
 
1.3.4. Terminal B cell differentiation. 
 
1.3.4.1. Plasma cell development. 
 
Following a T cell-dependent immune response, high-affinity B cells enter one of 
two possible differentiation routes and either become terminally differentiated PCs 
or memory B cells. Differentiation into functional antibody-secreting PCs is a step-
wise process that requires the combined expression of TFs Blimp1, Irf4 and Xbp1 
(Figure 9). The activation of Blimp1 is critical in PC precursors to extinguish  the 
(GC) B cell transcriptional programs through the direct repression of Pax5 and 
Bcl6 (Lin et al., 2002; Shaffer et al., 2002). In line with this, PC differentiation is 
phenotypically characterized by loss of B-cell specific markers including CD19, 
CD23 and surface Ig, and the acquisition of PC-specific ones such as 
CD138/Syndecan 1. 
 
1.3.4.2. Regulation of PC development. 
 
1.3.4.2.1. Blimp1. 
 
The transcription factor Blimp1 is encoded by the Prdm1 (positive-regulatory-
domain-containing 1) gene. Blimp1 is required for the formation of both short-lived 
and long-lived PCs (Angelin-Duclos et al., 2000; Kallies et al., 2004) (Shapiro-
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Shelef et al., 2003). In GC B cells, Prmd1 is repressed by the concerted actions of 
Bcl6 and Metastasis-associated 1 family, member 3 (MTA3), which bind to intron 5 
of the gene (Fujita et al., 2004; Tunyaplin et al., 2004). In late GC B cells, induction 
of Blimp1 depends on: i) signaling through the IL-21 receptor, which induces the 
activation of the TF STAT3 and ii) CD40 signaling, which leads to NF-kB 
dependent up-regulation of Interferon Regulatory Factor 4 (IRF4) (Kwon et al., 
2009). Together, STAT3 and IRF4 bind to an IL-21 responsive element 
downstream the Prmd1 gene and mediate its full expression (Kwon et al., 2009). 
Recent evidence from our group has demonstrated a critical role for Ezh2 in the 
modulation of IL-21-dependent terminal differentiation. Indeed, we could show that 
Ezh2 limits, through H3K27me3, the induction of Blimp1 in response to IL-21 
stimulation, thereby contributing to the persistence of B cells within the GC 
(Caganova et al., 2013). To induce PC differentiation Blimp1 acts both as a 
transcriptional inducer and repressor. It : i) inhibits  cell proliferation induced by c-
MYC and E2F1 (Lin et al., 1997; Shaffer et al., 2002), ii) induces Irf4 expression 
(Klein et al., 2006; Sciammas and Davis, 2004; Shaffer et al., 2002); iii) silences 
the (GC) B cell-specific transcriptional program via repression of Pax5 and Bcl6 
(Lin et al., 2002; Shaffer et al., 2002) and iv) activates the TF X-box binding 
protein 1 (Xbp1) to allow sustained secretion of Ig molecules (Reimold et al., 1996; 
Shaffer et al., 2002) (Figure 9). Importantly, Blimp1 appears also to be critical for 
the maintenance of long-lived BM PCs (Shapiro-Shelef et al., 2005). 
 
1.3.4.2.3. Interferon Regulatory Factor 4. 
 
Interferon regulatory factor 4 (Irf4) is a TF essential for PC development (Klein et 
al., 2006; Sciammas et al., 2006). Its expression is not restricted to PCs, as Irf4 is 
also required to support B cell function at early developmental stages (Lu et al., 
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2003; Mittrucker et al., 1997). In GC B cells, Irf4 levels are low in centroblasts, but 
rise in centrocytes as a result of CD40 signaling. In these cells, high levels of Irf4 
together with IL-21 contribute to activate Blimp1 expression, promote CSR and 
hence drive PC development. Blimp1 can also induce Irf4 expression (Sciammas 
et al., 2006) thereby generating a feed-forward positive loop that is needed to 
ensure repression of Bcl6 (Sciammas and Davis, 2004). Recently, Sciammas and 
co-workers reported a dynamic control of Irf4 abundance, which contributes to the 
stepwise differentiation of B cells during a GC response. Specifically, low levels of 
Irf4 were required for the recruitment of B cells into the GC through the up-
regulation of Bcl6 and Pou2af1. Instead, high levels of the TF diverted cells into 
the PC developmental path. Differential expression of Irf4 in developing B cells 
was shown to determine shifts in genome-wide binding of the TF, ultimately 
resulting in distinct patterns of gene expression (Ochiai et al., 2013). Irf4 is also 
required to induce Xbp-1 and thereby sustained Ig secretion in PCs (Sciammas et 
al., 2006; Skalet et al., 2005). 
 
1.3.4.2.2. X-box binding protein 1 and the unfolded protein response 
 
The TF Xbp1 activates a transcriptional program that sustains the high rate of Ig 
synthesis of PCs (Calfon et al., 2002; Reimold et al., 2001). Loss of Xbp1 leads to 
impaired Ig secretion, ultimately resulting in failure to control infections (Reimold et 
al., 2001). In PCs, transcription of Xbp1 is induced by Blimp1 (Shaffer et al., 2004), 
Activating Transcription Factor 6 (ATF6) and IL-4 (Iwakoshi et al., 2003; Yoshida 
et al., 2000). Xbp1 mRNA is then cleaved through the endoribonuclease function 
of the activated IRE1 dimers to yield a spliced form of the transcript. Spliced Xbp1 
displays the same DNA binding region as its precursor, but yields a more stable 
and more efficient transcriptional activator (Calfon et al., 2002; Lee et al., 2002; 
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Yoshida et al., 2001). Xbp1 activates genes that elicit a PC-specific unfolded 
protein response (UPR) whereby, in contrast with stress-induced UPR, increase in 
size of the endoplasmic reticulum (ER) and enhanced protein synthesis co-exist 
and apoptosis is not induced (Gass et al., 2002). Xbp1 target genes encode 
factors that regulate protein targeting to the ER, protein folding, degradation of 
mis-folded proteins, protein glycosylation, trafficking between ER and Golgi and 
targeting of secretory vescicles to the plasma membrane. In addition, Xbp1 
regulates cell and organelle size (Shaffer et al., 2004). 
 
1.3.4.2. Memory B cell development. 
 
 
Memory B cells represent a subset of resting long-lived, antigen-experienced 
lymphocytes. Memory B cells are predominantly, but not exclusively, generated 
during the GC reaction and provide life-long protection against foreign antigens 
(Kaji et al., 2012) (Rajewsky, 1996). Memory B cells can express either IgM or Ig-
class switched antibodies. Recent work by the Weill/Reynaud group has assigned 
different functions to IgM and Ig-switched memory B cells. Whereas IgM+ memory 
B cells are preferentially recruited into the GC during secondary immune 
responses, Ig-switched memory cells differentiate directly into PCs upon antigen 
re-encounter (Dogan et al., 2009). These results partition memory B cells into two 
groups, of which one (IgM+ cells) is devoted to the generation of increasingly 
higher BCRs as a result of subsequent rounds of Ig SHM in GCs, whereas the 
other (Ig-switched cells) provides a ready source for high-affinity neutralizing 
antibodies (Weill et al., 2013). The different fate of IgM vs. IgG memory B cells 
may depend on the different signaling properties of the BCRs expressed by the 
two types of cells (Pierce and Liu, 2013) (Martin and Goodnow, 2002) (Kometani 
et al., 2013). The mechanisms leading to B cell memory formation remain poorly 
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understood. Activation of the TF STAT5 as a result of cytokine stimulation of late 
GC B cells has been proposed as a mechanism driving memory B cell formation 
(Scheeren et al., 2005). Also, sustained CD40 signaling during the GC response 
has been proposed to skew differentiation towards the memory B cell fate (Arpin et 
al., 1995). Finally, recent evidence has suggested that differentiation into memory 
B cells expressing different Ig isotypes relies on divergent genetic programs 
activated by different transcriptional regulators (Wang et al., 2012). Another yet 
open question is how memory B cells are maintained. Whereas work by 
Maruyama and Rajewsky has excluded a role for antigen in memory B cell 
maintenance, recent work has challenged this conclusion (Dogan et al., 2009) 
(Maruyama et al., 2000). 
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Figure 9. Opposing transcriptional networks in GC and PC development. 
Several TFs, including Bcl6, Mta3, Mitf (microphthalmia-associated transcription factor) 
and Pax5 prevent PC development by repressing Blimp1, Xbp1 and Irf4. In PCs, Blimp1 
represses B cell gene expression programs. This mutual repression system prevents 
premature terminal differentiation and the reversion of plasma cells to a B cell stage. In 
addition to PC determinants, Bcl6, Mta3, Pax5 and Mitf also regulate the expression of 
genes required for B cell and GC functions, which are outlined in the pink box. Blimp1, 
Xbp1 and Irf4 induce the expression of genes that are required for plasma cells, whose 
categories are outlined in the blue box. From Shapiro-Shelef and Calame, Nat Rev 
Immunol. 2005 March;5(3):230-42. 
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2. Materials and Methods 
2.1. Mice 
 
Mice were housed and bred in animal facility at the IFOM-IEO Campus Institute, 
Milan, Italy. Animal handling followed European Community recommendations.  
 
Wt. 
C57BL/6J mice were purchased from Charles River 
 
Mutants (genetic background). 
  
Ring1a-/- (del Mar Lorente et al., 2000)(BL/6)  
Ringbfl (Cales et al., 2008) (BL/6)    
R26-EYFPfl-STOP (Srinivas et al., 2001) (BL/6)   
 
Cre lines (genetic background). 
 
Mb1-cre (Hobeika et al., 2006) (BL/6) 
Cd23-cre (Kwon et al., 2008) (BL/6) 
Cγ1-cre(Casola et al., 2006) (BL/6) 
Aicda-cre (Crouch et al., 2007) (BL/6) 
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2.1.2. Genomic DNA extraction from tail biopsy 
 
 
Tail lysis buffer  100 mM Tris-HCl pH 8.5 
 5 mM EDTA  
 200 mM NaCl  
 0.2 % SDS  
 
1 cm of a tail biopsy was incubated in 400 µl of lysis buffer  with Proteinase K (100 
µg/ml) at 56˚C, shaking at 850 rpm, overnight in Thermomixer compact. 350 µl of 
lysate were transferred into a new tube and 1 ml of isopropanol was added, mixed 
by inverting and centrifuged at maximum speed for 1 min. DNA pellet was 
dissolved in 200 µl of miliQ water by incubation at 60˚C for 20 min. 
2.1.3. Genotyping strategy 
 
 
The genotypes of all mice offsprings were analyzed by polymerase chain reaction 
(PCR) performed on genomic DNA extracted from tail. For amplification, primers 
summarized in Table 1 and PCR reagents listed in Table 2 were used. PCR 
conditions are summarized in Table 3. PCRs were run in automatic thermocycler 
GeneAmp PCR System9700 (Applied Biosystems). 
Table 1. Primers used for genotyping, annealing temperatures and amplicon 
sizes. 
Gene Primer ID Sequence TA 
(°C) 
Product (bp) 
Ring1b 
WT vs Fl 
Ring1b Fl Rv GTTCCATTTGTCTGCACAGCCTGAG 58 Ring1b WT 
250 bp 
Ring1bfl 
270 bp 
Ring1bΔ 
500 bp 
Ring1b Del Fw TAATTCCATGAAAGCATCAAAGT 
Ring1b Del Rv AGCACTGTGCTCCTTTTTGAT 
Ring1a 
WT vs 
KO 
Ring1a WT Fw CTTCCGCAGACCTCTCTCAG 60 Ring1a WT 
221 bp 
Ring1a KO 
Ring1a WT Rv TTGCGCTCATCTTAGGCTTT 
Ring1a KO Fw TGCTCGAGATGTCATGAAGG     
 
 
63 
Ring1a KO Rv TATGTCCCCCGTTGACTGAT    196 bp 
Mb1-cre Mb1cre_Fw CCCTGTGGATGCCACCTC 58 Mb1-cre 
430 bp Mb1cre_Rv GTCCTGGCATCTGTCAGAG 
Cγ1-cre IgG1 Fw TGTTGGGACAAACGAGCAATC 58 Cγ1-cre 450 
bp 
Cγ1 WT 240 bp 
IgG1 Rv GTCATGGCAATGCCAAGGTCGCTAG 
Cγ1-creF GGTGGCTGGACCAATGTAAATA 
Cd23-
cre 
Cd23-cre Fw GATGTGAGGGACTACCTCCTGTACC 60 Cd23-cre 
348 bp Cd23-cre Rv CCAGCATCCACATTCTCCTT 
Aicda-
cre 
UCre F ACGAACCAAGGTGACAGCAATG 60 Cre 
350 bp UCre R CTCGACCAGTTTAGTTACCC 
 
 
Table 2. PCR Reagents 
PCR master mix µl 
H2O 14.4 
5x flexi buffer 5 
MgCl2 25 mM  2 
dNTPs 2.5 mM 2 
primer Fw 50 µM 0.2 
primer Rv 50 µM 0.2 
GO Taq 0.2 
DNA 1 
total 25 
  
Table 3. Genotyping PCR conditions. 
PCR cycle   
Temperature(°C) Time (min)  
94 2:30  
94 0:30 
33x TA 0:30 
72 0:30 
72 5:00  
4 hold  
 
2.1.4. Mice immunization 
 
6 to 8 weeks old mice were immunized with Alum (Imject ® Alum, aqueous 
solution of aluminium hydroxide (40 mg/ml) and magnesium hydroxide (40 mg/ml), 
Pierce) precipitated NP25CGG (100µg per mouse, 4-Hydroxy-3-nitrophenylacetyl 
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hapten conjugated to Chicken gamma globulin, Biosearch Tech.) intraperitoneally. 
For recall responses, secondary immunizations with 50 µg of Alum precipitated 
NP25CGG were performed 60 days after primary immunization. For 
immunohistochemical visualization of BCL6+ GCs, mice were immunized with 108 
sheep red blood cells (Thermo Scientific) and analysis of GC formation was 
performed 8 days later. 
 
2.1.5. In vivo proliferation assay 
 
Mice immunized with NP25CGG were injected with 200 µg EdU (BrdU analog, 
Invitrogen) intraperitoneally on day 12 post-immunization, 1 h prior to analysis. For 
EdU detection, EdU detection kit (Click-iT™ EdU Alexa Fluor® 647, Invitrogen) 
was used following the manufacturer's instructions. 
 
2.2. Cell culture techniques 
 
2.2.1. B cell purification  
 
Erythrocyte lysis buffer 
solution A 0.17 M Tris pH 7.65 
solution B 0.83 % NH4Cl 
working solution 9 parts B + 1 part A 
 
B cell medium DMEM 
 10 % FCS 
 2 mM glutamine 
 200 U/ml pen/strep 
 NEAA 
 50 µM b-ME 
 1 mM Na Pyruvate 
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FACS buffer 1x PBS 
 1 % BSA 
 0.05 % NaN3 
 
For B cell analysis, mice of 6-8 weeks of age were used.  
BM cell suspension was obtained by flushing tibia with 5 ml B cell medium. 
SPL and LN were collected and smashed for single cell suspensions. Erythrocyte 
lysis was performed on SPL and BM cell suspensions using 1 ml of erythrocyte 
lysis buffer with incubation of 3 min on ice. Reaction was stopped by adding 10 ml 
of B cell medium and cells were washed in Fluorescence-activated cell sorting 
(FACS) buffer. Live cells were counted using Erythrosin B dye to distinguish live 
and dead cells. All centrifugation steps were performed for 5 min at 280 g at 4°C. 
 
2.2.2. In vitro B cell culture 
MACS 
buffer 1x PBS 
 0.5 % BSA 
 2 mM EDTA 
 
Splenic B cells were purified following the protocol of B cell purification with the 
exception of using magnetic cell sorting (MACS) buffer instead of FACS buffer. B 
cells were purified through LS columns (Miltenyi Biotec) following manufacturer’s B 
Cell Isolation Kit depletion protocol (Miltenyi Biotec). Specifically, CD43-expressing 
B cells (activated B cells, PCs and B1a cells) T cells, NK cells, dendritic cells, 
macrophages, granulocytes, and erythroid cells were indirectly magnetically 
labeled by using a cocktail of biotin-conjugated antibodies against CD43 (Ly-48), 
CD4 (L3T4), and Ter-119, followed by Anti-Biotin MicroBeads incubation. This 
procedure allows the isolation of untouched resting B cells from single cell 
suspensions of lymphoid tissues. 
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Purified B cells were cultured in B cell medium and stimulated with 20 µg/ml LPS 
(Lipopolysacharide, Sigma) with or without 15 ng/ml IL-4 (Recombinant Murine 
Interleukin 4, GRF-10600, Immunological Sciences); or 1 µg/ml RP105 
(Monoclonal rat-anti mouse CD180, functional grade purified RP/14, 
eBiosciences). Cells were cultured at a density of 0.5 - 1 x 106 cells/ml at 37°C at 
6 % CO2. 
For iGB cultures, purified B cells were seeded on a feeder layer of irradiated (120 
Gy, 1 hour) 40 LB cells that had previously received 120 Gy irradiation over a 1 
hour interval. Cells were seeded at a starting density of 2x104 cells/mL in 40 mL of 
B cell medium supplemented with 1 ng/ml IL-4. Cells were left at 37°C at 6 % 
CO2. Medium was changed at day 2 following activation. At day 4, iGB cells were 
harvested and counted. To induce plasma cell differentiation, iGB cells were 
seeded on a freshly irradiated 40LB feeder layer at a density of 2x104 cells/ml in 
40 mL of B cell medium supplemented with 10 ng/ml IL-21 (Peprotech). 
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2.3. Imaging Techniques 
 
2.3.1. Immunostaining for flow cytometry and cell sorting  
 
Cells were stained in 10 µl / 1x106 cells of FACS buffer containing antibodies of 
choice for 20 min at 4˚C in dark and subsequently washed twice with 200 µl of 
FACS buffer. List of antibodies as well as working dilutions are listed in Table 4. 
 
 
Table 4. Antibodies used for flow cytometry. 
Antibodies and antigen Company dilution 
Monoclonal Rat-anti mouse CD5 (PE) eBiosciences 1/200 
Anti mouse CD95 (Fas) eBiosciences 1/170 
Anti mouse IgM clone R331.12 (Alexa 488)  home made 1/400 
Anti mouse Kappa clone R331.18 (Alexa 488) home made 1/800 
Monoclonal Rat-anti mouse CD138 (PE) BD Biosciences 1/200 
Monoclonal Rat-anti mouse CD19 (Cy7 PE) eBiosciences 1/400 
Monoclonal Rat-anti mouse CD21/CD35 (PE) eBiosciences 1/1000 
Monoclonal Rat-anti mouse CD23 (FITC) eBiosciences 1/100 
Monoclonal Rat-anti mouse CD25 (APC) eBiosciences 1/200 
Monoclonal Rat-anti mouse CD38 (APC) eBiosciences 1/600 
Monoclonal Rat-anti mouse CD43 (PE) eBiosciences 1/100 
Monoclonal Rat-anti mouse IgD (PE) eBiosciences 1/3000 
Monoclonal Rat-anti mouse IgG1 (biotin) BD Biosciences 35064 
Monoclonal Rat-anti mouse/human CD45R(B220) 
(Cy7PE) eBiosciences 1/400 
Monoclonal Rat-anti mouse/human CD45R(B220) 
(FITC) eBiosciences 1/200 
Monoclonal Rat-anti mouse CD24/HSA  (PE) eBiosciences 1/400 
Monoclonal Rat-anti mouse CD93/AA4.1 (APC) eBiosciences 1/600 
Monoclonal Rat-anti mouse CD268/BAFF-R (APC) Biolegend 1/600 
NIP (PE) home made 1/4000 
Antigen Fluorescein Peanut Agglutinin (PNA)  Vector Laboratories 1/800 
Streptavidin (APC) eBiosciences 1/800 
Streptavidin (FITC) eBiosciences 1/400 
 
 
2.3.2. Intracellular immunostaining for flow cytometry 
 
Cells were stained in 10 µl / 1x106 of FACS buffer containing antibodies of choice 
(Table 4) for 20 min at 4˚C in dark and subsequently washed twice with 200 µl of 
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FACS buffer. Surface stained cells were fixed in BD Cytofix/Cytoperm™ buffer for 
20 min on ice in U bottom 96 well microplate, washed by Perm/Wash™ Buffer 
(P/W) and refixed in BD Cytofix/Cytoperm™ buffer for 20 min on ice. Cell were 
then incubated in blocking buffer (10 % normal goat serum in P/W buffer) for 30 
min at RT shaking and stained Alexa488-labeled Rat-anti mouse IRF4 (IRF4 3E4, 
BioLegend, working dilution 1/400) in staining solution for 60 min at RT, shaking. 
Cells were washed twice with P/W buffer and fixed in 1 % formaldehyde in PBS. 
Samples were acquired and analyzed using FACSCalibur (Becton Dickinson) and 
FlowJo software. All centrifugation steps were performed at 780 g for 10 sec at 
4°C. 
2.3.4. Immunostaining of SPL sections 
 
2.3.4.1. Immunofluorescence 
 
Fluorescent immunostaining was performed on frozen SPL sections obtained from 
immunized C57BL6/J mice (snap-frozen, OCT-embedded samples). Spleens were 
cut in 6 µm-thick slices and placed on Microscope Slides Superfrost ultra Plus® 
(Thermo Scientific). Samples were washed once in 1x PBS, hen fixed for 5’ at RT 
in 80% ethanol. Slides were then again washed 3x for 5’ with 1x PBS. Avidin 
solution from the Avidin/biotin Blocking System (Covance) was added and 
incubated 10’ at RT. Slides were then briefly washed 3x in 1x PBS and incubated 
10’ at RT with Biotin solution from the Avidin/biotin Blocking System (Covance). 
Slides were then briefly washed 3x in 1x PBS and incubated for 45’ with pre-
incubation solution (1x PBS, 0,005% FBS, 0,001% BSA). Following incubation, 
antibodies were added in sequence. The primary antibody used was a monoclonal 
rat anti-human MOMA-1 (Abcam, diluted 1:50 in pre-incubation solution). 
Incubation was performed at RT for 90’ in the dark. Slides were then washed 5’ 
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each with 1x PBS and secondary Streptavidin coupled to Cy3 (SouthernBiotech) 
was added at a 1:250 dilution. Incubation was performed for 60’ at RT. Following 3 
washes, of 5’ each, with 1x PBS, slides were incubated with Monoclonal Rat-anti 
mouse/human CD45R(B220) (eBioscience) at a 1:100 dilution for 60’ at RT, 
shielded from light. Slides were washed 3x in 1x PBS for 5’. DNA was stained with 
4',6-diamidino-2-phenylindole (DAPI) for 5’ and washed with 1x PBS immediately 
after. Slides were then mounted in 50% Glycerol and stored in the dark at +4°C 
until acquisition. Images were acquired on a Widefield BX61 microscope 
(Olympus) using the MetaMorph (Molecular Devices) software. Image analysis 
was performed using ImageJ (NIH).  
 
2.3.4.2. Immunohistochemistry. 
 
Histochemical analysis was performed for GC scoring. Spleens were snap-frozen 
in liquid N2 and isopentane, fixed in 4 % buffered formalin and embedded in 
paraffin. Tissue cross-sections were cut at 3 or 5 µm thickness for 
immunostaining, mounted Microscope Slides Superfrost ultra Plus® (Thermo 
Scientific) and stored at room temperature. Before immunostaining, the slides 
were passed through ethanol steps decreasing in concentration (100%, 95%, 
80%), for 3’ each to remove paraffin. Slides were then re-hydrated 5’ in RT H2O. 
Removal of bonds between paraffin and internal antigen was performed at 95°C 
for 1 hour in sodium citrate buffer (2.1% citric acid, 2.94% sodium citrate in 1 L 
distilled water) followed by air-drying for 40’ below a fume hood. Sections were 
used for routine stains (eosin and hematoxylin) or immunohistochemistry. Before 
immunohistochemistry, slides were incubated with Avidin/biotin Blocking System 
(Covance) as described in paragraph 2.3.4.1. Slides were then washed with 1x 
PBS and incubated for 2 hours at RT in pre-incubation solution (1x PBS, 0,005% 
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FBS, 0,001% BSA). Incubation with rabbit polyclonal anti-Bcl6 antibody (Cell 
Signaling, #4242) 1:200 in pre-incubation solution was performed overnight at 
+4°C. On the following day, slides were washed 3x, 5’ in 1x PBS and incubated 
with secondary antibody (anti-rabbit IgG coupled to HRP, 1:200, Vector) for 45’ at 
RT. Binding of secondary antibody was then revealed upon incubation with ABC 
kit (VECTASTAIN Elite ABC Kit) and eosin. Slides were rinsed in water and de-
hydrated in alcohol series (80%, 95%, 100%) for 10’’ each. Slides were then 
mounted in glycerol and stored at RT until acquisition. Images were acquired on a 
Full Manual BX51  (Olympus) Microscope using the MetaMorph (Molecular 
Devices) software. Image analysis was performed using ImageJ software (NIH).  
 
2.3.5. Immunostaining for detection of apoptosis.  
 
For detection of apoptotic cells CaspGLOWTM Fluorescein Active Caspase 
Staining Kit was used with specific modifications in protocol. Ex vivo purified or in 
vivo cultured cells were incubated in 100 µl of B cell medium containing 1 µl of 
FITC-VAD-FMK (carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl] 
fluoromethylketone), a cell-permeant pan caspase inhibitor that irreversibly binds 
to the catalytic site of caspase proteases, for 1 h at 37°C and 6 % CO2. Cells were 
collected by centrifugation (280 g for 5 min) and washed with 200 µl of wash 
buffer. If required cells were stained following the protocol of chapter 2.3.1. 
(Immunostaining for flow cytometry), acquired by FACSCalibur (Becton Dickinson) 
and analyzed using FlowJo software.  
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2.3.6. Cell cycle analysis 
 
2.3.6.1. In vitro. 
 
One million of in vitro activated B cells was collected by centrifugation for 5 min at 
280 g and washed in PBS. cells were fixed in 100 µl of BD Cytofix/Cytoperm buffer 
(BD Biosciences) for 30 min on ice and washed with P/W and incubated in BD 
Cytoperm Plus Buffer (BD Biosciences) for 10 min on ice. After washing in P/W 
buffer cells were re-fixed in 100 µl of BD Cytofix/Cytoperm buffer for 5 min on ice 
and washed by P/W buffer again. For DNA staining cells were resuspended in 1 
ml of cold propidium iodide (50 µg/ml) + RNase (250 µg/ml) and incubated 
overnight at 4°C. Samples were acquired by FACSCalibur (Becton Dickinson) and 
analyzed using FlowJo software. 
2.3.6.2. Ex vivo. 
 
Purified splenic B cells were stained following the protocol of chapter 2.3.1. 
(Immunostaining for flow cytometry). Surface stained cells were fixed in 100 µl of 
BD Cytofix/Cytoperm buffer (BD Biosciences) for 30 min on ice and washed with 
P/W and incubated in BD Cytoperm Plus Buffer (BD Biosciences) for 10 min on 
ice. After washing in P/W buffer cells were re-fixed in 100 µl of BD 
Cytofix/Cytoperm buffer for 5 min on ice and washed by P/W buffer again. For 
DNA staining cells were resuspended in 1 ml of cold propidium iodide (50 µg/ml) + 
RNase (250 µg/ml) and incubated overnight at 4°C. Samples were acquired by 
FACSCalibur (Becton Dickinson) and analyzed using FlowJo software. 
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2.4. Biochemical techniques. 
 
2.4.1. Enzyme-Linked Immunosorbent Assay (ELISA). 
 
ELISA methods are immunoassay techniques that combine the specificity of 
immunological reaction with the sensitivity of enzyme assays and allow 
quantification of immunoglobulins or antigens. One of the most common ELISA 
applications is to measure the amount of immunoglobulins in blood serum. Coating 
was performed with 50 µl of capture antibodies (Table 5) or antigens (Table 6) 
diluted to working concentration in coating buffer (0.5 M Carbonate-bicarbonate 
buffer pH 9.6) overnight at 4˚C in NUNC Maxisorp white 96 well microplate. 
Coating solution was removed and plate washed 3 times with 450 µl of washing 
buffer (0.05 % Tween20 in PBS). Plate was blocked in blocking buffer (3 % BSA in 
PBS) for 1 h at 37°C. 50 µl of serum or standard. in Reagent Diluent (1 % BSA in 
PBS) was added to the plate and incubated 1 h at RT. Plate was washed 4 times 
with 450 µl of washing buffer. 50 µl of the Detection Antibody (Table 5 and Table 
6). was added and plate was incubated 1 h at RT. Plate was washed 5 times with 
450 µl of washing buffer. 50 µl of the Streptavidin-Eu3+ (Perkin Elmer, 1/15000 
dilution in reagent diluent) was added and plate was incubated for 30 min at RT in 
the dark. Plate was washed 6 times with 450 µl of washing buffer. 50 µl of room 
temperature DELFIA Enhancement Solution (4001-0010 Perkin Elmer) was added 
and incubated for 15 min at RT, shaking (50 - 100 rpm). Absorbance 
measurement was performed using Victor3 TM 1420 Multilabeled Counter and 
Wallac 1420 Workstation Software (Perkin Elmer™). ELISA based quantification of 
antibody titers in blood serum of resting/immunized mice was performed according 
to the Bethyl ELISA Protocol supplied with Mouse ELISA Quantitation Set. 
Table 5. ELISA reagents for total antibody titers detection of resting mice. 
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capture antibodies clone company working conc. 
Monoclonal rat anti-mouse IgM L-OMM-3 AbD Serotec 1 µg/ml  
Monoclonal rat anti-mouse IgG1 LO-MG-13  AbD Serotec 1 µg/ml  
Monoclonal goat anti-mouse IgG3 LO-MG3-13 AbD Serotec 1 µg/ml  
Monoclonal goat anti-mouse Ig2a LO-MG2a-9 AbD Serotec 0.5 µg/ml 
Monoclonal goat anti-mouse Ig2b LO-MG2b-1 AbD Serotec 1 µg/ml  
Monoclonal goat anti-mouse IgA A90-130-A Bethyl 1 µg/ml  
    
standards    
mouse IgM 11E10 Southern Biotech 10 ng/ml 
mouse IgG1 15H6 Southern Biotech 10 ng/ml 
mouse IgG3 B10 Southern Biotech 100 ng/ml 
mouse IgG2a HOPC-1 Southern Biotech 100 ng/ml 
mouse IgG2b A-1 Southern Biotech 100 ng/ml 
mouse IgA S-107 Southern Biotech 400 ng/ml 
    
detection antibodies    
anti-mouse IgM (biotin) R33.24.12 home made 125 ng/ml 
anti-mouse IgG1 (biotin) A85-1 BD Pharmingen 125 ng/ml 
anti-mouse IgG3 (biotin) R40.81 BD Pharmingen 500 ng/ml 
anti-mouse IgG2a (biotin) LO-MG2a-7  AbD Serotec 500 ng/ml 
anti-mouse kappa chain (biotin) R331.18 home made 500 ng/ml  
anti-mouse IgA (biotin) 11-44-2  Southern Biotech 500 ng/ml  
 
 
Table 6. ELISA reagents for antigen specific antibody titers detection of 
immunized mice. 
 
antigens clone company 
working 
conc. 
NP(4)-BSA N505010 Biosearch Technologies 2 µg/ml  
NP(23)-BSA N505010 Biosearch Technologies 2 µg/ml  
BSA   2 µg/ml  
capture antibodies    
Monoclonal rat anti-mouse IgM L-OMM-3 AbD Serotec 1µg/ml  
Monoclonal rat anti-mouse IgG1 LO-MG-13  AbD Serotec 1µg/ml  
standards    
mouse IgM 11E10 Southern Biotech 10 ng/ml 
mouse IgG1 15H6 Southern Biotech 10 ng/ml 
Detection antibody    
anti-mouse IgM (biotin) R33.24.12 home made 125ng/ml 
anti-mouse IgG1 (biotin) A85-1 BD Pharmingen 125ng/ml 
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2.4.2. Immunoblot analysis. 
 
Cells were harvested by centrifugation for 5 min at 280 g and washed in cold PBS. 
For protein extraction cell pellet was resuspended in 8 M Urea lysis buffer (8 M 
Urea, 0.1 M NaH2PO4, 0.01 M Tris pH 8.0) and incubated 30 min in rotation at RT. 
Sonication was performed in 2 cycles of 10 sec each. Lysates were centrifuged at 
maximum speed for 10 min to remove debris. Lysates were quantified with a 
protein assay reagent (Bio-Rad Laboratories). 20 - 50 µg of proteins, in Laemmli 
loading buffer (62.5 mM Tris-HCl pH 6.8, 2 % (w/v) SDS, 5 % (v/v) 2-
mercaptoethanol and 10 % (v/v) glycerol) and 10 µl of NOVEX ® Sharp Pre 
Stained protein standard (Invitrogen) were loaded onto home-made 12% 
polyacrylamide minigels and transferred by dry iBlot® Dry Blotting Device 
(Invitrogen) to nitrocellulose membranes (iBlot® Transfer Stack, Invitrogen) in 7 
min. After blotting, the membranes were stained with Ponceau S staining solution 
(0.1 % Ponceau S (w/v) and 5 % acetic Acid (w/v)) to verify equal loading and 
transfer. Membranes were briefly washed in water and blocked for 1 h at RT in 
blocking solution 5 % BSA in TBS-T (20 mM Tris HCl pH 7.4, 500 mM NaCl, 0,1 % 
Tween). After blocking, filters were incubated with primary antibodies (Table 7), 
diluted in blocking solution, for 1-2 hours at RT or overnight at 4°C. After three 
washes, of 5 min each in TBS-T, membranes were incubated with the appropriate 
horseradish peroxidase conjugated secondary antibody diluted in blocking solution 
for 30 min at room temperature. Membranes were washed three times for 5 min in 
TBS-T and the bound secondary antibody was revealed using the ECL Western 
Blotting Substrate (Pierce) and detected using the ChemidocTM XRS+ imaging 
System (Biorad). Image analysis was perforfmed using the Image LabTM software 
(Biorad). 
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2.4.3. Immunoprecipitation. 
 
Cells belonging to the A20 mouse B lymphoma were harvested by centrifugation 
at 4°C for 5 min at 280 g and twice washed in cold PBS. For protein extraction, the 
cell pellet was resuspended in 200 µl S300 lysis buffer (25 mM Tris HCl pH 7.6, 
300 mM NaCl, 10% Glycerol 0,25% NP-40)/107 cells. Chromatin was 
mechanically sheered via pipetting up and down with a p1000 tip. Lysates wer 
then kept on ice for 10 minutes and cellular debris was removed via centrifugation 
at 17.900 g for 15 minutes. Lysates were quantified with a protein assay reagent 
(Bio-Rad Laboratories). 50 µl of protein G agarose slurry/sample were washed 2x 
in ice-cold 1x PBS, centrifuged at 4390 g and equilibrated with 50 µl of S300 lysis 
buffer . 1 mg of lysate/ip was then added to protein G and left to rotate at +4°C for 
1 hour. Following lysate pre-clearing, 10% of lysate from the isotype control was 
stored at -80°C to serve as input. 1 mg of lysate was precipitated using 5 µg of 
anti-Ring1b (Cell Signaling) and a corresponding amount was precipitated with 5 
µg of an isotype-matched antibody (monoclonal mouse anti-FLAG M2, Clone M2, 
Sigma-Aldrich), overnight at 4°C. On the following day, 50 µl of equilibrated protein 
G slurry was added to each immunoprecipitation, and left to rotate for 1-2 hours at 
4°C. Subsequently, beads were precipitated by centrifugation at 4390 g and 
washed three times, 5 minutes each, at 4°C and on rotation, with cold S300 buffer.  
Immunoprecipitated and input material were then resuspended in Laemmli loading 
buffer (see paragraph 2.4.2). Samples were run, loaded and interactions 
visualized as described in paragraph 2.4.2, using primary and secondary 
antibodies listed in Table 7. 
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Table 7. Antibodies used for immunoblot protein detection. 
 
primary antibodies clone company dilution 
Rabbit anti-Ring1b D22F2 
Cell 
Signaling 1/1000 
Rabbit anti-H2AK119Ub D27C4 
Cell 
Signaling 1/1000 
Rabbit anti-Ring1a  
Cell 
Signaling 1/1000 
Rabbit anti-Bcl6  
Cell 
Signaling 1/1000 
Rabbit anti-H2A total 07-690 Millipore 1/1000 
Rabbit anti-BCOR 12107-1-AP Proteintech 1/1000 
    
secondary antibodies    
Polyclonal Goat anti mouse 170-6516 BioRad 1/20000 
Polyclonal Goat anti rabbit 170-6515 BioRad 1/20000 
Polyclonal Goat anti rat NA935 Amersham 1/5000 
 
 
2.5. Molecular Biology Techniques 
 
2.5.1. RNA and DNA extraction 
  
From more than 1x105 cells, total RNA was extracted using QIAGEN RNeasy 
minikit following the manufacturer’s protocol. A DNAse (QIAGEN) digestion step 
was added before elution to ensure the complete elimination of contaminant DNA. 
For sorted cells with total cell numbers lower than 1x105, RNeasy AllPrep MicroKit 
(QIAGEN) was used following the manufacturer’s protocol. This kit enables 
separate elution of total RNA and genomic DNA from one cell pellet. 
 
2.5.2. cDNA synthesis 
 
Complementary DNA (cDNA) was produced using SuperScript® VILO™ cDNA 
Synthesis Kit (Invitrogen) following the manufacturer’s protocol. Specifically, 
master mix (containing 5X VILOTM Reaction Mix, 10X SuperScript® Enzyme Mix, 
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water and RNA) was incubated for 10 min at RT. For increased yields of cDNA 
incubation time was prolonged to 120 min at 42°C. Reaction was terminated by 5 
min incubation at 85°C. 1 - 5 ng of cDNA were used for real time PCR reaction. 
Eventually, cDNA was used for Microfuidic cards (AB). 
 
2.5.3. Real-time quantitative PCR (RT-QPCR). 
 
For gene expression analysis RT-QPCR was performed using 1 - 5 ng of DNA, 
500 nM primers mix and 10 µl of LightCycler 480 SYBR Green I Master 
containing Hot-start polymerase (Roche) in a final volume of 20 µl per reaction in 
96-well format. Reaction conditions were: 95°C for 10 min, 45 cycles of 95°C for 1 
sec, 60°C for 10 sec, 72°C for 1 sec. Accumulation of fluorescent products was 
monitored using a LightCycler® 480 Real-Time PCR System (Roche). Specificity 
of PCR reaction was controlled by the melting-temperature profiles of final 
products (dissociation curve). Ribosomal protein large p0 (Rplp0) gene gene was 
used as a control house-keeping gene for normalization. ), primers are listed in 
Table 8. Transcript fold enrichment was calculated by DDct method.To measure 
the deletion efficiency (DE) of Ring1b lox-P flanked exon 2, QPCR analysis was 
performed on genomic DNA. Ring1bΔ primers were used to detect remaining 
Ring1b exon 2 and primers annealing to Gapdh gene used as a loading control 
(Table 13). DE was calculated as DE (%) = 100% - retained exon 2 (%) for 
Ring1bfl/fland DE (%) = 50% / retained exon 2 (%) x 100 for Ring1bfl/+. 
 
Table 8. Primer sequences for quantitative PCR analysis. 
 
Rplp0 Fw TTCATTGTGGGAGCAGAC RNA 
Rplp0 Rv CAGCAGTTTCTCCAGAGC RNA 
   
Ring1b Δ Fw GTTCCATTTGTCTGCACAGCCTGAGA DNA 
Ring1b Δ Rv AGATGCTGAAGACTGGAGGGGTGT DNA 
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p21Cdkn1a Fw CCACAGCGATATCCAGACATTC RNA 
p21Cdkn1a Rv CGGAACAGGTCGGACATCA RNA 
   
Ring1a Fw AACTGAGTCTCTATGAGCTGCA RNA 
Ring1a Rv CACTCCTTGTTCCCGCTCCCG RNA 
   
Prmd1 Fw GACGGGGGTACTTCTGTTCA RNA 
Prmd1 Rv GGCATTCTTGGGAACTGTGT RNA 
   
Irf4 Fw CAATGTCCTGTGACGTTTGG RNA 
Irf4 Rv GGCTTCAGCAGACCTTATGCT RNA 
   
Xbp1 Fw TAGAAAGAAAGCCCGGATGA RNA 
Xbp1 Rv CACCAGCCTTACTCCACTCC RNA 
   
Gapdh4d FW AGCGCTGACCTTGAGGTCTCCTTG  DNA 
Gapdh4d Rv GTTGCCTACGCAGGTCTTGCTGAC  DNA 
   
   
 
2.5.4. RT-QPCR using TaqMan® Micro Fluidic Cards. 
 
 
For quantitative analysis of 95 gene transcript levels (Table 9), RT-QPCR using 
customed TaqMan® Array 384-well Micro Fluidic Cards (Applied Biosystems) was run 
on the ABI PRISM® 7900HT Real-Time PCR System and analyzed with Sequence 
Detection System software (SDS 2.1 software). Relative gene expression values were 
obtained from 7900HT system data using the Comparative CT Method for relative 
quantification. 
 
Table 9. List of genes of the TaqMan® Microfluidic Cards. 
 
Assay ID Gene Symbol 
Mm00545720_m1 Ada,mCG5441 
Mm00507774_m1 Aicda,m32207 
Mm01223702_m1 Apaf1,m0338 
Mm00431867_m1 Atm,mCG5641 
Mm01223652_m1 Atr,m0240 
Mm00464379_m1 Bach2,m2764 
Mm00432042_m1 Bad,m4907 
Mm00432045_m1 Bak1,m24181 
Mm00432050_m1 Bax,mCG23178 
Mm00477631_m1 Bcl2,m28637 
Mm01333921_m1 Bcl2l11,m1895 
Mm00477633_m1 Bcl6,m25078   
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Mm00551516_m1 Bcor,m5540 
Mm00432073_m1 Bid,m29741 
Mm01197846_m1 Blnk,mCG2382 
Mm03053308_g1 Bmi1 
Mm00515386_m1 Brca1,mCG20241 
Mm01218747_m1 Brca2,m45046 
Mm00442712_m1 Btk,m15066 
Mm00432322_m1 Casp7,m4266 
Mm00483084_m1 Cbx2,m3903 
Mm00520006_m1 Cbx7,m1514 
Mm00438070_m1 Ccnd2,m29731 
Mm01273583_m1 Ccnd3,m5576 
Mm00438084_m1 Ccng1,mCG3474 
Mm01301785_m1 Ccr7,m5362 
Mm00515420_m1 Cd19,mCG22404 
Mm00432423_m1 Cd79a,mCG7279 
Mm00434143_m1 Cd79b,mCG3044 
Mm00444543_m1 Cd86,m30169 
Mm01303209_m1 Cdkn1a,m26433 
Mm00438168_m1 Cdkn1b,mCG22259 
Mm00494449_m1 Cdkn2a,m23699 
Mm00483243_m1 Cdkn2c,mCG2421 
Mm01255578_m1 Cflar,m17843 
Mm01176757_m1 Chek1,mCG4138 
Mm00501607_m1 Creb1,m13880 
Mm01219960_m1 Crtc2,mCG22212 
Mm01292123_m1 Cxcr4,mCG20049 
Mm00445735_m1 Diablo,m1111 
Mm00432939_m1 E2f1,mCG3689 
Mm00395519_m1 Ebf1,m40647 
Mm00469651_m1 Eed,m14758 
Mm00468440_m1 Ezh1,mCG20227 
Mm00468464_m1 Ezh2,mCG2028 
Mm00487425_m1 Fos,mCG5518 
Mm00514924_m1 Foxm1,m32524 
Mm00490672_m1 Foxo1,m648 
Mm01185722_m1 Foxo3,m8802 
Mm01234672_m1 Gpr183,m42733 
Mm01246322_m1 Grb2,mCG6612 
Mm00442838_m1 Hoxc4,mCG15669 
Mm00711781_m1 Id2,mCG3640 
Mm00456421_m1 Ikzf1,mCG3994 
Mm01306721_m1 Ikzf3,mCG21902 
Mm00516431_m1 Irf4,mCG4922 
Mm00492567_m1 Irf8,mCG21199 
Mm00434561_m1 Jak2,mCG9104 
Mm00802897_m1 Lck,mCG12243 
Mm01217488_m1 Lyn,mCG3575 
Mm00442479_m1 Mapk1,mCG131169 
Mm00725832_s1 Mcl1,mCG16749 
Mm01233136_m1 Mdm2,mCG3393 
Mm00484944_m1 Mdm4,mCG12581 
Mm01227378_m1 Msh6,mCG15886 
Mm00504304_m1 Myb,mCG140750 
Mm00435502_m1 Pax5,mCG2326 
Mm00478032_m1 Pdcd6ip,mCG14774 
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Mm01282781_m1 Pik3r1,mCG115224 
Mm00777269_mH Pin1,mCG67927 
Mm00549397_m1 Plcg2,mCG127079 
Mm00451763_m1 Pmaip1,mCG12628 
Mm00712819_m1 Polq,mCG128238 
Mm00448326_m1 Pou2af1,mCG4163 
Mm00476128_m1 Prdm1,mCG17867 
Mm00440894_m1 Prkce,mCG20408 
Mm00433209_m1 Ptk2,mCG18061 
Mm00487905_m1 Rad51,mCG6194 
Mm01270936_m1 Rag1,mCG12558 
Mm00501300_m1 Rag2,mCG12559 
Mm00441097_m1 Rasgrf1,mCG122247 
Mm00803291_m1 Rev3l,mCG125811 
Mm00501395_m1 Ring1,mCG23002 
Mm00803321_m1 Rnf2,mCG8545 
Mm01974474_gH Rplp0,mCG17387 
Mm01719550_s1 Spib,mCG147775 
Mm01304152_m1 Suz12,mCG19060 
Mm01333032_m1 Syk,mCG121753 
Mm01175598_m1 Tcfe2a,mCG145500 
Mm01731287_m1 Trp53,mCG20908 
Mm00557629_m1 Trp53bp2,mCG4715 
Mm00457357_m1 Xbp1,mCG14698 
Mm00445118_m1 Xrcc2,mCG1077 
Mm00459213_m1 Xrcc4,mCG116563 
Mm00456392_m1 Yy1,mCG13054 
 
2.6. Statistical Analysis 
 
2.6.1 Student’s t-test. 
 
Statistical analysis of normally distributed values (Gaussian) was performed by two-
tailed unpaired Student’s t-test. Differences were considered significant at p-
value<0.05. 
 
2.6.2. 2-way ANOVA. 
 
Statistical analysis to compare two independent variables in grouped samples was 
performed using 2-way ANOVA test. Differences were considered significant at 
p<0.05. 
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2.6.3. Microarray analysis. 
  
Af ymetrix GeneChip® Arrays were performed at GeneChip® Mouse Gene 1.0 ST Array 
platform. The GeneChip® Mouse Gene 1.0 ST Array with more than 750,000 unique 
25-mer oligonucleotides covers the whole genome transcript. Each of the 28,853 
covered genes is represented on the array by approximately 27 probes spread across 
the full length of the gene. Raw data (CEL files) were filtered and normalized with 
Affymetrix Power Tools (APT) Software Package, using the rma-sketch algorithm to 
generate Log2 transformed intensity values.   Log2 transformed data were annotated 
and analyzed using the annotation “pd.mogene.1.1.st.v1” (Benilton Carvalho, Platform 
Design Info for Affymetrix MoGene-1_1-st-v1; R package version 3.6.0), 
“mogene11stprobeset.db” (Arthur Li, Affymetrix Mouse Gene 1.1 - ST Array  Probeset 
Revision 4 annotation data (chip mogene11stprobeset); R package version 4.0.1.), 
“mogene11sttranscriptcluster.db” (Arthur Li, Affymetrix Mouse Gene 1.1-ST Array 
Transcriptcluster Revision 4 annotation data (chip mogene11sttranscriptcluster); R 
package version 4.0.1.) and the “affy” (Gautier et al., 2004) package of R software 
version 2.16.0 (http://www.r-project.org). In order to identify genes with significant 
changes in their expression, a t-test was applied. A false discovery rate (FDR) 
correction was also introduced when p values were calculated. Genes with a cut-off of 
1.5-fold change and p value ≤ 0.05 were considered up- or down- regulated between 
different groups.  
 
2.6.4. Gene Ontology Analysis. 
 
Gene pathway enrichment was assessed using Ingenuity Pathway Analysis software 
Gene Set Enrichment analysis was performed accessing the Gene Set Analysis Tool 
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kit V2 (Zhang et al., 2005) (http://bioinfo.vanderbilt.edu/webgestalt/) in September 
2013. A hypergeometric test was run to identify ten overrepresented Gene Ontology 
categories among Biological Process, Molecular Functions and Cellular Component.   
Adjusted p values were calculated applying Benjamini & Hochberg multiple test. 
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3. Results 
3.1. Normal B cell development in Ring1a and Ring1b single 
mutants. 
 
To address the roles of Ring1a and Ring1b in B cell development, we analyzed 
the effects of the deletion of single PRC1 components on lymphocyte 
homeostasis. Previous work in the lab had shown that transcripts for Ring1a and 
Ring1b are detected throughout B cell development (Figure 10). 
 
 
 
Figure 10. PRC1 catalytic subunits are expressed throughout B cell development.  
(A) Ring1a mRNA levels in sorted B cell populations. (B) Ring1b mRNA levels in sorted B 
cell populations. mRNA levels were normalized to the housekeeping gene RPPLO and to 
levels measured in pro B cells. Pro=Pro B, Pre=Pre B, Fo= follicular B, MZ= marginal 
zone B, GC= germinal center B cells. 
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Figure 11. Structure of conditional Ring1b and Ring1a null alleles in PRC1 mutant 
mice. 
Schematic depiction of the (A) floxed Ring1b locus (Ring1bfl) and (B) the incativated 
Ring1a (Ring1a-) allele. 
 
 Given the embryonic lethality of Ring1b-deficient mice, we employed conditional 
gene targeting (Figure 11) to achieve B cell-specific E3 ligase inactivation 
(Voncken et al., 2003). Ring1bfl/fl mice carry loxP sites flanking exon 2 of the 
Ring1b gene that contains the starting ATG codon (Cales et al., 2008) (Figure  
11A). Ring1a-/- mice were generated by homologous recombination-mediated 
replacement of Ring1a coding exons with an HPRT minigene in embryonic stem 
cells (Figure 11B). Ring1a-/- animals are viable and fertile and show no overt 
phenotypes (del Mar Lorente et al., 2000). Work in our lab has shown that ablation 
of Ring1b at early stages of B cell development (Ring1bfl; Mb1-cre mutants, Figure 
12) or in peripheral B cells (Ring1bfl; Cr2-cre mutants, Figure 12) did not affect B 
cell maturation. Furthermore, ability of Ring1b-/- cells to participate in T cell-
dependent immune responses was unaffected (L. D’Artista, F. Mainoldi and S. 
Casola, unpublished data). In a similar fashion, analysis of mice devoid of Ring1a 
did not reveal major impairments in B cell development.  
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Figure 12. Schematic view of B cell development and timing of Mb1-cre- and Cr2-
cre- mediated deletion. 
 
 
Analysis of BM subsets of Ring1a-deficient animals revealed normal distribution 
among B cell subsets (Figure 13). 
 
 
Figure 13. Ring1a-/- cells are able to proceed through early B cell developmental 
stages. 
Flow cytometric analysis of control (left) and mutant (right) BM B cell subsets. Numbers 
indicate frequency of corresponding gated populations and are representative of 3 
independent experiments. R1a=Ring1a. 
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In the periphery, B cell numbers were comparable to those of wild-type animals, 
and so was the distribution of B cells between the follicular (FO) and marginal 
zone (MZ) B cell subsets (Figure 14 and Figure 15).  
 
 
Figure 14. Absolute numbers of CD19+ cells in spleens of control and mutant 
animals. 
 
We then asked whether lack of Ring1a would influence the ability of mature B cells 
to participate in T-dependent immune responses. To test this, experimental and 
control animals were immunized with alum-precipitated 4-nytrohenyl-acetyl (NP) 
coupled to chicken gamma globulin (CGG) and germinal center (GC) formation 
was analyzed 14 days later. Flow cytometric analysis of cell frequencies within the 
CD19+CD38loFAShi GC subset indicated no substantial differences between wild-
type and mutant animals (Figure 16). 
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Figure 15. Ring1a is dispensable for peripheral B cell development. 
Flow cytometric analysis of the main control (left) and mutant (right) splenic B cell subsets. 
Numbers indicate frequency of corresponding gated populations and are representative of 
7 independent experiments. 
 
 
 
Figure 16. Ring1a-/- cells can give rise to germinal centers. 
Flow cytometric analysis of the control (left) and mutant (right) splenic GC formation at 
day 14 following immunization with NP-CGG. Numbers indicate frequency of 
corresponding gated populations and are representative of 3 independent experiments. 
 
 
Given early embryonic lethality of Ring1b mutant animals, we wondered whether 
failure to detect any defect in Ring1b-deficient B cells may reflect strong counter-
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selection of mutant B cells in the periphery. To address this, we purified naïve B 
cells from spleens of Ring1bfl; Cr2-cre and control animals and estimated protein 
levels of Ring1a and Ring1b. Immunoblotting revealed efficient deletion of Ring1b 
in peripheral B cells and levels of monoubiquitinated H2A (H2AK119Ub) similar to 
those of control animals. This may reflect the fact that the mark is not diluted in the 
absence of cell proliferation and active ubiquitin removal, or may reflect 
compensatory mechanisms employed by the cell to avoid the loss of the 
H2AK119Ub mark. Up-regulation of Ring1a in Ring1b-deficient B cells argues in 
favor of the latter hypothesis (Figure 17).  
 
 
 
Figure 17. Up-regulation of Ring1a following Cre-mediated deletion of Ring1b in 
peripheral B cells. 
Immunoblot analysis of levels of Ring1a, Ring1b and H2AK119Ub (H2AUb) in CD19+ 
cells isolated from spleens of control (R1b fl/+, left column) and mutant (R1b fl/fl, right 
column) animals. Results shown are representative of 3 independent experiments. 
 
 
R1a 
R1b 
H2AUb 
H2A 
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Taken together, this suggests that PRC1 activity is important in B cell 
development, and that lack of the major E3 ubiquitin ligase, Ring1b, activates a 
compensatory mechanism that involves up-regulation of its paralog, Ring1a. 
 
3.2. PRC1 in early B cell development. 
 
To overcome possible compensatory mechanisms activated by loss of only one of 
the PRC1 ubiquitin ligases, we generated compound Ring1a-/-Ring1bfl/fl mutant  
mice and bred them to Mb1-cre knock-in animals to address the role of PRC1 in 
early B cell development. In Mb1-cre mice, Cre-mediated recombination starts in 
pro-B cells and continues throughout B-cell development (Hobeika et al., 2006) 
(Figure 12). Flow cytometric analysis of bone marrow (BM) cell suspensions 
revealed a significant block in B cell development in PRC1 conditional mutant 
mice. In the latter animals, most B cells represented B220+IgM-CD43+ pro B cells 
(Figure  18A and B). 
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Figure 18. B cells devoid of PRC1 are blocked at the pro B cell stage. 
Flow cytometric analysis of control (left) and mutant (right) BM (a) and B220+IgM- (b) 
pro/pre B cells. Numbers indicate frequency of corresponding gated populations and are 
representative of 3 independent experiments. R1b=Ring1b. 
 
 
Such increase in the proportion of pro B cells was not mirrored by absolute B cell 
numbers, which remained unchanged (Figure 19).  
 
 
A 
B 
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Figure 19. Absolute numbers of progenitor (pro and pre) and IgM+ (immature and 
recirculating) B cells upon conditional PRC1 ablation in pro-B cells. 
 
Bars represent absolute cell numbers within each compartment. Pro= Pro-B cells 
(B220+IgM-CD43+). Pre=Pre B cells (B220+IgM-CD43+), immature (B220+IgMloCD43-) and 
recirculating (B220+IgMhiCD43+). Results are shown as average +/- SEM of 3 independent 
animals/genotype. 
 
 
Instead, the pre B cell compartment of mutant animals was more than 4-fold 
decreased in both frequency and absolute numbers. As a consequence of the 
observed block in transition from the pro- to the pre- B cell stage, frequency and 
numbers of immature (B220loIgM+) and recirculating (B220+IgM+) B cells were 
significantly reduced (Figure 18A and Figure 19). Additionally, the few CD19+ B 
cells retrieved in the spleen of Ring1a-/-; Ring1bfl/fl;Mb1-cre mice retained Ring1b 
expression (Figure 20), suggesting that only escapers of Cre-mediated 
recombination could give rise to mature peripheral B cells. 
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Figure 20. Counter-selection of Ring1a-/-Ring1b-/- B cells. 
Western blot analysis of MACS-sorted CD19+ splenic B cell suspensions from animals of 
the indicated genotypes. H3= histone H3. 
 
 
Together, the block in transition from the pro-B to the pre-B cell stage and the 
counter-selection of PRC1 mutant B cells in peripheral lymphoid organs highlight 
an essential contribution of PRC1 in early B cell development. 
 
3.3. PRC1 in peripheral B cell development 
 
3.3.1. PRC1 is critical for peripheral B cell maturation 
 
To address the role of Ring1a and Ring1b in peripheral B cell development, we 
bred Ring1a-/-Ring1bfl/fl mice to Cd23-cre transgenic animals. In compound 
mutants, the deletion of the PRC1 is induced in the majority of B cells expressing 
the FcεRII low affinity IgE receptor (Kwon et al., 2008). Such receptor starts being 
expressed in B cells at the late transitional stage, which then develop into mature 
B lymphocytes. PRC1 inactivation in peripheral B cells marginally affected the 
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number of CD19+ B cells in the spleen, mesenteryc lymph nodes and Peyer’s 
patches (Figure 21).  
 
 
 
Figure 21. Absolute numbers of Cd19+ cells in secondary lymphoid organs are not 
affected by loss of Ring1a and Ring1b. 
 
 
PRC1-deficient peripheral B cells were then subjected to a comprehensive 
immunophenotypic analysis. This revealed aberrant expression of several surface 
markers in mutant B cells when compared to controls. The most striking alteration 
in PRC1 conditional mutant mice was the overepresentation of B cells expressing 
the CD93/AA4.1 marker, which typically identifies transitional and immature B cells 
(Allman et al., 2001b)  (Figure 22 and Figure 23).  
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Figure 22. The majority of CD19+ cells in the periphery of mutant animals are 
AA4.1+. 
Flow cytometric analysis of control (left) and mutant (right) spleens. Numbers indicate 
frequency of corresponding gated populations and are representative of at least 9 
independent experiments. 
 
 
 
Figure 23. Absolute numbers of AA4.1+ and AA4.1- cells in spleens of control and 
mutant animals. 
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In mutant splenic B cells, expression of AA4.1 was associated with that of the 
immature marker CD24/HSA and the pro-apoptotic receptor CD95/FAS to levels 
comparable to those detected in bona fide B220+AA4.1+ immature transitional B 
cells in control animals (Figure 24).  
 
 
Figure 24.  Levels of surface markers within AA4.1+ cells in Ring1a/Ring1b mutants 
is comparable to those of wild-type transitional B cells. 
Flow cytometric analysis of surface marker expression comparing levels of AA4.1, FAS 
and CD24 between immature transitional B220+AA4.1+ cells from controls (light grey line) 
and the over-grown B220+AA4.1+ found in mutant Ring1a-/-;Ring1bff/fl;Cd23-cre animals 
(dark grey line). Data are representative of 6 independent experiments. 
 
 
These results highlighted the possibility that PRC1 inactivation in late transitional B 
cells (when Cd23-cre expression is induced) impairs their differentiation into 
mature follicular (FO) and marzinal zone (MZ) B cells. Quite surprisingly, the 
majority of AA4.1+ B cells in the spleen of Ring1a-/-;Ring1bfl/fl;Cd23-cre mice also 
expressed high levels of the complement receptor Cr2/Cd21, which marks mature 
B cells. Moreover, levels of the pro-survival receptor BAFF-R, which increases 
during B cell maturation, were comparable between PRC1 mutant B220+AA4.1+ B 
cells and control bona fide mature B cells (B220+AA4.1-) (Figure 25). Next, we 
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addressed whether expression of the BCR, which mediates tonic signaling 
required for survival of peripheral B cells, was retained on B cells of Ring1a-/-
;Ring1bfl/fl;Cd23-cre. Mutant B cells expressed IgM and IgD similar to their WT 
counterparts, suggesting that surface BCR expression is retained in B cells devoid 
of PRC1 (Figure 26). Of note, IgM expression was higher in PRC1 deficient B 
cells, which is in agreeement with higher abundance of immature cells in mutant 
animals (Figure 26B).  
 
 
 
Figure 25. Levels of Cr2/CD21 and BAFF-R are similar between AA4.1+ PRC1 mutant 
cells and AA4.1- wild-type cells. 
Flow cytometric analysis of surface expression the B cell maturation-associated marker 
Cr2/CD21 and BAFF-R comparing bona fide mature B cells (B220+AA4.1-) from spleens 
of control animals (light grey line) and B220+AA4.1+ cells constituting most of the B cells 
retrieved in the periphery of Ring1a/Ring1b mutants (dark grey line). The wild-type 
B220+AA4.1+(full ivory histogram) population displaying lower levels of both Cr2/CD21 
and BAFF-R is shown. Data are representative of 6 independent experiments. 
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Figure 26. Ring1a/Ring1b mutant cells express surface IgM and IgD. 
(A) Flow cytometric analysis of IgM and IgD expression on B220+ cells in the spleens of 
mutant (right) and control animals (left). (B) Comparison of IgM expression on B cells from 
spleens of control (light grey line) and mutant animals (black line). Data are representative 
of 3 independent experiments. 
 
To assess the degree of PRC1 inactivation, AA4.1+B220+ B cells were purified 
from the spleens of Ring1a-/-;Ring1bfl/fl;Cd23-cre mice and tested by 
immunoblotting analysis for Ring1a and Ring1b expression. Lack of Ring1a was 
coupled to reduced levels of the Ring1b protein. A similar analysis was also 
performed on a minor fraction of B220+AA4.1- mature B cells detected in 
compound mutants. In those cells, levels of Ring1b and H2AK119Ub were more 
reduced than in their AA4.1+ counterparts, in accordance with their longer 
A 
B 
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exposure to Cre activity. These results suggest that PRC1 is required for correct 
maturation of transitional B cells (Figure 27). 
 
 
 
Figure 27. Loss of Ring1a and Ring1b is compatible with peripheral B cell 
maturation. 
Western blot analysis of sorted splenic B cell populations from animals of the indicated 
genotypes. Results are representative of 2 independent experiments. 
 
 
 
3.3.2. PRC1 mutant B cells migrate into follicles and the marginal 
zone 
 
B cell maturation is associated with the ability of cells to home to B cell follicles in 
secondary lymphoid organs. Also, a fraction of mature B cells in the spleen resides 
in the MZ, in close proximity with the blood stream where it is involved in the 
recognition and response to blood-borne pathogens (Lopes-Carvalho and 
Kearney, 2004). To address whether expression of the Cr2/CD21 and the BAFF-R 
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markers reflected the acquisition of FO and MZ properties by PRC1 mutant cells, 
we performed both immunophenotypic and histological analyses. By flow 
cytometric analysis, we identified both bona fide FO (CD19+CD21+CD23+CD38+) 
and MZ (CD21hiCD23loCD38hi) B cells in the spleens of PRC1 mutant mice (Figure 
28 and Figure 29), which resembled peripheral B cells retrieved in spleens of 
control animals. Further analysis of relative frequencies and absolute numbers of 
FO and MZ B cells revealed that loss of PRC1 mainly affects the former subset, 
leaving the latter relatively untouched (Figure 29). 
 
 
Figure 28. Ring1a/Ring1b mutant cells display markers of mature cells and 
segregate into mature B cell subsets. 
 
 
100 
Flow cytometric analysis of the FO (CD19+CD21+CD23+CD38+) and MZ 
(CD21hiCD23loCD38hi) B cell subsets in spleens of control (left) and mutant (right) animals. 
Data are representative of 6 independent experiments. 
 
 
 
Figure 29. Loss of PRC1 impairs maturation in the follicular B cell subset. 
Absolute numbers of  (A) splenic FO (CD19+CD21+CD23+CD38+) B cells in and (B) MZ 
(CD21hiCD23loCD38hi) wild-type and mutant animals. 
 
The concomitant presence of surface markers typical of immature (Cd24/HSA, 
Cd95/FAS and Cd93/AA4.1) and mature (Cr2/Cd21, Cd38) B cells suggests that 
the loss of Ring1a and Ring1b in resting peripheral B lymphocytes leads to a 
defect in maturation whereby cells undergo aberrant maturation towards the 
mature B cell compartment. The identity of FO and MZ B cells was further 
assessed performing immunofluorescence analysis of splenic sections of PRC1 
control and mutant mice. This analysis showed proper distribution of PRC1 mutant 
B cells within B220+ folicular B cell areas. Moreover, lack of PRC1 did not preclude 
the ability of a subset of mutant B cells to reside in the marginal zone delimited by 
MOMA1+ macrophages (Figure 30 and Figure 31A and B). Additionally, in spite of 
A B 
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reduced frequency and absolute numbers of FO B cells revealed by 
immunophenotypic analysis, no difference between the size of mutant and control 
follicles was highlighted by immunofluorescence analysis (Figure  31A). 
 
 
Figure 30. Ring1a-/-Ring1b-/- B cells home to spleen follicles and form the marginal 
zone layer. 
Immunufluorescence analsysis of control (left) and mutant (right) spleen sections for B220 
(green) and MOMA-1 (red). Indicated are the B220+ marginal zone (MZ) B cell layer, the 
follicle (FO) and the MOMA1+ metallophilic macrophages (MM).  
 
 
 
Figure 31. Marginal zone and B cell follicles are formed upon knock-out of Ring1a 
and Ring1b. 
A B 
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Quantification of (A) marginal zone thickness and (B) of B cell follicles diameter in control 
and mutant animals. Results are shown as mean +/- SEM of a total of 30 measurements 
(A) per sample from two independent animals and 22 measurements for (B). 
 
 
3.3.3.  PRC1 inactivation in mature B cells delays bone marrow 
exhaustion  
 
The recruitment of B cells into the mature B cell pool is marked by their ability to 
recirculate through secondary lymphoid organs and to the BM. Presence of 
adequate numbers of mature B cells in peripheral lymphoid organs is sensed by 
the BM, which slows down progenitor B cell production. Conversely, lack of 
adequate B cell peripheral maturation results in homeostatic compensatory 
mechanisms leading to more sustained and prolonged B cell production (Keren et 
al., 2011). 
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Figure 32. Ring1a-/-Ring1b-/- mice display more sustained B cell production and 
lower frequencies of recirculating B cells. 
Flow cytometric analysis of bone marrow B cell suspensions from age-matched young (A) 
and aged (B) control and experimental animals. Frequencies of the indicated gates are 
representative of 4 independent experiments. 
 
 
The reduction in the number of PRC1 mutant FO B cells, coupled to their aberrant 
maturation could potentiate early B cell development as a feedback compensatory 
mechanism. Indeed, flow cytometric analysis of BM cells from control and PRC1 
mutant mice revealed lower frequencies of IgM+ B220+ recirculating B cells in the 
latter samples (Figure 32A). Morever, similar analysis on 14-month-old animals 
revealed a substantial higher frequency of progenitor B cells in the BM of PRC1 
mutant animals as compared with those from age-matched control mice (Figure 
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32B). These results suggest that PRC1 inactivation in mature B cells activates a 
compensatory mechanism based on potentiation of early B-cell lymphopoiesis in 
order to normalize the peripheral B cell pool. 
 
3.3.4.  PRC1 regulates  the transcriptome profile of mature B cells   
 
In an attempt to identify the molecular mechanism underlying the developmental 
aberrancies observed in PRC1 mutant mice, we performed transcriptome analysis 
of splenic CD19+ B cells of mutant and control mice. Such analysis revealed 
extensive alterations in the gene expression profile  of B cells in response to PRC1 
inactivation. Specifically, most differentially expressed genes were up-regulated in 
PRC1 mutant B cells (n=343, 88%), whereas only a handful (n=48, 12%) were 
down-regulated (Figure 33).  
 
Figure 33. Gene deregulation in Ring1a-/-Ring1b-/- CD19+ cells. 
Relative distribution of up- and down-regulated genes in transcriptome obtained from 
CD19+ cells of 3 mutant and 3 control animals. Results were filtered according to 
0,5<FC>1,5 and p-value<0,05. 
 
 
Up  
343 
down 
48 
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We performed gene ontology (GO) analysis to identify gene categories 
significantly overrepresented among up- and down regulated genes in PRC1 
mutant B cells.  In mature B cells, PRC1 was specifically required to repress 
genes involved in various developmental processes (Figure 34). Instead, PRC1 
acted as a positive regulator in the expression of genes controlling cell cycle 
regulation and S phase progression (Figure 34B).  
 
 
 
Figure 34. Up-and down-regulated genes in Ring1a;Ring1b double mutant B  cells 
belong to different functional GO categories. 
Gene ontology analysis of categories enriched within up-regulated (A) and down-
regulated genes (B).  
 
 
Next, we tried to assess whether genes de-regulated upon loss of Ring1a and 
Ring1b were direct PcG targets in peripheral B cells. To this end, since data 
concerning genome-wide occupancy of PRC1 in B cells was lacking, we 
intersected the list of differentially expressed genes in PRC1 mutant B cells to that 
of H3K27me3/PRC2 targets in splenic mature B cells (FO and MZ B cells) recently 
established by our group (C. Carrisi, F. Zanardi and S. Casola unpublished data; 
Figure 35). This analysis showed that 45% of genes de-repressed in PRC1 mutant 
B cells are marked by H3K27me3 and therefore bound by PRC2 (165 out of 387) 
in peripheral B cells, thereby representing bona fide PcG target genes. Instead, 
A B 
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only 22% (132 out of 609) of the down-regulated genes were also marked by 
H3K27me3, suggesting that most of them are controlled indirectly by PRC1. These 
results are consistent with PRC1 acting predominantly to promote transcriptional 
repression in mature B cells. 
 
 
 
Figure 35. Relative enrichment for H3K27me3-marked loci among genes up- and 
down- regulated in CD19+ cells from Ring1a/Ring1b mutants. 
Pie charts displaying relative enrichment of H3K27me3 loci among genes deregulated 
following loss of PRC1, Lists of up- and down- regulated genes were intersected with lists 
of H3K27me3 genome-wide occupancy and enrichment calculated based on the 
proportion of genes marked by H3K27me3 within each category. Preferential enrichment 
for H3K27me3 targets among up-regulated genes was found to be highly significant (p-
value <0.0001), whereas the enrichment for loci targeted by H3K27me3 and down-
regulated following PRC1 loss did not reach statistical significance (p-value=0.485) 
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3.4. PRC1 and B cell immunity 
 
3.4.1. PRC1 inactivation in GC B cell founders impairs germinal 
center responses  
 
Expression of PRC1 components is conserved in B cells recruited into the 
germinal center (GC) reaction during a T cell-dependent immune response (L. 
D’Artista, F. Mainoldi and S. Casola, unpublished data). To assess the effects of B 
cell-specific PRC1 inactivation on GC responses, we immunized controls and 
Ring1a-/-;Ring1bff/fl;Cd23-cre compound mutants with alum-precipitated 4-
nytrohenyl-acetyl (NP) coupled to chicken gamma globulin (CGG). GC responses 
were analyzed at day 14 post-immunization. PRC1 conditional mutant mice 
displayed a significant reduction in the frequency and numbers of splenic 
CD19+FAShiCD38lo GC B cells as compared to controls (Figure 36 and Figure 37).  
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Figure 36. GC B cell development is impaired upon loss of Ring1a and Ring1b. 
Flow cytometric analysis displaying GC B cell frequencies at day 14 post NP-CGG 
immunization in control (left) and experimental Ring1a-/-;Ring1bff/fl;Cd23-cre (right) 
animals. Frequencies of the indicated gates are representative of 8 independent 
experiments. 
 
 
 
 
 
Figure 37. GC B cell numbers are reduced upon PRC1 inactivation. 
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To confirm these results, we performed histological analysis of the GC master 
regulator Bcl6 on splenic sections of animals immunized with the T cell-dependent 
sheep red blood cell (SRBC) antigen, which induces a faster and more robust 
immune response as compared with NP (Figure 38) (Luster et al., 1988).  
 
 
 
Figure 38. Significant reduction of GC number in PRC1 mutants. 
Spleen samples were collected from sheep red blood cells-immunized mutant (n=3) and 
control (n=2) animals at day 8 post-immunization with SRBCs. Paraffin-embedded 
sections were stained for the GC reaction master regulator Bcl6. Representative stainings 
for control and mutant animals are shown with arrowheads indicating Bcl6+ foci. 
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Quantification of Bcl6+ GCs revealed a significant reduction in their number in 
spleen sections of PRC1 mutants as compared to controls (Figure 39). Instead, 
average GCs size remained unchanged after Ring1a/Ring1b loss. 
  
 
 
Figure 39. Significant reduction in GC frequency in Ring1a/Ring1b mutants. 
 
To assess whether the remaining B cells detected in the GCs of mutant animals 
had undergone Cre-mediated recombination at the Ring1b locus, we performed 
quantitative PCR (q-PCR) analysis on genomic DNA extracted from sorted cells. 
Whereas up to 80% of FO B cells in Ring1a-/-; Ring1bff/fl;Cd23-cre mice showed 
efficient deletion of the floxed segment, the frequency of Ring1b mutant B cells 
dropped to 60% when isolated from the GC (Figure 40). 
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Figure 40. Status of the Ring1b gene in GC B cells from Ring1a-/-Ring1bfl/fl Cd23-cre 
mutant and control mice. 
Q-PCR was performed on genomic DNA with primers annealing to the Ring1b region 
encoding the fragment excised upon Cre-mediated recombination. Data shown in (A) 
represent the percentage of retained Ring1b allele in follicular and germinal center B cells. 
Data shown in (B) represent deletion efficiency. Data are representative of 3 independent 
experiments analyzed and are presented as mean +/- SEM. 
 
This result is consistent with the preferential expansion of PRC1 proficient B cells 
carrying in most cases only one recombined Ring1b allele within the GC 
compartment. To address this hypothesis, Ring1a-/-Ring1bfl/flCd23-cre animals 
were bred to the Rosa26-EYFP (R26-EYFPfl-STOP) Cre reporter strain. In R26-
EYFP mice, EYFP expression is induced upon Cre-mediated excision of a 
transcription termination sequence (STOP cassette), flanked by loxP sites  
(Srinivas et al., 2001) (Figure 41). 
 
 
A B 
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Figure 41. Schematic view of the R26-EYFPfl-STOP reporter system. 
 
Flow cytometric analysis of GC B cells from NP-CGG immunized controls (Ring1a-
/-;Ring1bfl/+;Cd23-cre R26-EYFP) and PRC1 conditional mutants (Ring1a-/-; 
Ring1bff/fl;Cd23-cre;R26-EYFP) revealed a strong reduction of YFP/Cre-
expressing cells as a result of Ring1a/Ring1b double inactivation (Figure 42). 
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Figure 42. Ring1a-/-Ring1b-/- GC B cells are counter-selected in vivo. 
Flow cytometric analysis of CD19+ splenic GC B cells from control and mutant animals. 
Numbers indicate the percentage of GC B cells (A). (B) Histogram plot displaying 
percentages of EYFP-expressing cells within the GC compartment. Data shown are 
representative of 3 independent experiments. 
 
 
3.4.2. PRC1 inactivation triggers counter-selection of mutant GC 
B cells  
 
To exclude that the defects seen in GC responses of Ring1a-/-;Ring1blf/fl;Cd23-cre 
mutants resulted from developmental defects of PRC1 mutant GC B cell founders, 
we crossed Ring1a-/-Ring1bfl/fl mice to Cγ1-cre transgenic animals. In compound 
A 
B 
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mutants, PRC1 inactivation is specifically induced in GC B cells undergoing IgG1 
class-switch recombination (Casola et al., 2006) (Figure 43).  
 
 
Figure 43 . Schematic view of B cell development and timing of Cγ1-cre-mediated 
deletion. 
 
In apparent contrast to what observed in Ring1a-/-; Ring1bff/fl;Cd23-cre animals, 
mice deprived of PRC1 specifically in GC B cells formed GCs with efficiency 
comparable to that of their WT counterparts (Figure 44).  
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Figure 44. Efficiency of GC formation by Ring1a-/-; Ring1bfl/fl; Cγ1-cre animals is 
comparable to that of controls. 
Flow cytometric analysis displaying GC B cell frequencies at day 14 post NP-CGG 
immunization following Cγ1-cre-mediated deletion. Data shown are representative of 6 
independent experiments. 
 
To assess the efficiency of Cre-mediated recombination in Ring1a-/-; Ring1bfl/fl; 
Cγ1-cre GC B cells, we performed genomic q-PCR analysis for the Ring1b floxed 
segment on sorted cells. Strikingly, Ring1b inactivation in GC B cells caused a 
dramatic counter-selection of mutant cells, leading to the preferential rapid 
outgrowth of PRC1 proficient B cells that failed to express Cre recombinase 
(Figure 45).  
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Figure 45. Status of the Ring1b gene in GC B cells from Ring1a-/-Ring1bfl/fl Cγ1-cre 
mutant and control mice. 
Q-PCR was performed on genomic DNA with primers annealing to the Ring1b region 
coding for the fragment excised upon Cre-mediated recombination. Data shown in (A) 
represent the percentage of retained Ring1b allele in follicular and germinal center B cells. 
Data shown in (B) represent deletion efficiency. Data are representative of 3 
mice/genotype analyzed and data are presented as mean +/- SEM. 
 
When expression of Cre recombinase was induced in the vast majority of GC B 
cells, such as when Ring1a-/-/Ring1bfl/fl mice were bred to the Aicda-cre strain 
(Figure 46) (Crouch et al., 2007), the reduction in GC B cell frequencies and 
numbers became very substantial (Figure 47). 
 
  
Figure 46. Schematic view of B cell development and timing of Aicda-cre-mediated 
deletion. 
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Figure 47. Impaired GC formation in Ring1a-/-Ring1bfl/fl Aicda-cre animals. 
Flow cytometric analysis displaying GC B cell frequencies at day 14 post NP-CGG 
immunization following Aicda-cre-mediated deletion. Data are representative of 3 
independent experiments. 
 
All together, these results indicate that inhibition of PRC1 in GC B cells or their 
direct progenitors prevents their ability to clonally expand in response to the 
recognition of cognate antigen. 
 
3.4.3. Antibody responses are compromised upon PRC1 
inactivation 
 
In order to assess the role of PRC1 in the establishment of an antibody response 
to foreign antigens, we immunized mutant Ring1a-/-;Ring1bfl/fl;Cγ1-cre mutants and 
controls with the T cell-dependent antigen NP-CGG. 
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Figure 48. Sera collection scheme for the analysis of primary and secondary 
antibody responses. 
 
Blood sera samples were collected at different time points after immunization 
(Figure 48) and antigen-specific IgM and IgG1 titers were determined by 
Enzyme/linked immunosorbent assay (ELISA). NP-specific Ig titers were 
significantly reduced in response to GC B cell-specific inactivation of PRC1. The 
reduction affected mainly IgG1 serum titers, in accordance with the preferential 
expression of the Cγ1-cre transgene in IgG1-class switched B cells (Figure 49A 
and B). The impairment in antibody responses in PRC1 mutant mice was already 
detected 7 days after primary immunization and became increasingly evident at 
later time points. 
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Figure 49. PRC1-deficient mice display an impaired antibody response. 
ELISA analysis of blood sera collected from control and mutant mice at the indicated time 
points following NP-CGG immunization.  
 
 
We also measured how PRC1 mutant mice responded to antigenic re-challenges 
in recall responses. Specifically, PRC1 control and mutant (Ring1a-/-
;Ring1bfl/fl;Cγ1-cre) animals were immunized with NP-CGG and re-challenged 60 
days later with lower doses of the same antigen, when the primary response had 
faded away and high affinity memory B cells had been generated. Blood sera were 
collected 7 days following secondary immunization and high-affinity NP-specific 
IgG1 antibodies quantified by ELISA assay. Data revealed that PRC1 inactivation 
caused an over 10-fold reduction in high-affinity antibody responses (Figure 50). 
 
 
 
A B 
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Figure 50. PRC1-deficient mice display impaired recall resposes. 
ELISA analysis of blood sera collected from control and mutant mice at the indicated time 
points following NP-CGG boost. 
 
 
3.4.4. PRC1 is required for memory B cell formation 
 
The reduction in antibody titers produced during secondary immunizations 
suggested an impairment in memory B cell formation in Ring1a/Ring1b double 
mutants. To test this hypothesis, we measured the proportion of memory B cells in 
the spleen 60 days after NP-CGG immunization (Figure 51).  
 
 
 
Figure 51. Timeline for the analysis of memory B cell formation. 
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Antigen-specific memory B cells were identified by flow cytometric analysis as 
CD19+NIP+PNAloIgκloIgG1+. In Ring1a-/-;Ring1bfl/fl;Cγ1-cre mice, we observed a 
30-fold reduction in the frequency of antigen-specific IgG1 memory B cells as 
compared to controls (Figure 52 and Figure 53). 
 
 
Figure 52. Frequency of memory B cells in Ring1a-/-Ring1bfl/fl Cγ1-cre animals is 
lower  than that of controls. 
Flow cytometric analysis displaying frequency of memory B cells at day 60 post NP-CGG 
immunization in control (left) and mutant (right) animals. Data are representative of 6 
independent experiments. 
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Figure 53. Frequency of memory B cells is lower in Ring1a/Ring1b mutants 
compared to controls. 
Frequencies of CD19+PNAloκloNP+IgG1+ cells in control (left) and mutant (right) animals, 
each shown as a single dot. Data are presented +/- SEM. 
 
 
The strong reduction in memory B cells detected 2 months after primary 
immunization could have resulted from a defect in their formation and/or 
maintenance. To address this question, Ring1a-/-;Ring1bfl/fl;Cγ1-cre experimental 
and control mice were immunized with NP-CGG and the frequency of newly 
generated IgG1 memory B cells was analyzed by flow cytometry at day 14 post 
immunization, at the peak of the GC response. At this time, the frequency of 
memory B cells was significantly lower in PRC1 mutant animals in comparison to 
controls (0,08% vs 0,003%) (Figure 54).  
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Figure 54. Absence of Ring1a and Ring1b interferes with memory B cell formation. 
Flow cytometric analysis displaying frequency of memory B cells at day 14 post NP-CGG 
immunization in control (left) and mutant (right) animals. Data are representative of 4 
animals/genotype. 
 
 
We therefore conclude that Ring1a and Ring1b are essential for the formation of 
antigen-specific, high affinity long-lived memory B cells. 
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3.5. How does PRC1 regulate B cell function? 
 
3.5.1. PRC1 protects GC B cells from apoptosis 
 
The significant counter-selection of PRC1 mutant B cells seen in the GC could 
depend on impaired survival of the cells. To test this hypothesis, we first activated 
primary B cells from controls and Ring1a-/-;Ring1bfl/fl;Cd23-cre compound mutants 
with bacterial  lipopolysaccharide (LPS) to closely monitor their behavior in vitro. 
Three days after stimulation, B cells were stained with fluorescent-labeled VAD-
FMK (CaspGLOWTM), which binds to active caspases, and analyzed by flow 
cytometry. Inactivation of PRC1 increased by approximately 1.5-fold the proportion 
of apoptotic B cells in response to LPS stimulation (Figure 55). 
  
 
Figure 55. Increased apoptosis upon in vitro stimulation of Ring1a-/-Ring1b-/- cells. 
Flow cytometric analysis of Caspase glow+ cells from Ring1a-/-;Ring1bfl/fl;Cd23-cre and 
control cultures at day 3 of LPS and IL-4 (A) and LPS (B) stimulation. Data are 
representative of 3 independent experiments. 
 
On the basis of these results, similar analyses were performed in vivo on Ring1a-/-
;Ring1bff/fl;Cd23-cre mutant and control animals, which were  immunized with 
alum-NP-CGG. Assessment of the fraction of Caspase GLOW+ B cells among 
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CD19+FAShiCD38lo GC B cells was performed at the peak of the response. Flow 
cytometric analysis revealed a significant increase in the frequency of apoptotic 
GC B cells in response to PRC1 inactivation (Figure 56 and Figure 57). 
 
 
Figure 56. Apoptosis in GC B cells. 
Flow cytometric analysis of the fraction of Caspase glow+ cells within the 
CD19+CD38loFAShi GC compartment of control (left) and mutant (right) animals at day 14 
post NP-CGG immunization. Data shown are representative of 6 independent 
experiments. 
 
 
 
Figure 57. Increased frequency of apoptotic GC B cells upon lack of Ring1a and 
Ring1b. 
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To investigate the possible mechanisms responsible for the heightened apoptosis 
of PRC1 mutant GC B cells we quantified transcripts of several pro- (Apaf1, Bad, 
Bak1, Bax, Bcl2l11, Bid, Casp7, Diablo, Foxo3, Moap1, Pmaip1, Trp53bp2) and 
anti-apoptotic (Bcl2, Cflar, Mdm4, Pdcd6ip, Mcl-1) factors. Except for Foxo3, 
expression of the main pro-apoptotic factors, including several BCL2 family 
members were unaffected (Bax, Bax1, Bim, Bcl2l11) or down-regulated (Bad) in 
PRC1 mutant GC B cells. Instead, transcripts coding for anti-apoptotic proteins 
Mcl1 and Bcl2 were substantially up-regulated in Ring1a/Ring1b double mutant 
GC B cells (Figure 58).  
 
 
Figure 58. Loss of PRC1 leads to de-regulation of pro- and anti-apoptotic genes in 
GC B cells. 
Q-PCR of transcript levels for the indicated genes in GC B cells sorted from 11 Ring1a-/-
;Ring1bff/fl;Cd23-cre mutant and 11 Ring1a+/+-;Ring1+/+;Cd23-cre control animals. 
Transcript levels were normalized using Rplp0. Genes were filtered based on number of 
samples where consistent up- or down-regulation was detected in >= 5 samples and if 
0,5<FC>1,5. Bars represent mean values +/- SEM. 
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All together, our data assign to PRC1 a critical role in the protection of GC B cells 
from programmed cell death, which is independent of the activation of the 
mitochondrial pathway.  
 
3.5.2. Does AID contribute to apoptosis of PRC1 mutant B cells? 
 
Recent work in our laboratory has shown that Activation-Induced Cytidine 
Deaminase (AID) is a major trigger of cell death in GC B cells lacking the catalytic 
subunit of PRC2, Ezh2 (Caganova et al., 2013). Moreover, we could also show 
that apoptosis of Ezh2 mutant B cells correlated with the induction of genotoxic 
stress. To test whether AID contributed to the apoptosis of PRC1 mutant B cells, 
we initially measured the fraction of Ig class-switched B cells generated in vitro 
after LPS+/- IL-4 stimulation as a readout of AID activity. Flow cytometric analysis 
revealed a reduction in the proportion of PRC1 mutant B cells that switched to 
either become IgG3-(LPS) and IgG1-(LPS+IL-4) expressing B cells (Figure 59).  
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Figure 59. Reduction in frequency of isotype-switched cells in Ring1a-/-Ring1b-/- 
cultures.  
Flow cytometric analysis displaying frequency of (A) CD19+IgG1+ and (B) CD19+IgG3+ 
cells at day 3 following stimulation of purified naïve B cells with LPS and IL-4 or LPS 
alone, respectively, in control (left) and mutant (right) animals. Data are representative of 
3 independent experiments. 
 
This result is compatible with a scenario in which induction of AID prior to class-
switching reduces the viability of activated B cells lacking functional PRC1, as a 
consequence of impaired ability to cope with AID-induced DNA double-strand 
breaks. To corroborate this hypothesis, PRC1 mutant and control B cells were 
activated in vitro with an agonistic antibody against the Toll-like receptor RP-105. 
Similarly to LPS, stimulation through RP-105 induces intense B cell proliferation 
A 
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but, in contrast to endotoxin, it does not induce AID expression (Ogata et al., 
2000). Importantly, stimulation of PRC1 mutant B cells through RP-105 led to a 
robust mitogenic response (data not shown) without any detectable effect on 
apoptosis (Figure 60). 
 
 
Figure 60. Lack of AID induction prevents apoptosis of Ring1a-/-Ring1b-/- cells. 
(A) Representative histogram plot displaying frequency of apoptotic cells at day 3 of RP-
105 treatment. (B) Frequency of caspase positive cells presented as mean +/- SEM of 3 
independent experiments.  
 
 
3.5.3. PRC1 facilitates G1-to-S transition in activated B cells 
 
Given the high proliferative rate that characterizes B cells recruited into the GC 
reaction and considering the well-documented role of PcG proteins in regulating 
transcription of the Cdkn2a locus, we determined whether PRC1 inactivation 
affected expression of cell-cycle regulators in mutant GC B cells. To this end, we 
immunized Ring1a-/-;Ring1bff/fl;Cd23-cre and control mice with NP-CGG and 
compared mRNA expression between control and mutant GC B cells sorted at day 
14 post immunization (Figure 61). 
 
 
130 
We found that Cdkn2a/p16INK4A/p19ARF, Cdkn1a/p21CIP1 and Cdkn1b/p27KIP1 
transcripts, encoding for inhibitors of cyclin-dependent protein kinases (Cdk) 
regulating G1-to-S transition were significantly up- regulated in PRC1 mutant GC 
B cells. At the same time, we also detected up-regulation of loci encoding positive 
regulators of cell cycle progression, namely Ccnd2 and Ccng1.  
 
 
 
Figure 61. Loss of PRC1 leads to aberrant expression of cell cycle regulators.  
Q-PCR of transcript levels for the indicated genes in GC B cells sorted from 11 mutants 
and 11 control animals. Transcript levels were normalized using Rplp0. Genes were 
filtered based on number of samples where consistent up- or down-regulation was 
detected in >= 5 samples and if 0,5<FC>1,5. Bars represent mean values +/- SEM. 
 
 
In order to investigate whether transcriptional de-regulation of genes modulating 
cell cycle progression would affect proliferation of mutant PRC1 cells, and to 
overcome limitations due to the low cellularity observed in GCs of Ring1a-/-
;Ring1bff/fl;Cd23-cre, we employed an in vitro primary B cell culture system that 
generates highly proliferating GC B cell-like (iGB) cells (Figure 62) (Nojima et al., 
2011).  
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Figure 62. In vitro system to generate GC-like B cells from MACS-isolated naïve 
splenic B cells. 
 
 
Briefly, resting splenic B cells from Ring1a-/-;Ring1bfl/fl;Cγ1-cre and control animals 
were purified by magnetic cell sorting and stimulated with soluble BAFF, IL-4 and 
membrane-bound CD40L. Using this experimental approach, we achieved efficient 
and rapid induction of the Cγ1-cre transgene, which in turn led to inactivation of 
PRC1 in the majority of Ring1a-/-;Ring1bfl/fl activated B cells (Figure 63). 
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Figure 63. Efficient deletion of Ring1b and loss of H2AK119Ub in the iGB culture 
system. 
Immunoblot analysis of splenic CD19+ cells isolated from spleens of Ring1a-/-; Ring1bfl/fl; 
Cγ1-cre mutant and control animals and cultured for the indicated number of days in the 
presence of membrane-bound CD40L, soluble BAFF and IL-4. Results shown are 
representative of 2 independent experiments. 
 
 
Cell cycle distribution was determined by flow cytometric analysis on control and 
PRC1 mutant B cells at different days after stimulation following a brief pulse with 
BrdU and labeling of the cells with propidium iodide (PI) to determine the DNA 
content. Acute loss of PRC1 led to a progressive accumulation of activated B cells 
in the G0/G1 phase of the cell cycle (Figure 64). 
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Figure 64. Loss of Ring1a and Ring1b affects cell cycle progression in vitro. 
Flow cytometric analysis of cell cycle distribution of control (left) and mutant (right) 
induced GC B cells. Data shown are representative of data obtained in 3 independent 
experiments. 
 
 
In order to determine whether the arrest in cell cycle progression was likely to 
originate from de-regulation of cell cycle modulators, we analyzed transcript levels 
for Cdkn2a/p16INK4A/p19ARF, Cdkn1a/p21CIP1 and Cdkn1b/p27KIP1 from control and 
PRC1 mutant cultures. Preliminary data show results similar to those obtained in 
vivo (Figure 65).  
Day 2 
Day 3 
Day 4 
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Figure 65. Loss of PRC1 de-regulates expression of cell cycle regulators in vitro.  
Representative Q-PCR analysis of one of two independent experiments displaying 
aberrant modulation of cell cycle regulators following PRC1 loss in vitro. Cells were 
collected at the indicated time points following activation. Transcript levels were 
normalized using Rplp0 and expression levels of controls at day 0 of activation 
(Ring1a+/+;Ring1b+/+;Cγ1-cre, light gray bars). Mutant transcript levels are represented with 
dark grey bars. Error bars represent standard deviation across three technical replicates. 
 
 
Together, this suggests on the one hand that PRC1 supports proliferation of GC B 
cells through the repression of Cdk inhibitors that regulate G1-to-S transition. On 
the other hand, transcripts coding for cyclin-D2 and -G1 were also increased in 
PRC1 mutant GC B cells and in iGB cultures (Ccnd2 only), indicating a more 
complex regulation of the cell-cycle operated by Ring1a/Ring1b in GC B cells. 
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3.5.4. Bcl6 function is altered in PRC1 mutant GC B cells. 
 
Among the genes up- regulated in PRC1 mutant GC B cells, we found several 
targets of the transcriptional repressor Bcl6, which is essential for GC B cell 
responses (Dent et al., 1997) (Ye et al., 1997) (Fukuda et al., 1997). These 
included genes coding for chemokine receptors (Ccr7 and Gpr183), cell-cycle 
regulators (Cdkn1a, Cdkn1b, Cdkn2a, and Ccnd2), developmental regulators 
(Prmd1, Id2) and modulators of survival/apoptosis (Bcl2) (Figure 66).  
 
Figure 66. De-regulation of Bcl-6 target genes in GC B cells following loss of PRC1. 
Q-PCR of transcript levels for the indicated genes in GC B cells sorted from 11 mutants 
and 11 control animals. Transcript levels were normalized using Rplp0. Genes were 
filtered based on number of samples where consistent up- or down-regulation was 
detected in >= 5 samples and if 0,5<FC>1,5. Bars represent mean values +/- SEM. 
 
We tested the possibility that the reduction in GC B cell numbers observed in 
PRC1 conditional mutants was dependent on an impairment in Bcl6 expression 
and/or function. We quantified Bcl6 transcripts in PRC1 mutant GC B cells. RT-
qPCR analyses revealed a modest yet reproducible reduction in Bcl6 mRNA levels 
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in PRC1 mutant B cells (Figure 66). Since a substantial number of genes repressed 
by Bcl6 in GC B cells is also targeted by H3K27me3/PRC2 (Velichutina et al., 
2010), we explored the possibility that PRC1 could contribute to Bcl6-mediated 
gene silencing. This hypothesis was supported by recent evidence showing that 
PRC1 can form a macromolecular complex with the Bcl6 co-repressor BCOR 
(Gearhart et al., 2006). Therefore, we tested whether PRC1 interacted directly with 
Bcl6 in the Bcl6-expressing A20 lymphoma cell line. To this aim, we performed 
immunoprecipitation assays with an anti-Ring1b antibody using protein extracts 
from A20 lymphoma cells. Immunoblotting analysis of immunoprecipitated material 
confirmed the interaction of Ring1b with BCOR, but failed to identify Bcl6 within 
the same complex (Figure 67). These results are compatible with a scenario in 
which PRC1 supports Bcl6 repressor activity through an indirect mechanism. 
 
 
 
Figure 67. Ring1b and Bcl6 do not interact. 
Immunoblot analysis of mmunoprecipitated material from the A20 cell line. Endogenous 
Ring1b was immunoprecipitated with 5 µg of anti-Ring1b antibody from 1 mg protein 
lysate obtained from A20 cells. The blot shown is representative of 3 independent 
experiments. 
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3.5.5. PRC1 regulates plasma cell differentiation onset 
 
The ultimate goal of an immune response is the generation of terminally 
differentiated plasma cells that secrete neutralizing antibodies to mediate 
pathogen clearance. Plasma cells differentiate from GC B cells, but can also arise 
in a T cell-independent fashion. In the GC, PC differentiation is triggered in B cells 
that have undergone several rounds of proliferation and mutation of their Ig genes 
as a result of a stringent selection process (Victora et al., 2010). What prevents 
premature activation of the PC program in GC B cells remains yet poorly defined. 
We have recently identified through genome-wide mapping of H3K27me3 targets, 
the master regulator of PC development IRF4 as a target of H3K27me3/PRC2 in 
GC B cells (Caganova et al., 2013). In order to assess the contribution of Ring1a 
and Ring1b to the repression of Irf4 in GC B cells, the fraction of Irf4-expressing 
GC B cells in Ring1a-/-;Ring1bff/fl;Cd23-cre and control animals immunized with 
NP-CGG was determined by FACS analysis. We found that PRC1 inactivation 
caused a substantial increase in the proportion of IRF4hi GC B cells in comparison 
to controls (Figure 68 and Figure 69). 
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Figure 68. Absence of Ring1a and Ring1b accelerates plasma cell development. 
Flow cytometric analysis of the fraction of Irf4hi cells within the CD19+CD38loFAShi GC 
compartment of control (left) and mutant (right) animals at day 14 post NP-CGG 
immunization. Data shown are representative of 14 independent experiments. 
 
 
Figure 69. Increased fraction of Irf4-expressing cells in GCs of mutant animals. 
 
The increase in Irf4 expression in PRC1 mutant GC B cells correlated with an up-
regulation of transcripts for Irf4 and for another determinant of plasma cell 
differentiation, namely Prdm1/Blimp1 (Figure 70). 
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Figure 70. Loss of PRC1 in GC B cells leads to de-repression of plasma cell fate 
determinants. 
Q-PCR of transcript levels for the indicated genes in GC B cells sorted from 11 mutants 
and 11 control animals. Transcript levels were normalized using Rplp0. Genes were 
filtered based on number of samples where consistent up- or down-regulation was 
detected in >= 5 samples and if 0,5<FC>1,5. Bars represent mean values +/- SEM. 
 
These results suggest that in the absence of Ring1a and Ring1b, GC B cells 
activate prematurely the plasma cell program, hampering thereby their ability to 
persist within this compartment.  
In order to monitor the early steps of PC differentiation under conditions of PRC1 
deficiency, we performed in vitro stimulations with LPS +/- IL-4 of PRC1 control 
(Ring1a+/+;Ring1b+/+;Cd23-cre) and mutant (Ring1a-/-;Ring1bff/fl;Cd23-cre) primary 
B cells to induce terminal differentiation. Upon stimulation with endotoxin, Ring1b 
protein levels increased between day 2 and day 3 of activation, which correlated 
with a substantial increase in the levels of H2AK119Ub (Figure 71).  
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Figure 71. Expression of PRC1 members is modulated during B cell activation in 
vitro. 
Immunoblot analysis of Ring1a, Ring1b and H2AK119Ub levels in CD19+ splenic B cells 
isolated from C57/J animals. B cells were activated with LPS+IL-4 and harvested at the 
indicated time points.  Data shown are representative of 3 independent experiments. 
 
To assess the differentiation potential of PRC1 control and mutant B cells, flow 
cytometric analysis of LPS cultures was performed 3 days after stimulation. 
Strikingly, inactivation of PRC1 led to a substantial increase in the fraction of B 
cells that up-regulated the PC marker syndecan-1/CD138 (Figure 72 and Figure 
73). 
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Figure 72. Premature appearance of CD138+ plasmablasts in LPS+IL-4-stimulated 
Ring1a-/-Ring1b-/- cultures. 
Representative flow cytometric analysis displaying frequency of CD19+CD138+ cells at 
day 3 following stimulation of purified naïve B cells with LPS +/- IL-4 in control (left) and 
mutant (right) animals. Data are representative of 7 independent experiments.  
 
 
 
 Figure 73. Frequency of plasmablasts and plasma cells upon in vitro stimulation of  
Ring1a-/-Ring1b-/- cells. 
Frequency of CD138+ CD19+ plasmablasts and of CD138+ CD19lo plasma cells at day 3 of 
LPS +/- IL-4 activation. Data are shown +/- SEM and are representative of 7 
(plasmablasts) and 5 (plasma cells) independent experiments. 
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This was associated with increased expression in PRC1 mutant B cell cultures of 
Irf4, Xbp1 and Prmd1 transcription factors that are required for plasma cell 
development (Figure 74). 
 
Figure 74. Increased expression of plasma cell master regulators in mutant cells 
activated with LPS and IL-4. 
Q-PCR analsyis was performed on RNA extracted from cells at day 3 of LPS and IL-4 
activation. Data are representative of 3 independent experiments and are presented as 
mean +/- SEM. 
 
CD138+ B cells in PRC1 mutant cultures retained expression of the pan-B cell 
marker and PAX-5 target CD19, representing thereby early plasmablasts. In 
contrast, the subset of CD19loCD138hi PCs was only marginally affected by PRC1 
inactivation. These results indicate that loss of PRC1 facilitates onset of terminal B 
cell differentiation both in vivo and in vitro.    
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3.6. PRC1 is necessary to sustain PC function  
 
Next, we assessed whether PRC1 inactivation affected plasma cell generation in 
vivo. To this end, we immunized control (Ring1a+/+;Ring1b+/+;Cd23-cre) and PRC1 
conditional mutants (Ring1a-/-;Ring1bff/fl;Cd23-cre) with alum-precipitated NP-CGG 
and assessed the fraction of splenic CD19loIRF4hi cells generated 14 days later. 
Flow cytometric analyses revealed comparable frequencies of plasma cells in 
PRC1 mutant and control mice (Figure 75 and Figure 76). 
 
 
Figure 75. Plasma cells frequency in Ring1a/Ring1b mutants is comparable to that 
of controls. 
Flow cytometric analysis displaying frequency of CD19+IRF4+ cells at day 14 following 
NP-CGG immunization in control (left) and mutant (right) animals. Data are representative 
of 14 independent experiments. 
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Figure 76. . Plasma cell frequency is not affected by loss of Ring1a and Ring1b.  
 
 
Figure 77. Ring1a-/-Ring1b-/- plasma cells cells are counter-selected in vivo. 
Histogram plot displaying frequency of EYFP-expressing cells within the plasma cell 
compartment in control (left) and mutant (right) animals. Data are representative of 3 
independent experiments. 
 
 
To address whether PCs in PRC1 conditional mutant mice had undergone Cre-
mediated recombination at the Ring1b locus, I took advantage of the R26-EYFP 
Cre reporter allele.  Specifically, we measured the frequency of YFP+ cells among 
CD19loIRF4hi PCs in the spleen of PRC1 proficient (Ring1a-/-;Ring1bfl/+;Cd23-
cre;R26-EYFP) and mutant (Ring1a-/-;Ring1bff/fl;Cd23-cre;R26-EYFP) animals 
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after NP-CGG immunization. Strikingly, whereas most PCs expressed YFP in 
control animals, the counterparts in PRC1 mutants had to a large extent escaped 
Cre-mediated recombination (Figure 77). Counter-selection of PRC1 mutant cells 
within the plasma cell compartment was further confirmed by analysis of iGB cells 
induced to differentiate towards the plasma cell fate. Briefly, following a 4-day 
treatment, IL-4 was substituted with interleukin 21 (IL-21) in established iGB 
cultures, to induce plasma cell differentiation (Nojima et al., 2011). 
 
 
 
Figure 78. Counter-selection of Ring1b mutant cells upon induction of the plasma 
cell program. 
Immunoblot analysis displaying levels of Ring1b and H2AK119Ub following induction of 
the plasma cell program through IL-21 stimulation of iGB cells established after 4 days of 
culture in the presence of IL-4. 
 
 
Immunoblot analysis of iGB cells after 2 days of exposure to IL-21 showed a 
strong counter-selection of PRC1 mutant cells, with Ring1b proficient cells taking 
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over the culture (Figure 78). Together, in vitro and in vivo results indicate that 
PRC1 is required to sustain the developmental program that underlies the function 
of antibody-secreting plasma cells. 
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4. Discussion 
 
This study has addressed the role of the catalytic subunits of PRC1, Ring1a and 
Ring1b, in B cell development and their contribution to adaptive B cell immune 
responses. Using a conditional gene targeting approach, we have initially explored 
the function of Ring1b in B lineage cells. Our lab could show that Ring1b 
inactivation alone had no detectable consequences on the development of B cells 
(L. D’Artista and S. Casola, unpublished data). In accordance with this, Ring1b 
mutant B cells had almost wild-type levels of H2AK119Ub, suggesting that Ring1b 
close homologue, Ring1a, may be the main catalytic subunit of PRC1 in B cells. 
However, Ring1a gene-targeted animals showed normal B cell development. This 
led us to hypothesize functional redundancy between Ring1a and Ring1b proteins 
in developing B cells. We addressed this possibility by generating compound 
Ring1a-/-Ring1bfl/fl mutant animals crossed to Cre transgenic strains allowing 
PRC1 ablation at defined stages of B cell development. These experiments 
showed that concomitant ablation of Ring1 proteins caused major defects at 
multiple stages of B cell differentiation.  
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4.1. PRC1 in early B cell development 
 
PRC1 inactivation induced in pro-B cells by the Mb1-cre transgene caused a 
significant block in the transition from pro-B to the pre-B cells. Impairment in the 
transit through this differentiation step may reflect defective V(D)J recombination. 
A similar mechanism was described in Ezh2 mutants, where defects in VH gene 
rearrangements caused impaired transition from the pro- to the pre-B cell stage, 
resulting in a reduced peripheral B cell pool (Su et al., 2003). A causal relationship 
between defective IgH rearrangement and impairment in B cell production 
following loss of PcG is also supported by previous work carried out on Bmi1-/- 
animals in our lab (F. Alberghini and S. Casola, unpublished data). In these 
animals, the block in transition from the pro-B to the pre-B cell stage was 
substantially rescued by the expression of a pre-rearranged B1-8f Ig heavy chain 
in progenitor cells (Lam et al., 1997). 
The early developmental block could also depend on the inability of 
Ring1a/Ring1b mutant progenitors to cope with DNA double strand breaks (DSBs) 
induced by RAG proteins during V(D)J recombination. Involvement of PRC1 
members in DNA DSBs repair is supported by a number of studies reporting the 
presence of Polycomb members and repressive histone modifications including 
H2AK119Ub at sites of DNA breaks (Facchino et al., 2010) (Ismail et al., 2010) 
(Ginjala et al., 2011) (Chagraoui et al., 2011) (Chou et al., 2010). In these studies, 
early recruitment of PRC1 members Bmi1 and Ring1b followed by ubiquitination of 
histones H2A and H2AX was observed to promote DNA repair (Ismail et al., 2010). 
Supporting an important role for PcG proteins in DNA repair, absence of Polycomb 
members results in enhanced sensitivity to ionizing radiation and increased levels 
of spontaneous DNA breaks (Facchino et al., 2010) (Chagraoui et al., 2011) 
(Caganova et al., 2013). Together, this indicates an important role for PcG 
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proteins in DNA repair and supports a scenario whereby absence of PRC1 impairs 
B cell differentiation by preventing efficient repair of RAG-induced DNA DSBs. 
This is likely to result from de-repression of loci encoding the main cell cycle-
dependent kinase (Cdk) inhibitors, which encode tumor suppressors that mediate 
cell cycle arrest, senescence and apoptosis (Fan et al., 2011) (Park et al., 2003) 
(Bruggeman et al., 2005) (Velichutina et al., 2010). This hypothesis is supported 
by a large body of evidence showing substantial rescue of PcG-deficient cells 
upon inactivation of the Polycomb target Cdkn2a/ p16INK4A/ p19ARF locus (Park et 
al., 2003) (Bruggeman et al., 2005). In support of this, our lab could recently show 
that the block in pro-B to the pre-B cell transition observed in Ezh2-/- animals is 
substantially relieved by concomitant inactivation of Cdkn2a (M. Caganova and S. 
Casola, unpublished data). To conclude, several mechanisms may account for the 
defects observed in PRC1 deficient progenitors. The partial recovery of the defects 
of Polycomb mutant B cell progenitors via inactivation of Cdk inhibitors or by-pass 
of V(D)J recombination suggests that PRC1 exerts a critical control at multiple 
levels to promote early B cell differentiation (M. Caganova and S. Casola, 
unpublished data and F. Alberghini and S. Casola, unpublished data).   
 
4.2. PRC1 in peripheral B cell maturation 
 
Since PRC1 function has remained largely unexplored in differentiated cells, this 
study focused primarily on the contribution of PRC1 in mature B cells before and 
after their encounter with a foreign antigen. Using the Cd23-cre mouse strain, we 
achieved over 90% efficiency of Ring1b inactivation starting from late 
transitional/immature B cells that also carried a Ring1a mutant allele. By studying 
resting B cells, we ruled out any effect of PRC1 inactivation on cell cycle 
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progression and addressed how PRC1 regulates peripheral B cell maturation in a 
cell autonomous fashion. 
PRC1 inactivation in late transitional B cells had marginal effects on total B cell 
numbers in secondary lymphoid organs. Instead, it caused a substantial mis-
regulation of surface markers on mutant B cells, pointing to a defect in their 
differentiation. Indeed, loss of PRC1 combined the immunophenotype of immature 
B cells, characterized by the expression of CD93/AA4.1, HSA/CD24 and high 
levels of CD95/FAS, with that of mature B cells featuring high levels of CD21 and 
BAFF-R expression. Moreover, mutant B cells were proficient in the homing to B 
cell follicles and formed a marginal zone in the spleen. In spite of the normal 
number and localization of Ring1a/Ring1b mutant peripheral B cells, the analysis 
of B cell development at different ages unveiled sustained bone marrow B cell 
production in aged Ring1a/Ring1b deficient animals as compared to controls. 
Such condition may represent a compensatory homeostatic mechanism 
responding to a shorter life- span of peripheral B cells, as previously observed in 
other mouse mutants showing defects in peripheral B cell development (Keren et 
al., 2011). Experiments to determine the life- span of PRC1 deficient B cells are 
ongoing at the moment.  Importantly, recent evidence implicates Ring1b in the 
maintenance of the quiescent state characterizing mature lymphocytes. In their 
work, Frangini and colleagues unveil a previously unreported role for Ring1b as a 
transcriptional activator in a complex involving Bmi1 and the Aurora B kinase. In 
resting B cells, Ring1b was bound to a substantial number of transcriptionally 
active genes in combination with Aurora B, which contributed to inhibit Ring1b-
dependent H2AK119Ub. Ring1b/Aurora B kinase targets included several genes 
necessary to help the survival of resting lymphocytes.  These results have led to 
the hypothesis that Ring1b is necessary to support lymphocyte quiescence 
through the positive regulation of quiescence-associated genes (Frangini et al., 
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2013). The extended B cell lymphopoiesis observed in Ring1a/Ring1b mutant 
mice sustains a model whereby PRC1 controls viability of quiescent mature B 
cells. On the other hand, in contrast to what described by Frangini and co-workers, 
the majority of differentially expressed genes were up- regulated in resting PRC1 
mutant B cells. This result is in line with the function of PRC1 as a transcriptional 
repressor. Moreover, the comparison with genome-wide occupancy of H3K27me3 
in peripheral B cells (C. Carrisi and S. Casola, unpublished data) revealed that 
45% of the up-regulated genes in PRC1 mutant B cells were marked by 
H3K27me3, and thus target of PRC2. This suggests that close to half of the genes 
de-regulated in PRC1 mutant B cells represent bona fide Polycomb targets, which 
require PRC1 for stable repression. Genes de-regulated following PRC1 removal 
were enriched among Gene Ontology categories enriched for developmental 
regulators, in line with previous data obtained from analyses on Polycomb mutant 
ES and differentiated cells (Boyer et al., 2006) (Morey et al., 2013) (Ezhkova et al., 
2011). In particular, we observed the substantial re-activation of genes expressed 
in stem and progenitor cells, including several members of the Hox gene family, 
and genes expressed in the neuronal lineage (Terunuma et al., 2004). 
Interestingly, Ring1a/Ring1b resting mutant B cells showed high transcript levels 
for Hoxa9 and Meis1, which in myeloid progenitors is sufficient to induce malignant 
transformation (Kroon et al., 1998; Lawrence et al., 1999). Surprisingly, even aged 
PRC1 conditional mutant animals did not suffer from any form of B cell 
malignancy, indicating either that the oncogenic role of Hoxa9/Meis1 is restricted 
to the myeloid lineage and/or that B cell transformation requires intact PRC1 
activity.  
In spite of the de-repression of lineage- and stage-inappropriate genes, PRC1 
inactivation did not overtly affect B cell identity. PRC1 mutant CD23+ B cells did 
neither revert to an earlier developmental stage nor suffered from trans-
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differentiation to other lineages, as confirmed by the lack of expression of the Cre-
reporter YFP allele in other hematopoietic lineages assessed in Ring1a-/-
;Ring1bff/fl;Cd23-cre;R26-EYFP compound mutants. These results are thus 
discordant with the substantial reprogramming of mature B cells undergoing 
conditional inactivation of the transcription factor Pax5 (Cobaleda et al., 2007a). 
In conclusion, results obtained so far suggest that PRC1 supports maintenance of 
peripheral B cells cell identity, but place its activity hierarchically downstream of 
TFs sustaining B cell identity such as Pax5 (Cobaleda et al., 2007a). 
 
4.3. PRC1 in immune responses 
 
Next, we analyzed the effects of PRC1 inactivation on resting B cells upon their 
recruitment into an immune response after recognition of a T-cell dependent 
antigen. We employed the Cg1-cre transgene to specifically inactivate PRC1 in 
GC B cells. The striking counter-selection of Ring1a/Ring1b double mutant GC B 
cells indicated an essential role for PRC1 in these cells. This was confirmed in a 
second set of experiments in which the Cγ1-cre transgene was replaced by Aicda-
cre. In the latter animals, the higher efficiency of Cre-mediated recombination 
compared to Cγ1-cre led to a significant loss of GC B cell numbers in secondary 
lymphoid organs of immunized mice. Similar results were also observed in 
compound mutants in which PRC1 was deleted using the Cd23-cre transgene in 
pre-GC B cells. In accordance with the observed defect in GC formation, PRC1 
conditional mutant mice displayed impaired primary antibody responses following 
immunization with the T cell-dependent antigen NP-CGG. In addition, 
Ring1a/Ring1b inactivation led to a severe impairment in memory B cell formation, 
as revealed by the reduction in antigen-specific IgG1+ B cells two weeks following 
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primary immunization. A defect in B cell memory differentiation was confirmed by 
the failure of PRC1 mutant animals to produce high-affinity antigen-specific 
antibodies in recall immune responses. To investigate the mechanisms involved in 
the reduction in GC B cells, we investigated the effects of Ring1a/Ring1b loss on 
apoptosis, proliferation and differentiation of GC B cells. The detection of an 
increased fraction of GC B cells expressing active forms of caspase(s) indicated a 
higher susceptibility of PRC1 mutant GC B cells to programmed cell death. We 
hypothesized that PRC1 inactivation sensitized cells to mitochondrial apoptosis. 
Therefore, we investigated the expression of the Noxa/Mcl1 axis, which is the 
major regulator of GC B cell apoptosis (Vikstrom et al., 2010). Loss of PRC1 
activity failed to up-regulate Pmaip1/Noxa. Moreover, quite surprisingly, we 
consistently detected increased levels of Mcl-1 transcripts in Ring1a/Ring1b 
double mutant GC B cells. Therefore, these results seem to exclude a contribution 
of mitochondrial apoptosis in the death of PRC1 defective GC B cells. Increased 
apoptosis may also be brought about by inability of the cells to cope with genotoxic 
damage. Several recent studies have shown that PRC1 components are rapidly 
recruited to sites of DNA breaks, where they contribute to the repair process 
(Ginjala et al., 2011) (Ismail et al., 2010). Thus, it is possible that GC B cells 
lacking PRC1 acquire increased sensitivity to genotoxic stress. A likely candidate 
for the induction of genotoxic damage in GC B cells is AID. Here, upon onset of Ig 
class switch recombination, AID is recruited to the IgH locus, where it promotes 
the accumulation of DNA DSBs at high frequency. This allows the replacement of 
the Cµ constant region coding sequence with that of another isotype though a 
process that is primarily mediated by non-homologous end joining proteins (Xu et 
al., 2012). Loss of PRC1 may impair the repair of DNA breaks at IgH constant 
region genes, ultimately causing the death of the cells. In support of this 
hypothesis, in vitro Ig CSR assays revealed a smaller percentage of Ig switched B 
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cells in PRC1 mutant cultures. Moreover, heightened apoptosis of PRC1 deficient 
B cells was primarily observed under culture conditions, such as LPS stimulation, 
when AID is strongly induced. In contrast, stimulation of PRC1 mutant B cells with 
mitogens that fail to induce AID expression (such as stimulation through the Toll-
like receptor RP-105) had minor effects on their death (Ogata et al., 2000). A 
genetic proof for the role AID in the induction of apoptosis of Polycomb mutant 
cells has recently come from our laboratory studying the effects of Ezh2 
inactivation on GC B cells (Caganova et al., 2013). Inactivation of Ezh2 in GC B 
cells led to a significant increase in the fraction of apoptotic cells. Such phenotype 
was fully normalized by concomitant inactivation of AID. The involvement of AID in 
the acquired sensitivity of Polycomb mutant GC B cells may also result from 
excessive recruitment of the deaminase to genomic off-target sites. Indeed, 
previous work has shown that AID recruitment is favored by the presence of 
epigenetic marks associated to active transcription such as H3K4me3. In contrast, 
genome-wide recruitment of AID is limited by the presence of repressive histone 
marks such as H3K27me3 (Yamane et al., 2011). It remains to be seen whether 
PRC1 and its associated repressive mark H2AK119Ub may contribute to 
prevent/limit genome-wide AID attack. 
The impairment in GC B cell responses resulting from PRC1 inactivation may also 
stem from proliferation defects. Given the technical limitations associated with the 
analysis of PRC1 mutant GC B cells in vivo, due to their strong counter-selection, 
we took advantage of a recently developed in vitro culture system to generate GC 
B-like (iGB) cells from primary resting CD19+ splenic B cells after activation with 
membrane-bound CD40L, BAFF and IL-4 (Nojima et al., 2011). Under these 
experimental conditions, we achieved acute in vitro PRC1 inactivation in activated 
Ring1a-/-; Ring1bfl/fl; Cγ1-cre B cells. Cell cycle distribution analysis of CD40-
stimulated PRC1 mutant B cells revealed a prominent defect in the G1-to-S 
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transition. In search of the mechanisms underlying the observed phenotypes, we 
measured the expression of several cell-cycle regulators in PRC1 proficient and 
mutant B cell cultures. Concomitant loss of Ring1a and Ring1b in CD40-activated 
B cells led to the consistent up-regulation of Cdk inhibitors p16INK4A and p21CIP1, 
which are known Polycomb targets. Our lab has recently shown that p16INK4A 
encoded by the Cdkn2a locus is not responsible for the G1-to-S transition defect 
observed in activated B cells lacking Ezh2. Indeed, the numbers of GC B cells and 
the proliferative defects observed in in vitro- generated iGB cells lacking functional 
Ezh2 could not be rescued by concomitant loss of Cdkn2a (Caganova et al., 
2013). Along the same line, despite the up-regulation of p21CIP1 detected in both 
PRC1 and Ezh2 mutant GC B cells, Cdkn1a transcripts remained unaltered in 
G0/G1 arrested Ezh2 mutant iGB cells (Caganova et al., 2013). The latter result is 
in contrast with recent work by the Melnick group that showed a partial rescue in 
the proliferation defects of Ezh2-inhibited human B lymphoma cells following p21 
knock-down(Beguelin et al., 2013). All together, these results point to additional 
contributions made by PRC1 in the regulation of S-phase entry in B cells. 
A defect in G1-to-S transition may result from the interference with the function of 
the E2F family of transcription factors (Wu et al., 2001). Ezh2 is a downstream 
target of E2F transcriptional activity required for cell proliferation (Bracken et al., 
2003). Importantly, a master regulatory analysis recently performed in our lab on 
genes down-regulated in PRC1 mutant resting B cells revealed a significant 
enrichment for an E2f1 gene signature (F. Alberghini, F. Zanardi, S. Casola, data 
not shown). In a similar fashion, a gene signature associated with E2f2 function, 
which exerts a negative regulation on cell-cycle progression (Infante et al., 2008) 
was enriched among the genes up-regulated in PRC1 mutant B cells.  
The loss of GC B cells following acute PRC1 inactivation could also be contributed 
by uncoordinated activation of developmental programs underlying the exit of B 
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cells from the GC. This could result from a premature activation of the plasma cell 
program and/or by interference with the activities of transcriptional repressors such 
as Bcl6 that sustain the GC B cell response (Fukuda et al., 1997). To this end, we 
quantified mRNA levels for transcription factors playing a crucial role in terminal B 
cell differentiation. Inactivation of PRC1 in GC B cells led to a consistent up-
regulation of Blimp1 and Irf4, which represent major determinants of plasma cell 
(PC) development (Shapiro-Shelef et al., 2003) (Klein et al., 2006). To have a 
closer look at the initial stages of PC development in the absence of PRC1, we 
performed in vitro LPS stimulation assays. Loss of Ring1a/Ring1b caused a 
substantial increase in the fraction of CD19+CD138+ plasma blasts generated after 
endotoxin stimulation. Similarly to what had been observed in GC B cells, in vitro-
activated PRC1 mutant B cells showed substantial higher expression of Blimp1 
and Irf4. The finding that Irf4 and Blimp1 loci are marked by H3K27me3 in both 
mouse and human GC B cells (Caganova et al., 2013) supports a scenario 
whereby Ezh2 controls onset of PC differentiation in GCs by directly regulating the 
expression of PC lineage determinants. Similar results were confirmed by our 
group and by Melnick and colleagues analyzing human Diffuse Large B lymphoma 
cell lines after treatment with a highly specific small molecule inhibitor to Ezh2 
(Beguelin et al., 2013; Caganova et al., 2013). The observation that, similarly to 
Ezh2 inhibition, Ring1a/Ring1b inactivation facilitated PC differentiation strongly 
argues for the coordinated activity of PRC1 and PRC2 in the temporal control of 
GC B cell differentiation. 
Lastly, PRC1 may sustain the persistence of B cells within the GC by supporting 
the repressor activity of the GC B cell master regulator Bcl6. This hypothesis is 
supported by the observation that several genes that were de-regulated in PcG 
mutant B cells are highly significant Bcl6 targets (Ccr7, Gpr183, Cdkn1a, Cdkn1b, 
Cdkn2a, Ccnd2, Prmd1, Id2 and Bcl2) (Basso et al., 2010). We hypothesized that 
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PRC1 could directly interact with Bcl6 to support its repressor function in GC B 
cells. To address this, we performed immunoprecipitation assays using protein 
extracts from GC-derived A20 B lymphoma cells. These studies failed to detect 
physical interaction between PRC1 and Bcl6, supporting a model whereby PRC1 
influences indirectly the repression by Bcl6 on common targets. Indeed, recent 
work has identified the Bcl6 co-repressor BCOR as an essential component of 
PRC1 (Gao et al., 2012) (Gearhart et al., 2006) (Sanchez et al., 2007). Future 
studies will reveal the degree of overlap between Bcl6 and PRC1 targets and 
which of them requires the interaction between Bcl6 and BCOR for stable 
repression (Huang et al., 2013). The functional relationship between Polycomb- 
and Bcl6-mediated gene silencing is supported by recent work by our group and 
others showing a substantial degree of overlap between H3K27me3/Ezh2 and 
Bcl6 targets in both human and mouse GC B cells (Caganova et al., 2013) 
(Velichutina et al., 2010). Moreover, we could show that Ezh2 is required to 
sustain Bcl6 repressive activity (but not its expression) in GC B cells (Caganova et 
al., 2013). 
4.4. PRC1 in B cell terminal differentiation 
 
In spite of the facilitated onset of plasma cell differentiation, the generation of bona 
fide antibody-secreting CD19loCD138+ PCs was impaired in the absence of PRC1 
both in vitro and in vivo after immunization with a T-cell dependent antigen. These 
results suggest that PRC1 exerts a dual role during terminal differentiation. In GC 
B cells, PRC1 prevents premature activation of the PC program, possibly through 
a direct repression of Blimp1 and Irf4 expression. Once PCs are generated, PRC1 
is required to sustain their function. This may be achieved by guaranteeing stable 
repression of B-cell specific genes and those expressed in other lineages. This 
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hypothesis is supported by the frequent dysregulation of lineage-inappropriate 
genes when PcG function is inhibited (Ezhkova et al., 2009) (Ezhkova et al., 
2011). Inactivation of Ring1a/Ring1b in B cells also had a major impact on the 
generation of long-lived memory B cells. The loss of memory B cells resulting from 
inactivation of PRC1 in pre-GC B cells (using the Cd23-cre transgene) or in the 
vast majority of GC B cells (Aicda-cre) is likely the consequence of the 
disaggregation of the GC reaction. Instead, using the Cg1-cre transgene, which 
allowed the preferential outgrowth of GC B cells that retained PRC1 function, we 
could determine the effects of PRC1 inactivation in newly generated IgG1-
switched memory B cells. Loss of PRC1 almost completely abolished the pool of 
long-lived antigen-specific IgG1 memory B cells, highlighting an essential 
contribution of Ring1a/Ring1b to memory B cell maintenance. 
 
Together, data presented in this PhD thesis indicate that PRC1 is critical at 
multiple stages of B cell differentiation, affecting both cycling and resting B cell 
subsets. Phenotypes observed from the analysis of conditional PRC1 mutant mice 
are to a large extent overlapping with those observed in mutants for Ezh2, the 
main catalytic subunit of PRC2. These results are in agreement with the model 
based on concerted activity of the two PRCs in ensuring transcriptional silencing of 
the majority of their targets. Our data also suggest that deposition of H3K27me3 
alone is not sufficient to achieve heritable gene repression, which is strictly 
dependent on the over imposing activity of PRC1. 
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